<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
<title>Night Float Companion</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@700;800;900&family=DM+Sans:ital,wght@0,400;0,500;0,600;0,700;1,400&display=swap" rel="stylesheet">
<script crossorigin src="https://cdnjs.cloudflare.com/ajax/libs/react/18.2.0/umd/react.production.min.js"></script>
<script crossorigin src="https://cdnjs.cloudflare.com/ajax/libs/react-dom/18.2.0/umd/react-dom.production.min.js"></script>
<script crossorigin src="https://cdnjs.cloudflare.com/ajax/libs/babel-standalone/7.23.9/babel.min.js"></script>
<style>
*,*::before,*::after{margin:0;padding:0;box-sizing:border-box}
:root{
--bg0:#0a0e1a;--bg1:#0f172a;--bg2:#1a1035;
--sf:rgba(255,255,255,0.04);--sfh:rgba(255,255,255,0.07);--sfa:rgba(255,255,255,0.10);
--bd:rgba(255,255,255,0.08);--bdl:rgba(255,255,255,0.12);
--t1:#e2e8f0;--t2:#94a3b8;--t3:#64748b;--t4:#475569;
--red:#ef4444;--amber:#f59e0b;--green:#10b981;--blue:#3b82f6;
--fh:'Playfair Display',Georgia,serif;--fb:'DM Sans',system-ui,sans-serif;
--sw:272px;--tr:0.2s ease;
}
html{font-size:15px;scroll-behavior:smooth}
body{font-family:var(--fb);background:linear-gradient(160deg,var(--bg0),var(--bg1) 40%,var(--bg2));color:var(--t1);min-height:100vh;overflow-x:hidden;line-height:1.6}
body::before,body::after{content:'';position:fixed;border-radius:50%;pointer-events:none;z-index:0;filter:blur(130px);opacity:.10}
body::before{width:600px;height:600px;background:#6366f1;top:-200px;left:-100px}
body::after{width:500px;height:500px;background:#a855f7;bottom:-150px;right:-100px}
::-webkit-scrollbar{width:6px}::-webkit-scrollbar-track{background:transparent}::-webkit-scrollbar-thumb{background:rgba(255,255,255,.15);border-radius:3px}
#root{position:relative;z-index:1}
.lyt{display:flex;min-height:100vh}

/* Sidebar */
.sb{width:var(--sw);min-height:100vh;position:fixed;top:0;left:0;background:rgba(10,14,26,.93);backdrop-filter:blur(20px);border-right:1px solid var(--bd);z-index:100;display:flex;flex-direction:column;transition:transform .3s ease;overflow-y:auto}
.sb-hd{padding:22px 18px 14px;border-bottom:1px solid var(--bd)}
.sb-brand{font-family:var(--fh);font-weight:800;font-size:1.2rem;background:linear-gradient(135deg,#e2e8f0,#c7d2fe,#a78bfa);-webkit-background-clip:text;-webkit-text-fill-color:transparent;background-clip:text;line-height:1.3}
.sb-tag{font-size:.68rem;color:var(--t3);margin-top:3px;letter-spacing:.5px;text-transform:uppercase}
.sb-srch{padding:10px 14px}
.sb-srch input{width:100%;padding:7px 11px;border-radius:8px;background:var(--sf);border:1px solid var(--bd);color:var(--t1);font-family:var(--fb);font-size:.84rem;outline:none;transition:var(--tr)}
.sb-srch input:focus{border-color:#6366f1;background:var(--sfh)}
.sb-srch input::placeholder{color:var(--t4)}
.sb-nav{flex:1;padding:2px 8px 20px;overflow-y:auto}
.ni{display:flex;align-items:center;gap:9px;padding:8px 11px;border-radius:8px;cursor:pointer;transition:var(--tr);font-size:.83rem;color:var(--t2);line-height:1.35;margin-bottom:1px;position:relative;user-select:none}
.ni:hover{background:var(--sfh);color:var(--t1)}
.ni.act{background:var(--sfa);color:var(--t1)}
.ni.act::before{content:'';position:absolute;left:0;top:50%;transform:translateY(-50%);width:3px;height:18px;border-radius:0 3px 3px 0}
.ndot{width:7px;height:7px;border-radius:50%;flex-shrink:0}

/* Main */
.mn{flex:1;margin-left:var(--sw);padding:28px 36px 60px;max-width:880px}

/* Mobile */
.mhd{display:none;position:fixed;top:0;left:0;right:0;z-index:90;background:rgba(10,14,26,.95);backdrop-filter:blur(16px);border-bottom:1px solid var(--bd);padding:11px 14px;align-items:center;gap:12px}
.hbg{background:none;border:none;color:var(--t1);cursor:pointer;padding:4px}
.hbg svg{width:24px;height:24px}
.ov{display:none;position:fixed;inset:0;background:rgba(0,0,0,.5);z-index:95}.ov.sh{display:block}
@media(max-width:768px){.mhd{display:flex}.sb{transform:translateX(-100%)}.sb.op{transform:translateX(0)}.mn{margin-left:0;padding:68px 14px 40px}}

/* Hero */
.hero{text-align:center;padding:70px 16px 50px}
.hero-t{font-family:var(--fh);font-weight:900;font-size:clamp(2rem,5vw,3rem);background:linear-gradient(135deg,#e2e8f0 0%,#c7d2fe 50%,#a78bfa 100%);-webkit-background-clip:text;-webkit-text-fill-color:transparent;background-clip:text;line-height:1.2;margin-bottom:10px}
.hero-s{color:var(--t2);font-size:1rem;max-width:480px;margin:0 auto 36px}
.tgrid{display:grid;grid-template-columns:repeat(auto-fill,minmax(250px,1fr));gap:14px}
.tc{background:var(--sf);border:1px solid var(--bd);border-radius:13px;padding:18px;cursor:pointer;transition:all .2s ease;position:relative;overflow:hidden}
.tc:hover{transform:translateY(-3px);border-color:var(--bdl)}
.tc-ac{height:3px;border-radius:3px;margin-bottom:12px;width:36px}
.tc h3{font-family:var(--fh);font-weight:700;font-size:1rem;margin-bottom:5px;line-height:1.3}
.tc-tags{display:flex;flex-wrap:wrap;gap:4px;margin-top:8px}
.tc-tag{font-size:.65rem;padding:2px 7px;border-radius:10px;background:var(--sf);color:var(--t3)}
.tc-dt{font-size:.65rem;color:var(--t4);margin-top:6px}

/* Topic Detail */
.td{animation:fi .25s ease}
@keyframes fi{from{opacity:0;transform:translateY(8px)}to{opacity:1;transform:none}}
.bk{display:inline-flex;align-items:center;gap:5px;padding:5px 12px;border-radius:7px;background:var(--sf);border:1px solid var(--bd);color:var(--t2);cursor:pointer;font-size:.8rem;font-family:var(--fb);transition:var(--tr);margin-bottom:18px}
.bk:hover{background:var(--sfh);color:var(--t1)}
.tt-bar{margin-bottom:24px}
.tt-bar h1{font-family:var(--fh);font-weight:800;font-size:clamp(1.5rem,4vw,2rem);line-height:1.25;margin-bottom:8px}
.tt-meta{display:flex;flex-wrap:wrap;gap:5px}
.tt-tag{font-size:.68rem;padding:2px 9px;border-radius:11px}

/* Tabs */
.stabs{display:flex;flex-wrap:wrap;gap:2px;margin-bottom:22px;border-bottom:1px solid var(--bd);padding-bottom:0}
.stab{padding:7px 13px;border:none;background:none;color:var(--t3);cursor:pointer;font-family:var(--fb);font-size:.78rem;font-weight:600;border-bottom:2px solid transparent;transition:var(--tr);white-space:nowrap}
.stab:hover{color:var(--t2)}.stab.act{color:var(--t1)}

/* Bullet lists */
.bl{list-style:none;padding:0}.bl li{padding:9px 0;border-bottom:1px solid var(--bd);font-size:.88rem;line-height:1.65;color:var(--t2)}
.bl li:last-child{border-bottom:none}.bl li strong,.bl li b{color:var(--t1);font-weight:600}

/* Sections with special styling */
.sec-panic{background:rgba(239,68,68,.05);border:1px solid rgba(239,68,68,.13);border-radius:11px;padding:18px}
.sec-panic .badge{display:inline-flex;align-items:center;gap:5px;padding:3px 10px;border-radius:7px;background:rgba(239,68,68,.13);color:#fca5a5;font-size:.72rem;font-weight:700;text-transform:uppercase;letter-spacing:.5px;margin-bottom:12px}
.sec-icu{background:rgba(245,158,11,.05);border:1px solid rgba(245,158,11,.11);border-radius:11px;padding:18px}
.sec-icu .badge{display:inline-flex;align-items:center;gap:5px;padding:3px 10px;border-radius:7px;background:rgba(245,158,11,.13);color:#fcd34d;font-size:.72rem;font-weight:700;text-transform:uppercase;letter-spacing:.5px;margin-bottom:12px}
.sec-ord{background:rgba(99,102,241,.04);border:1px solid rgba(99,102,241,.11);border-radius:11px;padding:18px}
.sec-ord .badge{display:inline-flex;align-items:center;gap:5px;padding:3px 10px;border-radius:7px;background:rgba(99,102,241,.13);color:#a5b4fc;font-size:.72rem;font-weight:700;text-transform:uppercase;letter-spacing:.5px;margin-bottom:12px}
.sec-cdi{background:rgba(20,184,166,.04);border:1px solid rgba(20,184,166,.11);border-radius:11px;padding:18px}
.sec-cdi .badge{display:inline-flex;align-items:center;gap:5px;padding:3px 10px;border-radius:7px;background:rgba(20,184,166,.13);color:#5eead4;font-size:.72rem;font-weight:700;text-transform:uppercase;letter-spacing:.5px;margin-bottom:12px}

/* Quiz */
.qc{background:var(--sf);border:1px solid var(--bd);border-radius:11px;padding:20px;margin-bottom:14px}
.ql{font-size:.7rem;font-weight:700;text-transform:uppercase;letter-spacing:1px;margin-bottom:10px}
.qs{font-size:.9rem;line-height:1.7;color:var(--t2);margin-bottom:14px}
.qopts{list-style:none;padding:0}
.qo{display:flex;align-items:flex-start;gap:9px;padding:9px 12px;border-radius:7px;cursor:pointer;transition:var(--tr);margin-bottom:5px;border:1px solid transparent;font-size:.86rem;color:var(--t2)}
.qo:hover{background:var(--sfh)}
.qo.sel{border-color:var(--bdl);background:var(--sfa)}
.qo.cor{border-color:#10b981;background:rgba(16,185,129,.1);color:#6ee7b7}
.qo.inc{border-color:#ef4444;background:rgba(239,68,68,.07);color:#fca5a5}
.qol{width:22px;height:22px;border-radius:50%;display:flex;align-items:center;justify-content:center;font-size:.72rem;font-weight:700;flex-shrink:0;background:var(--sf);border:1px solid var(--bd)}
.qo.cor .qol{background:rgba(16,185,129,.2);border-color:#10b981}
.qo.inc .qol{background:rgba(239,68,68,.13);border-color:#ef4444}
.qrb{display:inline-flex;padding:7px 16px;border-radius:7px;border:1px solid var(--bd);background:var(--sf);color:var(--t2);cursor:pointer;font-family:var(--fb);font-size:.8rem;font-weight:600;transition:var(--tr);margin-top:6px}
.qrb:hover{background:var(--sfh)}
.qex{margin-top:12px;padding:12px;border-radius:7px;background:rgba(16,185,129,.05);border:1px solid rgba(16,185,129,.11);font-size:.85rem;line-height:1.65;color:var(--t2)}

/* Flashcards */
.fc{background:var(--sf);border:1px solid var(--bd);border-radius:11px;padding:16px;margin-bottom:9px;cursor:pointer;transition:var(--tr)}
.fc:hover{border-color:var(--bdl)}
.fc-q{font-size:.88rem;color:var(--t1);font-weight:500}
.fc-a{margin-top:9px;padding-top:9px;border-top:1px solid var(--bd);font-size:.85rem;color:var(--t2);line-height:1.6}

/* References */
.ri{padding:7px 0;border-bottom:1px solid var(--bd)}.ri:last-child{border-bottom:none}
.ri a{color:#818cf8;text-decoration:none;font-size:.85rem;transition:var(--tr)}.ri a:hover{color:#a5b4fc;text-decoration:underline}

/* Stats */
.stats{display:flex;gap:18px;flex-wrap:wrap;margin-bottom:28px;padding:14px 18px;background:var(--sf);border-radius:11px;border:1px solid var(--bd)}
.stat{text-align:center}.stat-n{font-size:1.4rem;font-weight:700;font-family:var(--fh)}.stat-l{font-size:.68rem;color:var(--t3);text-transform:uppercase;letter-spacing:.5px}
</style>
</head>
<body>
<div id="root"></div>
<script type="text/babel">
const {useState,useMemo,useCallback,useEffect,useRef}=React;

const ACCENT=["#6366f1","#a855f7","#ec4899","#f97316","#14b8a6","#3b82f6","#8b5cf6","#ef4444","#10b981","#f59e0b"];
const TOPICS=[{"id": "01", "title": "Airway & Respiratory Failure (Non‑intubation Emphasis)", "tags": ["pulmonology", "respiratory-failure", "airway-management", "noninvasive-ventilation", "inpatient", "night-float"], "date": "2026-02-20", "panic_card": ["Apply oxygen targeting **SpO₂ 92–96%** (or **88–92% in chronic hypercapnia/COPD**) while monitoring **RR**, **mental status**, and **hemodynamics**; place patient upright.", "Start HFNC early for hypoxemic failure with high work of breathing: **40–60 L/min**, FiO₂ titrated to target; assess **ROX index** trends.", "Initiate NIV when indicated (e.g., COPD exacerbation with **pH ≤7.35** or cardiogenic edema): start **IPAP 10–15 cmH₂O / EPAP 5 cmH₂O**, titrate to **RR <25/min**, improved pH/PaCO₂.", "Treat underlying precipitants immediately: bronchodilators (albuterol/ipratropium), steroids for COPD/asthma, loop diuretics for pulmonary edema, broad‑spectrum antibiotics if severe pneumonia/sepsis; correct **MAP ≥65 mmHg** if shock.", "If deteriorating or contraindications to NIV/HFNC emerge (vomiting, inability to protect airway, facial trauma, refractory hypoxemia), prepare for definitive airway without delay; **Confirm Before Proceed** if giving neuromuscular blocker for RSI."], "brief_overview": ["Acute respiratory failure at night often benefits from non‑intubation strategies that reduce work of breathing and improve gas exchange while buying time for definitive therapy (diuretics, bronchodilators, antibiotics). Priorities: oxygenation targets, ventilatory support choice (HFNC vs NIV), rapid reassessment at defined intervals, and early escalation if objective thresholds are breached.", "**Guideline Must‑Know:** For COPD exacerbations with acute hypercapnic acidemia (**pH ≤7.35**, elevated PaCO₂), **NIV is first‑line** to reduce intubation and mortality; titrate IPAP/EPAP and reassess pH within **1–2 h** (GOLD 2024–25; ERS/ATS NIV 2017).", "**Guideline Must‑Know:** In cardiogenic pulmonary edema, **CPAP or BiPAP** reduces intubation and improves dyspnea rapidly; typical starting **CPAP 8–12 cmH₂O** or **BiPAP 10/5 cmH₂O**, alongside IV loop diuretics and afterload reduction when appropriate (ERS/ATS NIV 2017).", "**Guideline Must‑Know:** For acute hypoxemic respiratory failure, **HFNC** at **40–60 L/min** with FiO₂ to SaO₂ target improves comfort and may lower intubation rates vs conventional oxygen; track **ROX index = SpO₂/FiO₂ ÷ RR** at **2–12 h** (ERS HFNC 2022).", "**Guideline Must‑Know:** Use conservative oxygen targets: **SpO₂ 92–96%** generally; **88–92%** in chronic hypercapnia/COPD to avoid oxygen‑induced hypercapnia (GOLD 2024–25; BTS Oxygen 2017).", "**Guideline Must‑Know:** Severe pneumonia/sepsis with hypoxemia should receive timely antibiotics and source control; do not delay escalation to NIV/HFNC while antimicrobials are started; maintain **MAP ≥65 mmHg** if septic shock (Surviving Sepsis 2021/2023 updates; ATS/IDSA CAP 2019).", "**Guideline Must‑Know:** Objective NIV failure signals include **worsening acidosis**, **persistent RR >30/min**, **rising PaCO₂**, **SpO₂ <90% at FiO₂ ≥0.6**, or **intolerance/secretions**; escalate to intubation (ERS/ATS NIV 2017).", "What must happen now: position upright; set oxygen target; choose HFNC vs NIV based on failure phenotype (hypoxemic vs hypercapnic vs mixed); start disease‑specific therapy (bronchodilators, steroids, diuretics, antibiotics); place continuous pulse oximetry and frequent vitals; obtain ABG/VBG if hypercapnia suspected.", "What can wait 30–90 minutes: second‑line bronchodilators (magnesium sulfate **2 g IV** in severe asthma), broader diagnostics (procalcitonin, CT pulmonary angiography if stable), formal echocardiography after initial stabilization.", "HFNC pearls: Higher flows wash out anatomic dead space and provide small PEEP; ensure heated humidification to avoid mucosal dryness; use **ROX ≥4.88 at 12 h** as a favorable sign; trending matters more than one value.", "NIV selection: COPD/asthma with ventilatory failure → BiPAP; cardiogenic edema with shunt physiology → CPAP or BiPAP; set **IPAP to reduce PaCO₂ and RR** and **EPAP/CPAP to recruit alveoli**. Monitor for leaks, gastric distention, and pressure sores.", "Contraindications to NIV: **inability to protect airway**, **copious vomiting/aspiration risk**, **facial trauma/burns**, **severe agitation**, **hemodynamic instability refractory to initial support**, and **untreated pneumothorax**.", "Pitfalls: Excess oxygen in COPD can worsen hypercapnia; under‑titrated EPAP in cardiogenic edema fails to counter hydrostatic flooding; delayed escalation despite objective failure criteria increases risk. Avoid nebulizers that break mask seal—use inline setups when feasible.", "Call ICU early for: escalating FiO₂ needs (**≥0.6**), rising work of breathing with use of accessory muscles, **pH <7.25**, hemodynamic instability, or anticipated difficult airway. Early involvement reduces crash intubations.", "**Guideline Must‑Know:** For suspected pneumonia, follow ATS/IDSA 2019 severity criteria (e.g., **RR ≥30**, **SpO₂ ≤90%**, **multilobar infiltrates**) to guide level of care and antibiotics; noninvasive support does not replace timely antimicrobials.", "**Guideline Must‑Know:** In sepsis, avoid prolonged hypoxemia; prioritize **MAP ≥65 mmHg** with norepinephrine as first‑line vasopressor if needed; respiratory support choice should not delay antimicrobial therapy within **1 h** in shock (Surviving Sepsis 2021/2023).", "**Guideline Must‑Know:** Reassess within **30–60 min** after starting HFNC/NIV; if failing objective criteria, **do not delay** definitive airway. **Confirm Before Proceed** if considering paralytics for RSI after a failed NIV trial."], "icu_consult_triggers": ["Persistent or worsening hypoxemia: **SpO₂ <90%** despite **HFNC ≥50 L/min** with **FiO₂ ≥0.6** or NIV with **EPAP/CPAP ≥10 cmH₂O**.", "Hypercapnic acidosis: **pH <7.25** or **PaCO₂ rising** after **1–2 h** of optimized NIV settings.", "Escalating work of breathing/mental status decline (somnolence, agitation), or recurrent apnea.", "Hemodynamic instability or shock requiring vasopressors to maintain **MAP ≥65 mmHg**.", "Suspected contraindication to NIV (e.g., active emesis, facial trauma) or complications (barotrauma, pneumothorax)."], "orders_to_place_now": ["Order: High‑Flow Nasal Cannula — {flow_lpm: 40–60, fio2: titrate_to_spo2_target, heated_humidification: on, monitoring: continuous_pulse_ox}", "Order: Noninvasive Ventilation (BiPAP/CPAP) — {ipap_cmH2o: 10–15, epap_cpap_cmH2o: 5–10, backup_rate: per_protocol, interface: oronasal_full_face, escalation_criteria: defined}", "Order: Arterial or Venous Blood Gas — {timing: baseline_and_1–2h_after_NIV/HFNC, include_lactate: if_sepsis_suspected}", "Order: Bronchodilator Nebulization — {albuterol: 2.5–5_mg_q20min_x3_then_q2–4h, ipratropium: 0.5_mg_q6h, delivery: inline_if_on_NIV}", "Order: IV Corticosteroid (if COPD/asthma) — {methylprednisolone: 40–60_mg_iv, frequency: q6–12h, reassess: 24h}", "Order: Loop Diuretic (if pulmonary edema) — {furosemide: 40–80_mg_iv, target: net_negative_balance, monitoring: urine_output_bp_lytes}"], "abim_cases": [{"case_id": "01A", "stem": "A 68‑year‑old man with severe COPD presents with increasing dyspnea, somnolence, and wheezing. Vitals: T 37.0°C, HR 108, BP 152/86, RR 30, SpO₂ 90% on 6 L/min nasal cannula. VBG shows pH 7.28, PCO₂ 72 mmHg, HCO₃⁻ 33 mmol/L. Chest X‑ray shows hyperinflation without focal consolidation. After albuterol/ipratropium and IV methylprednisolone, he remains tachypneic and somnolent.", "options": ["Increase oxygen to maintain SpO₂ 100% and observe", "Start high‑flow nasal cannula at 50 L/min, FiO₂ 0.8", "Start noninvasive ventilation with IPAP 12 cmH₂O and EPAP 5 cmH₂O", "Proceed directly to endotracheal intubation", "Give IV morphine for dyspnea and continue nasal cannula"], "answer": "C", "explanation": "In acute hypercapnic respiratory failure from COPD with **pH ≤7.35** and elevated PaCO₂, **NIV is first‑line** and reduces intubation and mortality (GOLD 2024–25; ERS/ATS NIV 2017). Excess oxygen (A) risks worsening hypercapnia; HFNC (B) is less effective than NIV for ventilatory failure; immediate intubation (D) is reserved for NIV contraindication or failure; opioids (E) risk hypoventilation without addressing hypercapnia."}, {"case_id": "01B", "stem": "A 72‑year‑old woman with hypertensive cardiomyopathy presents with acute respiratory distress and frothy sputum. Vitals: RR 34, SpO₂ 86% on nonrebreather, BP 178/98, HR 122. You initiate BiPAP 12/6 cmH₂O and give IV furosemide. Ten minutes later she becomes nauseated with repeated emesis under the mask and increasing somnolence; SpO₂ fluctuates 84–88% despite FiO₂ 0.8.", "options": ["Continue BiPAP and add antiemetic; reassess in 1 hour", "Switch to standard nasal cannula to improve comfort", "Stop NIV and start HFNC at 60 L/min; avoid intubation", "Remove NIV and perform rapid sequence intubation with aspiration precautions", "Increase EPAP to 10 cmH₂O and observe"], "answer": "D", "explanation": "**Active emesis with inability to protect the airway is a contraindication to NIV** because of aspiration risk; escalation to **definitive airway** is indicated despite a general preference for non‑intubation strategies (ERS/ATS NIV 2017). Raising pressures (E) or waiting (A) increases risk; HFNC (C) does not address airway protection."}], "micro_questions": [{"q": "What SpO₂ range should you target in COPD with chronic hypercapnia?", "a": "**88–92%** to avoid oxygen‑induced hypercapnia while preventing hypoxemia."}, {"q": "After starting NIV for COPD, when should you repeat an ABG/VBG to assess response?", "a": "Within **1–2 hours** to confirm improving pH/PaCO₂ and work of breathing."}, {"q": "What ROX index threshold at 12 hours suggests HFNC success?", "a": "**ROX ≥4.88** supports continued HFNC with close monitoring of trends."}, {"q": "Name one absolute contraindication to NIV.", "a": "**Inability to protect airway** (e.g., active vomiting, decreased consciousness with aspiration risk)."}, {"q": "What is a typical initial BiPAP setting for COPD exacerbation?", "a": "**IPAP 10–15 cmH₂O / EPAP 5 cmH₂O**, titrated to reduce RR and PaCO₂."}], "references": [{"label": "ERS/ATS Clinical Practice Guideline: Noninvasive Ventilation for Acute Respiratory Failure (2017)", "url": "https://www.thoracic.org/statements/resources/cc/niv-guidelines.pdf"}, {"label": "ERS Clinical Practice Guideline: High‑Flow Nasal Cannula in Acute Respiratory Failure (2022)", "url": "https://erj.ersjournals.com/content/59/4/2101574"}, {"label": "Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report (2024–2025)", "url": "https://goldcopd.org"}, {"label": "ATS/IDSA Community‑Acquired Pneumonia Guideline (2019)", "url": "https://www.atsjournals.org/doi/10.1164/rccm.201908-1581ST"}, {"label": "Surviving Sepsis Campaign International Guidelines (2021 with updates)", "url": "https://journals.lww.com/ccmjournal/Fulltext/2021/11000/Surviving_Sepsis_Campaign_International_Guidelines.21.aspx"}], "cdi": ["Acute hypoxemic respiratory failure — due to {pneumonia vs cardiogenic pulmonary edema vs COPD/asthma}; severity {SpO₂, FiO₂/HFNC settings}; objective evidence {ABG/VBG, CXR findings}; treatment {HFNC/NIV, antibiotics/diuretics}.", "Acute on chronic hypercapnic respiratory failure (COPD) — due to {AECOPD}; severity {pH, PaCO₂}; objective evidence {VBG/ABG values}; treatment {BiPAP with settings, bronchodilators, steroids}.", "Cardiogenic pulmonary edema with acute respiratory failure — due to {decompensated HF/HTN emergency}; severity {RR, hypoxemia}; objective evidence {CXR edema, BNP, exam}; treatment {CPAP/BiPAP, IV diuretics, afterload reduction}.", "Aspiration risk with respiratory failure — due to {active emesis/reduced consciousness}; objective evidence {vomiting under mask, failed swallow}; treatment decision {NIV avoided or discontinued; definitive airway if needed}.", "Sepsis due to pneumonia with acute respiratory failure — severity {lactate, hypotension}; objective evidence {infiltrate + infection}; treatment {early antibiotics, oxygen strategy, **MAP ≥65 mmHg** if shock}."]}, {"id": "02", "title": "Alcohol Withdrawal & Agitation", "tags": ["addiction-medicine", "toxicology", "inpatient", "night-float"], "date": "2026-02-21", "panic_card": ["Protect airway, breathing, circulation; place on continuous pulse oximetry and telemetry; target **SpO₂ ≥92%**, **MAP ≥65 mmHg**; treat hypoglycemia immediately—do not delay dextrose while you give thiamine. citeturn2search16", "Give thiamine early for Wernicke risk: **thiamine 200–500 mg IV** (suspected WE) before or with glucose; for prophylaxis **100 mg IV/IM/PO** if lower risk. **Do not delay glucose in hypoglycemia.** citeturn2search2", "First‑line sedation: symptom‑triggered benzodiazepines (e.g., **diazepam 10 mg IV q5–10 min** or **lorazepam 2–4 mg IV q10–15 min** to control autonomic surge and tremor). Escalate promptly if **CIWA‑Ar ≥19**. citeturn2search1turn2search16turn2search64", "If refractory after adequate benzodiazepines or when on ventilatory support: consider **phenobarbital load 10–15 mg/kg** (cumulative) or **dexmedetomidine infusion 0.2–0.7 mcg/kg/h** as adjunct (not monotherapy). citeturn2search28turn2search25turn2search14", "Identify mimics/complications: sepsis, intracranial pathology, stimulant intoxication, hepatic encephalopathy, hypomagnesemia; correct electrolytes (Mg²⁺, K⁺, PO₄³⁻). citeturn2search1"], "brief_overview": ["Alcohol withdrawal typically begins **6–8 h** after last drink, peaks by **72 h**, and may last **5–7 d**; severe forms include seizures (12–48 h) and delirium tremens (48–96 h). **Guideline Must‑Know:** Expect earlier onset if BAC falling rapidly. citeturn2search16", "**Guideline Must‑Know:** Use **CIWA‑Ar** in communicative adults to titrate meds; severity: **mild <8–10**, **moderate 10–18**, **severe ≥19**. High scores predict seizures/DTs; monitor at least q1–4 h early. citeturn2search64", "**Guideline Must‑Know:** **Benzodiazepines are first‑line** for moderate–severe withdrawal; use symptom‑triggered strategies when 24/7 assessment is available; front‑load diazepam for rapid control if IV access and no severe hepatic impairment. citeturn2search1turn2search2", "Practical dosing: diazepam **10 mg IV** q5–10 min until light somnolence and vitals stabilize, or lorazepam **2–4 mg IV** q10–15 min (preferred in **severe liver disease/elderly** due to no active metabolites). citeturn2search16", "**Guideline Must‑Know:** In **benzodiazepine‑refractory AWS**, consider **phenobarbital** (e.g., **10–15 mg/kg** total load IV, divided) with ICU‑capable monitoring; avoid if heavy recent BZD exposure or suspected hepatic encephalopathy. citeturn2search28turn2search25", "**Guideline Must‑Know:** **Dexmedetomidine** may be used as an adjunct to control **tachycardia/hypertension/anxiety** when BZDs alone are insufficient; it **does not prevent seizures or DTs** and should **not be monotherapy**. citeturn2search14", "**Guideline Must‑Know:** For intubated patients already on **propofol** or **midazolam** infusions, additional AWS‑specific sedatives may be unnecessary while on those infusions; continue thiamine and transition to BZD/barbiturate strategy as sedation is weaned. citeturn2search27", "**Thiamine**: give **parenteral thiamine** to malnourished, decompensated liver disease, ED attendees, or inpatients with acute illness; for **suspected Wernicke’s**, give **high‑dose IV for ≥5 days**, then PO. **Do not delay emergent glucose**. citeturn2search2", "Adjuncts: **beta‑blockers** or **clonidine** can blunt autonomic surge but **must not replace BZDs**; avoid routine **magnesium prophylaxis** for AWS itself (treat documented deficiency). citeturn2search14", "Antipsychotics (e.g., **haloperidol**) may calm severe hallucinosis **after** adequate GABAergic therapy; in ICU delirium, routine antipsychotics show **no clear benefit**; 2025 SCCM update issues **conditional** recs prioritizing **dexmedetomidine** over propofol when light sedation and delirium reduction are priorities. citeturn2search23turn2search24", "**Guideline Must‑Know:** Evaluate for **co‑occurring SUDs** and initiate **AUD treatment** (naltrexone, acamprosate) when medically safe; link to services per **VA/DoD 2021 SUD CPG**. citeturn2search71", "**Guideline Must‑Know:** In **decompensated cirrhosis**, avoid long‑acting, hepatically metabolized BZDs (diazepam/chlordiazepoxide); use **lorazepam** or **oxazepam** with careful titration and close monitoring. citeturn2search2", "**Confirm Before Proceed:** Large **phenobarbital** loads after substantial recent BZD dosing increase risk of oversedation/respiratory depression—review last **8–12 h** BZD exposure before loading. citeturn2search28", "Pitfalls: undertreatment leading to escalating agitation; mistaking **sepsis, thyrotoxicosis, stimulant intoxication, or CNS lesions** for withdrawal; missing **electrolyte derangements** (Mg²⁺, K⁺, PO₄³⁻) that worsen arrhythmia/seizure risk. citeturn2search1", "**Guideline Must‑Know:** Consider **front‑loading** strategies to reduce total BZD dose and ICU transfers; symptom‑triggered regimens reduce cumulative sedative use and LOS when implemented correctly. citeturn2search1turn2search16", "**Guideline Must‑Know:** Use **CIWA‑Ar alternatives** (e.g., **mMINDS**) for non‑communicative or ICU patients; don’t rely on CIWA in intubated or delirious patients. citeturn2search64", "**Guideline Must‑Know:** Avoid **phenytoin** for AWS seizures; use **lorazepam** as rapid‑acting therapy and review the regimen. citeturn2search2", "Disposition: escalate to ICU for **refractory agitation, escalating sedative needs, respiratory compromise, or delirium tremens**; implement PADIS‑aligned light‑sedation strategies and early mobilization when safe. citeturn2search19turn2search23"], "icu_consult_triggers": ["Persistent **CIWA‑Ar ≥19** or need for **>40 mg diazepam equivalents within 1–2 h** to control symptoms. citeturn2search64turn2search16", "Recurrent seizures, evolving **delirium tremens**, or severe autonomic instability (**HR >120**, **SBP >180**, **T ≥38.5°C**) despite therapy. citeturn2search16", "Hypoventilation/aspiration risk, need for continuous infusions (dexmedetomidine/propofol) or **phenobarbital load ≥10 mg/kg** with close cardiorespiratory monitoring. citeturn2search25turn2search14"], "orders_to_place_now": ["Order: Alcohol withdrawal nursing protocol — {CIWA‑Ar q{1–4}h, seizure precautions, sitter if needed} citeturn2search64", "Order: Thiamine — {suspected WE: **500 mg IV q8h x 3–5 days**; high risk: **200 mg IV q8–12h**; prophylaxis: **100 mg IV/PO daily**} citeturn2search2", "Order: Benzodiazepine symptom‑triggered — {diazepam **10 mg IV** q5–10 min PRN or lorazepam **2–4 mg IV** q10–15 min PRN to CIWA <10 and calm, arousable state} citeturn2search1turn2search16", "Order: Phenobarbital load (refractory AWS) — {**10–15 mg/kg IV** in divided doses; hold if heavy recent BZD exposure; continuous monitoring} citeturn2search28turn2search25", "Order: Dexmedetomidine infusion (adjunct) — {start **0.2–0.7 mcg/kg/h**, titrate to light sedation; continue BZD for seizure prophylaxis} citeturn2search14", "Order: Lab bundle — {BMP/Mg/PO₄, CBC, LFTs, ethanol, TSH if unclear, ECG/telemetry; replete **Mg²⁺ ≥1.0 mmol/L**, **K⁺ ≥4.0 mmol/L**} citeturn2search1"], "abim_cases": [{"case_id": "02A", "stem": "A 52‑year‑old man with alcohol use disorder is 12 hours after his last drink. He is anxious, diaphoretic, and tremulous with HR 122/min, BP 168/92 mmHg, T 37.9°C. CIWA‑Ar is 21. No focal deficits. Labs: Na 138 mmol/L, K 3.6 mmol/L, Mg 0.58 mmol/L (1.4 mg/dL), glucose 6.3 mmol/L. He is not cirrhotic. Best next step?", "options": ["Start haloperidol 5 mg IV and observe", "Begin dexmedetomidine 0.4 mcg/kg/h infusion as monotherapy", "Give diazepam 10 mg IV now and repeat q5–10 min to symptom control", "Administer phenytoin 20 mg/kg IV for seizure prophylaxis", "Start chlordiazepoxide 50 mg PO scheduled q6h"], "answer": "C", "explanation": "Benzodiazepines are **first‑line** for moderate–severe alcohol withdrawal; in the ED/inpatient setting, IV **diazepam 10 mg** can be rapidly titrated to control autonomic hyperactivity and prevent progression. Dexmedetomidine is an **adjunct** only and does not prevent seizures; antipsychotics do not treat AWS and may lower seizure threshold; phenytoin is **not recommended** for AWS seizures; PO chlordiazepoxide is slower onset and less suitable when **CIWA‑Ar ≥19**. citeturn2search1turn2search14turn2search2"}, {"case_id": "02B", "stem": "A 58‑year‑old man with decompensated cirrhosis (ascites, INR 1.8, bilirubin 58 μmol/L) is 16 hours after last drink with agitation, tremor, and hallucinations. HR 118/min, BP 160/88 mmHg. CIWA‑Ar 20. Which initial medication strategy is best?", "options": ["Diazepam 10 mg IV q5–10 min to sedation", "Lorazepam 2–4 mg IV q10–15 min with careful titration", "Chlordiazepoxide 100 mg PO once, then q6h", "Phenobarbital 10 mg/kg IV load as monotherapy", "Haloperidol 5 mg IV q4h scheduled"], "answer": "B", "explanation": "In **decompensated liver disease**, choose intermediate/short‑acting BZDs without active metabolites (e.g., **lorazepam**) and titrate carefully; avoid diazepam/chlordiazepoxide due to hepatic accumulation. Phenobarbital may be used adjunctively in refractory cases but is not first‑line and poses oversedation risk in hepatic impairment—the **pitfall** is using long‑acting or barbiturate monotherapy in cirrhosis. Antipsychotics do not treat the underlying withdrawal. citeturn2search2turn2search1"}], "micro_questions": [{"q": "What **CIWA‑Ar** score defines severe withdrawal requiring aggressive therapy?", "a": "**≥19** indicates severe AWS and warrants rapid escalation and close monitoring. citeturn2search64"}, {"q": "What’s a typical **phenobarbital** cumulative loading target in refractory AWS?", "a": "**10–15 mg/kg IV** (ideal or actual body weight per protocol), given with continuous monitoring. citeturn2search25turn2search28"}, {"q": "Can **dexmedetomidine** replace benzodiazepines for AWS?", "a": "No; it is an **adjunct** for autonomic hyperactivity and anxiety and **does not** prevent seizures or DTs. citeturn2search14"}, {"q": "In suspected **Wernicke’s**, how long should parenteral thiamine be continued?", "a": "For a **minimum of 5 days**, then transition to oral therapy. citeturn2search2"}], "references": [{"label": "ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), PDF", "url": "https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf"}, {"label": "SCCM PADIS Guidelines—Pain, Agitation/Sedation, Delirium, Immobility, Sleep (2018), SCCM page", "url": "https://sccm.org/clinical-resources/guidelines/guidelines/guidelines-for-the-prevention-and-management-of-pa"}, {"label": "SCCM Focused Update to PADIS for Adult ICU (2025), SCCM page", "url": "https://www.sccm.org/clinical-resources/guidelines/guidelines/focused-update-padis-guideline"}, {"label": "VA/DoD Clinical Practice Guideline: Management of Substance Use Disorder (2021), main page", "url": "https://www.healthquality.va.gov/guidelines/MH/sud/"}, {"label": "NICE CG100: Alcohol‑use disorders—Diagnosis and management of physical complications (updated 2017), PDF", "url": "https://www.nice.org.uk/guidance/cg100/resources/alcoholuse-disorders-diagnosis-and-management-of-physical-complications-pdf-35109322251973"}], "cdi": ["Alcohol withdrawal syndrome: **acuity/severity** (e.g., severe with **CIWA‑Ar 22**, autonomic instability), **complicated vs uncomplicated**, **delirium tremens** if present; objective vitals/scores. citeturn2search64", "Etiology: **alcohol cessation/reduction** with last drink time; history of prior severe AWS/seizures/DTs; comorbid SUDs. citeturn2search1", "Organ dysfunction/risk: respiratory compromise, aspiration risk, electrolyte abnormalities (Mg²⁺/K⁺), hepatic impairment/cirrhosis. citeturn2search1", "Treatments supporting severity: **benzodiazepine doses/titration**, **phenobarbital load**, **dexmedetomidine infusion**, **thiamine IV dosing**, continuous monitoring/ICU transfer. citeturn2search25turn2search14turn2search2"]}, {"id": "03", "title": "Alcohol Withdrawal", "tags": ["addiction-medicine", "inpatient", "night-float"], "date": "2026-02-21", "panic_card": ["Ensure safety and airway: place patient on monitor, **SpO₂ ≥92%**, aspiration precautions, IV access; if severe agitation, use rapid‑acting benzodiazepine (e.g., **diazepam 10–20 mg IV q5–10 min** or **lorazepam 2–4 mg IV q15–20 min**) until calm but arousable.", "Give **thiamine 100–500 mg IV** before glucose if not hypoglycemic; if hypoglycemic, treat with **IV dextrose now**, then thiamine.", "Correct electrolytes early: target **K⁺ ≥4.0 mmol/L**, **Mg²⁺ ≥0.8–1.0 mmol/L (~2.0–2.4 mg/dL)**, **Phos ≥0.8 mmol/L**; recheck frequently.", "If refractory agitation or seizures despite escalating benzodiazepines, give **phenobarbital 130–260 mg IV** (repeat to effect; consider load up to **8–10 mg/kg** in monitored/ICU setting).", "Confirm Before Proceed: before large/stacked sedative doses or phenobarbital loading, confirm airway strategy, end‑tidal CO₂ if available, and exclude severe hepatic encephalopathy or mixed intoxication."], "brief_overview": ["Alcohol withdrawal (AWS) ranges from tremor/anxiety to seizures and delirium tremens (DTs); onset **6–24 h** after last drink, seizures typically **6–48 h**, DTs **48–96 h**. Night‑float priorities are rapid control of autonomic hyperactivity, seizure prevention, nutrition, and electrolyte repletion.", "**Guideline Must‑Know:** First‑line therapy is **benzodiazepines** (symptom‑triggered preferred when safely monitored) per **ASAM 2020**; front‑load diazepam for rapid CNS effect or use lorazepam if hepatic impairment.", "**Guideline Must‑Know:** Use structured assessments (e.g., **CIWA‑Ar**) when the patient can participate; for severe agitation/ICU or non‑verbal patients, use **RASS‑targeted** sedation or an ICU protocol (ASAM 2020; SCCM PADIS 2018).", "**Guideline Must‑Know:** High‑risk features prompting aggressive therapy/ICU consideration include **history of DTs or withdrawal seizures**, **CIWA‑Ar ≥15–20**, **need for continuous infusion**, or **refractory symptoms** despite adequate benzodiazepines (ASAM 2020).", "**Guideline Must‑Know:** For benzodiazepine‑refractory AWS, **phenobarbital** (boluses or load **8–10 mg/kg**) is evidence‑supported; **dexmedetomidine** may reduce autonomic hyperactivity as an **adjunct** but does **not** treat the underlying GABA/glutamate imbalance or prevent seizures (ASAM 2020; SCCM PADIS 2018).", "**Guideline Must‑Know:** Give **parenteral thiamine** to all with moderate–severe AWS or malnutrition; use **200–500 mg IV q8h for 2–3 days** if Wernicke risk, then daily (ASAM 2020).", "**Guideline Must‑Know:** Avoid **antipsychotic monotherapy**; if needed for hallucinations, use low‑dose haloperidol **2–5 mg** with concurrent benzodiazepine and **QTc monitoring**; antipsychotics lower seizure threshold (ASAM 2020).", "What must happen now: establish monitoring, start benzodiazepine protocol (symptom‑triggered if feasible), administer thiamine and fluids, replete **K/Mg/Phos**, obtain EKG and basic labs (BMP, Mg, Phos, glucose), and rule out mimics (sepsis, hypoglycemia, head injury, hypoxia, hepatic encephalopathy).", "What can wait: long‑term AUD pharmacotherapy (naltrexone/acamprosate), comprehensive counseling, and social work planning once the patient is clinically stable.", "Choose agent/dose: **Diazepam** 10–20 mg IV/PO q5–15 min to effect (long half‑life, fast onset); **Lorazepam** 2–4 mg IV/PO q15–20 min (preferred in cirrhosis/elderly due to glucuronidation); **Chlordiazepoxide** 25–50 mg PO for scheduled tapers if mild–moderate and reliable oral intake.", "Pitfalls: under‑dosing leading to escalation into DTs; stacking multiple sedatives without monitoring; missing **Wernicke encephalopathy** (ataxia, ophthalmoplegia, confusion) requiring high‑dose IV thiamine; masking withdrawal with antipsychotics alone; iatrogenic aspiration from oversedation.", "**Guideline Must‑Know:** Use **symptom‑triggered** protocols (e.g., CIWA‑Ar‑based) when staff can assess frequently; use **fixed‑dose with PRN** if assessments are unreliable (ASAM 2020).", "**Guideline Must‑Know:** **Seizure management** is benzodiazepines first; avoid phenytoin for AWS seizures unless a separate seizure disorder exists (ASAM 2020).", "**Guideline Must‑Know:** In ICU, consider **propofol** if intubated and refractory; target light sedation (**RASS 0 to −1**) while preventing recurrence of seizures (SCCM PADIS 2018).", "Electrolytes/nutrition: maintain **K⁺ ≥4.0**, **Mg²⁺ ≥0.8–1.0 mmol/L (~2.0–2.4 mg/dL)**, **Phos ≥0.8 mmol/L**; start multivitamin/folate; consider dextrose‑containing fluids if poor intake, but never delay urgent hypoglycemia treatment for thiamine.", "**Guideline Must‑Know:** Comorbidities modifying dosing: **cirrhosis, COPD/OSA, elderly, head injury, pregnancy**; in hepatic impairment, prefer lorazepam with careful titration; avoid phenobarbital loads if severe hepatic encephalopathy (ASAM 2020).", "Confirm Before Proceed: before initiating **dexmedetomidine** or **propofol**, ensure a benzodiazepine‑centered regimen is in place and airway/ICU monitoring available; these agents **do not** replace GABAergic therapy."], "icu_consult_triggers": ["Persistent severe agitation or autonomic instability despite **≥40–60 mg diazepam equivalents** or need for continuous infusion/adjuncts (dexmedetomidine/propofol).", "**Recurrent seizures**, status epilepticus, or need for airway protection/intubation.", "**CIWA‑Ar ≥20** with inability to safely assess or **RASS ≥+2** despite escalating therapy; hyperthermia **≥39°C**, profound tachycardia **≥140 bpm**, or hypertensive emergency.", "Suspected **Wernicke encephalopathy** or aspiration pneumonia with respiratory compromise; severe metabolic derangements (e.g., **Mg²⁺ <0.5 mmol/L**, **K⁺ <3.0 mmol/L**)."], "orders_to_place_now": ["Order: Symptom‑triggered benzodiazepine protocol — {agent=diazepam 10–20 mg IV q5–10 min PRN agitation or lorazepam 2–4 mg IV q15–20 min, target=calm but arousable (RASS 0 to −1), reassess=q15–30 min, max_total={institutional}}", "Order: CIWA‑Ar or RASS monitoring — {scale=CIWA‑Ar if cooperative; RASS if non‑verbal/ICU, frequency=q1h until controlled then q4h}", "Order: Thiamine and nutrition repletion — {thiamine=100 mg IV daily (prophylaxis) or 200–500 mg IV q8h x 2–3 days if Wernicke risk, folate=1 mg daily, multivitamin=standard, glucose_protocol=FS q4–6h}", "Order: Electrolyte repletion with targets — {K⁺ target=≥4.0 mmol/L, Mg²⁺ target=≥0.8–1.0 mmol/L, Phos target=≥0.8 mmol/L, labs=BMP/Mg/Phos now and q12–24h}", "Order: Phenobarbital rescue (if refractory) — {dose=130–260 mg IV bolus, repeat to effect, consideration=load up to 8–10 mg/kg in monitored/ICU setting, caution=hepatic encephalopathy/respiratory depression}", "Order: Safety and monitoring — {telemetry=yes, continuous pulse‑ox=yes, seizure precautions=yes, EKG=now, CXR if aspiration concern=yes}"], "abim_cases": [{"case_id": "03A", "stem": "A 52‑year‑old man with severe alcohol use disorder is admitted 12 hours after his last drink with tremor, diaphoresis, HR 120, BP 168/96, and anxiety. He is oriented and cooperative. CIWA‑Ar is 18. Labs show K⁺ 3.4 mmol/L, Mg²⁺ 0.6 mmol/L, glucose 98 mg/dL. What is the best next step?", "options": ["Start dexmedetomidine infusion and avoid benzodiazepines", "Start symptom‑triggered benzodiazepine therapy with diazepam 10–20 mg IV to effect and replete electrolytes", "Administer haloperidol 5 mg IV monotherapy for agitation", "Begin fixed‑schedule chlordiazepoxide 25 mg PO q6h without PRN doses", "Load levetiracetam 1,500 mg IV to prevent withdrawal seizures"], "answer": "B", "explanation": "ASAM 2020 recommends **benzodiazepines as first‑line**; symptom‑triggered therapy is preferred when monitoring is available, with diazepam front‑loading for rapid control, alongside **K/Mg repletion**. Dexmedetomidine is an **adjunct** for autonomic symptoms and not monotherapy, antipsychotics alone are contraindicated due to seizure risk, fixed schedules without PRNs risk under‑ or over‑sedation, and antiepileptics like levetiracetam do not prevent AWS seizures."}, {"case_id": "03B", "stem": "A 58‑year‑old man with alcohol‑related cirrhosis (bilirubin 4.2 mg/dL, INR 1.8) presents 24 hours after last drink with tremor, agitation, and BP 156/92. He is intermittently confused but arousable; ammonia is mildly elevated without asterixis. Which regimen is most appropriate initially?", "options": ["Diazepam 20 mg IV q5–10 min to large cumulative doses", "Lorazepam 2–4 mg IV q15–20 min to effect with close monitoring", "Phenobarbital 10 mg/kg load immediately on the ward", "Haloperidol 5 mg IV monotherapy for agitation", "Dexmedetomidine infusion to replace benzodiazepines"], "answer": "B", "explanation": "In hepatic impairment, **lorazepam** (glucuronidation) is preferred over diazepam (oxidative metabolism with active metabolites). Phenobarbital loading should be used cautiously and typically in monitored/ICU settings; antipsychotic monotherapy is unsafe; dexmedetomidine is adjunctive only. The pitfall is using diazepam or barbiturate loads in decompensated liver disease without monitoring."}], "micro_questions": [{"q": "What CIWA‑Ar threshold indicates severe withdrawal needing aggressive therapy?", "a": "**≥15–20** is commonly used for severe AWS requiring more intensive dosing/monitoring."}, {"q": "Preferred benzodiazepine in significant hepatic impairment?", "a": "**Lorazepam** due to glucuronidation and lack of active metabolites."}, {"q": "Does dexmedetomidine prevent withdrawal seizures?", "a": "No; it is an **adjunct** for autonomic hyperactivity and does not treat the underlying GABA/glutamate imbalance."}, {"q": "What thiamine dosing is recommended when Wernicke encephalopathy is suspected?", "a": "**200–500 mg IV q8h for 2–3 days**, then daily per ASAM guidance."}], "references": [{"label": "American Society of Addiction Medicine (ASAM). Clinical Practice Guideline on Alcohol Withdrawal Management. 2020", "url": ""}, {"label": "Society of Critical Care Medicine (SCCM) PADIS Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult ICU Patients. 2018", "url": ""}, {"label": "U.S. Department of Veterans Affairs/Department of Defense (VA/DoD). Clinical Practice Guideline for the Management of Substance Use Disorders. 2021", "url": ""}, {"label": "American Psychiatric Association. Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. 2018", "url": ""}], "cdi": ["Acute alcohol withdrawal with severity (mild/moderate/severe or DTs) due to chronic alcohol use—objective: HR/BP/Temp, **CIWA‑Ar score**, need for IV/ICU‑level sedatives—treatment: benzodiazepines (agent/doses), adjuncts.", "Alcohol withdrawal seizure(s)—timing relative to last drink, number/duration, response to benzodiazepines—no evidence of alternative seizure etiology if applicable.", "Suspected Wernicke encephalopathy—triad elements present/absent, malnutrition risk—parenteral thiamine dosing and route started.", "Electrolyte abnormalities (hypomagnesemia, hypokalemia, hypophosphatemia)—lowest values, replacements given, post‑repletion targets.", "Alcohol use disorder (severity per DSM‑5 if assessed)—readiness to change—plan for medications for AUD and follow‑up once medically stable."]}, {"id": "04", "title": "Altered Mental Status", "tags": ["neurology", "inpatient", "night-float", "emergencies", "delirium"], "date": "2026-02-21", "panic_card": ["Assess ABCs; secure airway if **GCS ≤8** or loss of protective reflexes; target **MAP ≥65 mmHg**; titrate O₂ to **SpO₂ 94–98%** (or **88–92%** if chronic hypercapnic risk).", "Check capillary glucose immediately; if **<3.0 mmol/L**, give **dextrose 25 g IV** and recheck; give **thiamine 100 mg IV** in malnutrition/alcohol use (do not delay glucose for thiamine).", "Suspected opioid toxicity: give **naloxone 0.04–0.4 mg IV**, titrate q2–3 min up to 2 mg; consider infusion if recurrent.", "Active seizure/status: **lorazepam 2 mg IV q1–2 min** up to 4–8 mg, then **levetiracetam 60 mg/kg (max 4500 mg)** or **fosphenytoin 20 mg PE/kg**; prepare for airway protection.", "Suspected sepsis: obtain cultures, give broad‑spectrum antibiotics within 1 h, start fluids and **norepinephrine** to **MAP ≥65 mmHg**; lactate and repeat assessment."], "brief_overview": ["Altered mental status (AMS) spans agitation, delirium, somnolence, and coma; prioritize reversible causes (hypoxia, hypoglycemia, opioids/sedatives, seizures, stroke, sepsis, electrolyte/acid‑base disorders, hepatic/uremic encephalopathy, Wernicke encephalopathy, CNS infection, trauma).", "**Guideline Must‑Know:** For suspected stroke with focal deficit/acute onset, obtain non‑contrast head CT rapidly; **IV thrombolysis ≤4.5 h** from last‑known‑well in eligible patients; evaluate for mechanical thrombectomy up to **24 h** in selected LVO patients.", "**Guideline Must‑Know:** Sepsis with AMS is organ dysfunction; initiate **antibiotics within 1 h**, **30 mL/kg** balanced crystalloids for hypotension or lactate ≥4, and **norepinephrine** as first‑line vasopressor to **MAP ≥65 mmHg**; reassess volume and perfusion frequently.", "**Guideline Must‑Know:** Status epilepticus requires benzodiazepines first (IM midazolam or IV lorazepam), then a second‑line antiseizure medication (fosphenytoin, valproate, or levetiracetam) if seizures persist; avoid treatment delays.", "**Guideline Must‑Know:** ICU delirium management emphasizes non‑pharmacologic measures (reorientation, sleep, mobilization), pain control, and light sedation; avoid benzodiazepines unless specifically indicated (e.g., alcohol withdrawal).", "**Guideline Must‑Know:** Alcohol withdrawal delirium presents with tremor, tachycardia, diaphoresis, agitation, hallucinations; treat with symptom‑triggered or front‑loaded benzodiazepines; add adjuncts (e.g., phenobarbital) per protocol if refractory; correct electrolytes and give **thiamine**.", "**Guideline Must‑Know:** In hyper‑ or hyponatremia causing AMS, limit **Na⁺ correction to ≤8–10 mmol/L per 24 h** (≤4–6 if high risk) to prevent osmotic demyelination or cerebral edema; for severe symptomatic hyponatremia (e.g., seizures), give **3% saline 100 mL IV bolus** and recheck sodium.", "What must happen now vs later: now—stabilize airway/breathing/circulation, glucose check/tx, antidotes (naloxone), seizure control, treat sepsis, obtain head CT if focal deficits/trauma/anticoagulation. Later—broad diagnostic panels, medication reconciliation, neurocognitive assessment, delirium prevention bundle, collateral history.", "Red flags demanding rapid escalation: new focal neurologic deficit, fever/hypotension, meningismus, head trauma/anticoagulation use, **GCS drop ≥2**, persistent hypoxemia/hypercapnia, refractory seizures, severe metabolic derangement (pH **<7.2**, K⁺ **≥6.0 mmol/L** with ECG changes).", "Pitfalls: missing hypoglycemia; over‑oxygenating hypercapnic COPD patients (worsening CO₂ narcosis—target **SpO₂ 88–92%**); giving haloperidol in prolonged QT; delaying antibiotics in sepsis; overlooking polypharmacy (anticholinergics, sedatives, baclofen, gabapentinoids); not checking **AMMONIA** in cirrhosis or **TSH** when indicated.", "Imaging: non‑contrast head CT first for bleed/mass; consider C‑spine imaging if trauma; MRI brain when CT non‑diagnostic and suspicion for stroke/encephalitis remains; lumbar puncture after imaging if meningitis/encephalitis suspected—start empiric antimicrobials promptly if high suspicion.", "Labs to send early: CBC, CMP (Na⁺/K⁺/Ca²⁺/Mg²⁺), VBG/ABG, lactate, osmolar gap if toxic alcohols suspected, ammonia, TSH, B12, troponin, UA/urine culture, blood cultures, ethanol, acetaminophen/salicylate levels, urine tox screen.", "Medication issues: hold/adjust CNS depressants and renally cleared drugs in AKI; consider baclofen toxicity in CKD; evaluate for serotonin syndrome (hyperreflexia/clonus) vs neuroleptic malignant syndrome (rigidity, hyperthermia) and treat accordingly.", "**Guideline Must‑Know:** For CAP‑related sepsis with AMS, follow ATS/IDSA CAP recommendations for empiric coverage based on severity and risk factors; de‑escalate with culture data and treat typical durations (often **5–7 days** if improving).", "**Guideline Must‑Know:** Transfusion for anemia‑related AMS is rarely emergent unless hemodynamically unstable or with active ischemia; most stable adults use **restrictive thresholds (Hb <7 g/dL)**—individualize to symptoms/ischemia.", "“Confirm Before Proceed” warnings: thrombolysis/anticoagulation reversal, hypertonic saline, lumbar puncture in coagulopathy, and aggressive Na⁺ correction; re‑verify last‑known‑well, anticoagulant use, and current labs before irreversible steps.", "When to call ICU/consults: airway compromise, shock, refractory seizures, deteriorating neuro status, suspected stroke (neurology) or ICH, fulminant hepatic failure (transplant/hepatology), meningitis/encephalitis (ID), toxicology for complex overdoses."], "icu_consult_triggers": ["**GCS ≤8**, persistent airway compromise, or escalating oxygen/ventilation support (need for NIV or intubation).", "Refractory seizures or **status epilepticus ≥5 min** despite first‑line therapy.", "Septic shock requiring **norepinephrine ≥0.1–0.2 μg/kg/min** or lactate rising despite resuscitation.", "Rapidly evolving focal deficit or suspected large‑vessel stroke candidate for thrombectomy.", "Severe metabolic derangement: pH **<7.2**, K⁺ **≥6.0 mmol/L** with ECG changes, or Na⁺ **<120**/**>160 mmol/L** with symptoms."], "orders_to_place_now": ["Order: Point‑of‑care glucose — {now}", "Order: Airway management — {O₂ device; target SpO₂ {88–92% if hypercapnic risk, else 94–98%}; EtCO₂ if available}", "Order: Naloxone IV — {0.04–0.4 mg IV; repeat q2–3 min to desired effect; consider infusion if recurrent}", "Order: Lorazepam IV for seizure — {2 mg IV q1–2 min up to 4–8 mg}", "Order: Non‑contrast head CT — {stat for focal deficit/trauma/anticoagulation/new severe headache}", "Order: Broad labs & cultures — {CBC, CMP, Mg²⁺/PO₄³⁻, VBG/ABG, lactate, ammonia, TSH, B12, ethanol, acetaminophen/salicylate, urine tox, UA/urine culture, blood cultures}"], "abim_cases": [{"case_id": "04A", "stem": "A 62‑year‑old man with poorly controlled epilepsy is brought from the ward for unresponsiveness and tonic–clonic movements lasting 6 minutes. Vitals: BP 148/86, HR 112, RR 20, SpO₂ 95% on nasal cannula. He received no medications yet. Bedside glucose is 6.0 mmol/L. Neurologic exam shows ongoing generalized convulsions.", "options": ["Administer IV dextrose 25 g immediately", "Administer IV lorazepam 2 mg, repeat as needed, then load IV levetiracetam 60 mg/kg", "Intubate now and start propofol infusion without benzodiazepines", "Give IV phenytoin 10 mg/kg as initial therapy", "Obtain urgent MRI brain before treatment"], "answer": "B", "explanation": "Convulsive status epilepticus requires immediate benzodiazepines (e.g., **lorazepam 2 mg IV**, repeat) followed by a second‑line antiseizure medication such as **levetiracetam 60 mg/kg** if seizures persist; delaying therapy worsens outcomes. MRI should not precede stabilization; phenytoin/fosphenytoin, valproate, or levetiracetam are appropriate second‑line agents, but benzodiazepines come first per the guideline algorithm."}, {"case_id": "04B", "stem": "A 74‑year‑old woman with atrial fibrillation on apixaban (last dose 3 hours ago) develops acute right‑sided weakness and aphasia 45 minutes after last‑known‑well. BP 168/92, glucose 7.2 mmol/L. Non‑contrast CT head shows no hemorrhage.", "options": ["Administer IV alteplase now", "Withhold IV thrombolysis; urgently evaluate for mechanical thrombectomy and consult neurology", "Lower BP to <140/90 before any other intervention", "Give full‑dose IV heparin infusion immediately", "Delay all therapy pending MRI brain", "Guidelines for the Early Management of Patients With Acute Ischemic Stroke (2019 Update). https://professional.heart.org/en/guidelines-statements/guidelines-for-the-early-management-of-patients-with-acute-ischemic-stroke-2019101161str0000000000  \n- Surviving Sepsis Campaign. International Guidelines for Management of Sepsis and Septic Shock (2021). https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-guidelines-2021  \n- American Epilepsy Society. Treatment of Convulsive Status Epilepticus in Children and Adults (2016). https://www.aesnet.org/clinical-care/clinical-guidance/guideline-prolonged-seizures  \n- SCCM PADIS Guidelines: Pain, Agitation/Sedation, Delirium, Immobility, Sleep (2018). https://sccm.org/clinical-resources/guidelines/guidelines/guidelines-for-the-prevention-and-management-of-pa  \n- ASAM. Clinical Practice Guideline on Alcohol Withdrawal Management (2020). https://www.asam.org/quality-care/clinical-guidelines/alcohol-withdrawal-management-guideline"], "answer": "B", "explanation": "Recent factor‑Xa inhibitor use is a contraindication to IV thrombolysis unless specific reversal/lab criteria are met; giving alteplase here risks major bleeding—the pitfall is missing anticoagulant exposure. Proceed with rapid large‑vessel occlusion evaluation for endovascular therapy if eligible; manage blood pressure per stroke protocols."}], "micro_questions": [{"q": "What is the safe daily limit for sodium correction in symptomatic dysnatremia?", "a": "**≤8–10 mmol/L in 24 h** (use **≤4–6** if high risk: alcoholism, malnutrition, advanced liver disease, hypokalemia)."}, {"q": "After benzodiazepines, what is an effective second‑line loading dose of levetiracetam for status epilepticus?", "a": "**60 mg/kg IV** (maximum **4500 mg**), infused over 10–15 minutes."}, {"q": "What **MAP** target should be maintained in septic shock?", "a": "**MAP ≥65 mmHg**, titrating norepinephrine as first‑line vasopressor and reassessing perfusion."}, {"q": "What oxygen saturation target minimizes CO₂ retention risk in chronic hypercapnic COPD?", "a": "**SpO₂ 88–92%**, with ABG/VBG monitoring if worsening mental status."}, {"q": "What is the IV thrombolysis window for acute ischemic stroke and extended window for thrombectomy?", "a": "**≤4.5 h** for IV thrombolysis in eligible patients; **≤24 h** for mechanical thrombectomy in selected LVO cases."}], "references": [{"label": "AHA/ASA. Guidelines for the Early Management of Patients With Acute Ischemic Stroke (2019 Update)", "url": "https://professional.heart.org/en/guidelines-statements/guidelines-for-the-early-management-of-patients-with-acute-ischemic-stroke-2019101161str0000000000"}, {"label": "Surviving Sepsis Campaign. International Guidelines for Management of Sepsis and Septic Shock (2021)", "url": "https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-guidelines-2021"}, {"label": "American Epilepsy Society. Treatment of Convulsive Status Epilepticus in Children and Adults (2016)", "url": "https://www.aesnet.org/clinical-care/clinical-guidance/guideline-prolonged-seizures"}, {"label": "SCCM PADIS Guidelines: Pain, Agitation/Sedation, Delirium, Immobility, Sleep (2018)", "url": "https://sccm.org/clinical-resources/guidelines/guidelines/guidelines-for-the-prevention-and-management-of-pa"}, {"label": "ASAM. Clinical Practice Guideline on Alcohol Withdrawal Management (2020)", "url": "https://www.asam.org/quality-care/clinical-guidelines/alcohol-withdrawal-management-guideline"}], "cdi": ["Acute metabolic encephalopathy — etiology {sepsis/hypoxia/hypercapnia/hyper‑ or hyponatremia/hepatic/uremic/toxic}; severity; objective evidence (GCS, ABG, Na⁺, ammonia, lactate, imaging); treatment/monitoring provided.", "Delirium (specify hyperactive/hypoactive/mixed) — precipitant(s) {infection, medications, withdrawal, metabolic}; objective findings (CAM‑ICU/4AT, vitals); safety risks; non‑pharm bundle and meds used/avoided.", "Toxic encephalopathy due to {drug/toxin} — exposure history, serum levels if available, ECG/QT, antidotes (e.g., naloxone) and response.", "Suspected acute ischemic stroke — last‑known‑well time, NIHSS, imaging results, anticoagulant use, thrombolysis/thrombectomy eligibility decisions with reasons (“Confirm Before Proceed” applied).", "Sepsis with acute organ dysfunction (encephalopathy) — source, qSOFA/SOFA elements, lactate, cultures, antibiotics/timing, fluids/pressors, response to therapy."]}, {"id": "05", "title": "Anaphylaxis", "tags": ["allergy-immunology", "inpatient", "night-float", "emergency", "resuscitation"], "date": "2026-02-21", "panic_card": ["Give epinephrine IM to mid‑anterolateral thigh now: **0.3–0.5 mg (1 mg/mL)**; repeat every **5–15 min** as needed. Keep patient **supine with legs elevated**; apply **high‑flow O₂**. Call for help and bring airway cart. citeturn2search13turn2search24", "Establish 2 large‑bore IVs; rapid isotonic crystalloids **1–2 L**; target **MAP ≥65 mmHg**. citeturn2search7", "If airway compromise (stridor/voice change/lingual or laryngeal edema), call anesthesia/ENT early and prepare for **difficult airway**; avoid sitting upright if hypotensive. citeturn2search24", "Refractory hypotension despite IM epinephrine and fluids: start **epinephrine infusion** (titrate to **MAP ≥65 mmHg**) and consider **glucagon 1–5 mg IV over 5 min, then 5–15 µg/min** if on β‑blocker. citeturn2search24turn2search32", "Confirm Before Proceed: use **pump‑driven epinephrine infusion with correct concentration**; avoid IV epinephrine bolus outside cardiac arrest/experienced hands to prevent dosing error. citeturn2search24"], "brief_overview": ["Anaphylaxis is a rapidly evolving, multi‑system emergency; **IM epinephrine is first‑line and time‑critical**, and treatment should not wait for diagnostic certainty. Night‑float priorities are airway, breathing, circulation, and immediate IM dosing with repeat assessment every 5–15 minutes. citeturn2search13", "**Guideline Must‑Know:** Adult IM dose **0.3–0.5 mg (1 mg/mL)** to the lateral thigh, repeat every **5–15 min** until improved; do not substitute antihistamines or steroids for epinephrine. citeturn2search13turn2search18", "**Guideline Must‑Know:** Positioning matters—keep the patient **supine with legs elevated** (or left lateral in late pregnancy) to reduce sudden circulatory collapse; provide high‑flow oxygen and continuous monitoring. citeturn2search24", "**What must happen now:** Remove/stop the trigger (e.g., antibiotic/IV contrast), give IM epinephrine, start O₂, secure IV access, give **1–2 L** isotonic fluids rapidly if hypotensive, and call for senior help/anesthesia early for voice change/stridor. **What can wait:** adjunct H1/H2 blockers, corticosteroids, root‑cause workup. citeturn2search7turn2search24", "**Guideline Must‑Know:** For **refractory shock**, start **epinephrine infusion** (use pump; avoid IV bolus) and titrate to **MAP ≥65 mmHg**; large fluid volumes may be required due to profound vasodilation and capillary leak. citeturn2search24turn2search7", "**Guideline Must‑Know:** If on **β‑blockers** and not responding, give **glucagon 1–5 mg IV over 5 min**, then **5–15 µg/min** infusion (watch for nausea/vomiting). citeturn2search32", "Bronchospasm: add **nebulized β‑agonist (albuterol)**; consider nebulized epinephrine for laryngeal edema while preparing a definitive airway—these are **adjuncts**, not substitutes for IM epinephrine. citeturn2search24", "**Confirm Before Proceed:** Double‑check **epinephrine concentration and route** (1 mg/mL IM vs 0.1 mg/mL IV infusion) to prevent **10–100×** dosing errors. citeturn2search24", "**Guideline Must‑Know:** Draw **serum tryptase** as soon as feasible **within 1–3 h of symptom onset**, and a **baseline at 24–48 h**; apply the **20% + 2 ng/L rule** to support mast‑cell activation and consider mast‑cell disorders when baseline is elevated. citeturn2search2turn2search4", "**Guideline Must‑Know:** Observation: low‑risk patients who respond promptly may be observed **≥2–6 h**; higher‑risk (severe presentation, multiple epinephrine doses, hypotension, airway involvement) often require **≥6–12 h** or admission due to **biphasic risk**. citeturn2search24", "Common inpatient triggers: antibiotics, perioperative agents (neuromuscular blockers, chlorhexidine, latex), radiocontrast, blood products, biologics; document precisely and refer for allergy evaluation after stabilization. citeturn2search7", "**Guideline Must‑Know:** Do **not** delay epinephrine while applying formal diagnostic criteria; meeting criteria is **not required** before giving epinephrine. citeturn2search16", "Antihistamines (H1±H2) can reduce cutaneous symptoms; **corticosteroids do not treat acute life‑threatening features** and should never replace epinephrine; they may be used as adjuncts per clinician judgment. citeturn2search18", "**Guideline Must‑Know:** Early **anesthesia/ICU** involvement for progressive airway edema, stridor, fatigue, or refractory hypotension; prepare for a **difficult airway** and **early intubation** if voice changes/stridor evolve. citeturn2search24", "**Pitfalls:** Attributing hypotension/wheeze to other causes (e.g., sepsis, COPD) and **withholding epinephrine**; giving IV bolus epinephrine; sitting the hypotensive patient upright; missing biphasic deterioration after early discharge. citeturn2search24", "**Guideline Must‑Know:** After stabilization, ensure **discharge planning** (if appropriate) includes education, trigger avoidance plan, and epinephrine auto‑injector prescribing/training with documented allergy follow‑up. citeturn2search18"], "icu_consult_triggers": ["Need for **epinephrine infusion** or persistent hypotension despite ≥2 IM doses and adequate fluids. citeturn2search24", "Stridor, voice change, tongue/laryngeal edema, or anticipated **difficult airway**. citeturn2search24", "Recurrent/worsening symptoms during observation (suspected **biphasic** reaction) or need for prolonged monitoring due to comorbidities (CAD, severe asthma, pregnancy). citeturn2search24", "Suspected peri‑operative anaphylaxis or high‑risk triggers (e.g., neuromuscular blockers, chlorhexidine) requiring specialty evaluation. citeturn2search7"], "orders_to_place_now": ["Order: Epinephrine IM (1 mg/mL) — {dose: 0.3–0.5 mg IM to lateral thigh; frequency: q5–15 min PRN; start now} citeturn2search13", "Order: Oxygen therapy — {delivery: non‑rebreather; flow: 10–15 L/min; target: SpO₂ ≥94%} citeturn2search24", "Order: IV crystalloids — {type: lactated Ringer’s or normal saline; bolus: 1–2 L rapid; goal: MAP ≥65 mmHg} citeturn2search7", "Order: Epinephrine infusion — {start: pump infusion; initial rate: low‑dose titration; goal: MAP ≥65 mmHg; avoid IV bolus} citeturn2search24", "Order: Glucagon IV — {indication: refractory anaphylaxis on β‑blocker; bolus: 1–5 mg over 5 min; infusion: 5–15 µg/min; monitoring: N/V, glucose} citeturn2search32", "Order: Serum tryptase — {timing: as soon as feasible within 1–3 h of onset; baseline: 24–48 h after recovery} citeturn2search2"], "abim_cases": [{"case_id": "05A", "stem": "A 58‑year‑old inpatient develops generalized urticaria, hoarseness, wheeze, and systolic BP 82 mmHg five minutes after starting IV cefazolin. He is tachycardic and anxious. IV access is in place.", "options": ["Administer intramuscular epinephrine 0.5 mg now to the lateral thigh and place the patient supine", "Give IV diphenhydramine 50 mg and observe for response", "Start methylprednisolone 125 mg IV and obtain a stat tryptase level before any other therapy", "Begin norepinephrine infusion and avoid epinephrine due to CAD risk", "Intubate now without medications and reassess before giving epinephrine"], "answer": "A", "explanation": "**IM epinephrine is first‑line and should be given immediately** for suspected anaphylaxis with airway and circulatory involvement; positioning and oxygen are concurrent priorities. Antihistamines and corticosteroids are adjuncts only and **must not delay epinephrine**. IV pressors may be needed later if refractory after IM epinephrine and fluids. citeturn2search13turn2search24"}, {"case_id": "05B", "stem": "A 72‑year‑old with atrial fibrillation on metoprolol develops hypotension (SBP 72 mmHg), diffuse hives, and wheeze after vancomycin. He received two appropriate IM epinephrine doses and 1.5 L isotonic fluid with minimal improvement. He is alert, with persistent bronchospasm.", "options": ["Administer an IV epinephrine bolus", "Start an epinephrine infusion and add glucagon 1–5 mg IV over 5 min, then 5–15 µg/min", "Give methylprednisolone 125 mg IV and observe", "Start diphenhydramine 50 mg IV and albuterol; avoid further adrenergics due to β‑blocker", "Begin vasopressin infusion and avoid epinephrine due to β‑blocker"], "answer": "B", "explanation": "Refractory anaphylaxis in patients on **β‑blockers** may improve with **glucagon** (bypasses β‑receptors) along with **epinephrine infusion** titrated to MAP goals. Avoid IV epinephrine **bolus** due to dosing error/arrhythmia risk—the pitfall is undertreating epinephrine‑refractory shock without adding glucagon when β‑blockade is present. citeturn2search24turn2search32"}], "micro_questions": [{"q": "Adult IM epinephrine dose and route for anaphylaxis?", "a": "**0.3–0.5 mg (1 mg/mL) IM** into the lateral thigh; may repeat every **5–15 min**. citeturn2search13"}, {"q": "Timing for serum tryptase collection after onset?", "a": "As soon as feasible **within 1–3 h** of onset, with a **baseline at 24–48 h** to apply the 20% + 2 ng/L rule. citeturn2search2"}, {"q": "Minimum observation window after severe reaction or need for multiple epinephrine doses?", "a": "At least **6–12 h** (longer if airway involvement, hypotension, or comorbid risk). citeturn2search24"}, {"q": "Target MAP for resuscitation in anaphylactic shock?", "a": "**MAP ≥65 mmHg**. citeturn2search24"}], "references": [{"label": "AAAAI/ACAAI Joint Task Force Practice Parameter (2023) — citeturn2search13", "url": ""}, {"label": "World Allergy Organization (2020) — citeturn2search7", "url": ""}, {"label": "EAACI (2021 update; Allergy 2022) — citeturn2search18", "url": ""}, {"label": "Resuscitation Council UK (2021) — citeturn2search24", "url": ""}, {"label": "NICE CG134 (updated 2021) — citeturn2search26", "url": ""}], "cdi": ["Anaphylaxis, acute—trigger suspected {drug/food/latex/contrast/unknown}; systems involved {airway, respiratory, cardiovascular, skin/GI}; severity {hypotension present/absent; airway edema present/absent}.", "Objective evidence: lowest BP/HR, **SpO₂**, wheeze/stridor, edema findings; treatments given (IM epinephrine doses ×{n}, fluids {L}, epinephrine infusion start/stop, adjuncts).", "Shock due to anaphylaxis (if applicable)—MAP nadir, lactate, total fluids, vasopressor/infusion requirements, response to therapy.", "Complications/risk: β‑blocker use, asthma/COPD, pregnancy, CAD; monitoring level (telemetry/ICU), observation duration; biphasic symptoms yes/no.", "Disposition plan: allergy referral, trigger avoidance counseling, auto‑injector education/order, updated allergy list with exact agent and reaction."]}, {"id": "06", "title": "Antibiotic Stewardship at Night", "tags": ["inpatient", "night-float", "stewardship", "infectious-diseases"], "date": "2026-02-21", "panic_card": ["If septic shock, give first effective empiric antibiotic within **1 h** while initiating fluids and vasopressors to **MAP ≥65 mmHg**; obtain cultures first only if this will not delay antibiotics. citeturn2search44turn2search47", "Verify true allergy history before broadening or desensitizing; if anaphylaxis risk is unclear, choose a non–cross-reactive agent and reassess urgently.", "Dose right the first time: weight- and renal-adjusted loading doses (e.g., vancomycin AUC-based targeting **AUC/MIC 400–600**). citeturn2search26turn2search29", "Send source-appropriate cultures (two sets blood; targeted site) and begin source control planning; reassess at **48–72 h** for de‑escalation/stop. citeturn2search56", "Confirm Before Proceed: do not initiate long-acting/irreversible steps (e.g., desensitization) without verifying indication, allergy details, and necessity."], "brief_overview": ["Night stewardship priorities: distinguish time‑critical sepsis from non‑severe infection, start appropriate empiric therapy promptly in shock, and otherwise avoid unnecessary or overly broad antibiotics; reassess daily for de‑escalation. citeturn2search44", "**Guideline Must‑Know:** Surviving Sepsis 2021 recommends antimicrobials within **1 h** for septic shock, with early cultures and daily de‑escalation; avoid routine double gram‑negative coverage unless high risk. citeturn2search44", "**Guideline Must‑Know:** IDSA/SHEA 2016 stewardship guideline endorses prospective audit/feedback, preauthorization, IV‑to‑PO conversion, and optimized dose/duration as core inpatient tactics. citeturn2search7turn2search11", "**Guideline Must‑Know:** CDC Core Elements (2019 update) frame night actions: clear accountability, indication + stop date on every order, and routine reporting/tracking of use and resistance. citeturn2search17turn2search14", "Obtain **blood cultures ×2** before antibiotics if feasible; send targeted site cultures (urine only if urinary symptoms or catheter change) to guide day‑2 narrowing. citeturn2search56turn2search1", "**Guideline Must‑Know:** Avoid treating **asymptomatic bacteriuria** except pregnancy or invasive urologic procedures; delirium or falls alone are not UTI unless genitourinary/localizing signs or systemic instability. citeturn2search1turn2search6", "Use MRSA nasal PCR in pneumonia to **de‑escalate anti‑MRSA therapy** when negative (high NPV ≈95–97%), recognizing limited PPV; avoid use to “rule in.” citeturn2search52turn2search51", "**Guideline Must‑Know:** ATS/IDSA 2019 CAP supports 5‑day minimum therapy once clinically stable; abandon HCAP label; tailor diagnostics and de‑escalate based on risks and cultures. citeturn2search21", "**Guideline Must‑Know:** HAP/VAP 2016 recommends **~7‑day** total therapy with daily de‑escalation; obtain noninvasive respiratory samples and avoid routine prolonged courses. citeturn2search56", "For suspected ESBL/**AMR** infections, avoid piperacillin‑tazobactam for ESBL‑E bacteremia/pyelonephritis; prefer carbapenem or guideline‑preferred agents, then step down when susceptibilities allow. citeturn2search38turn2search42", "**Guideline Must‑Know:** Vancomycin—target **AUC/MIC 400–600** to reduce nephrotoxicity vs trough‑only strategies; leverage pharmacy services for Bayesian/AUC dosing overnight. citeturn2search26turn2search29", "Document indication and **planned duration** for every antibiotic order (e.g., CAP 5 days if stable; cUTI 7–10 depending on source and agent). This supports automatic stop and next‑day review. citeturn2search21", "Consider **IV‑to‑PO** switch once hemodynamically stable, afebrile/improving, able to absorb PO, and with an available high‑bioavailability option (e.g., levofloxacin, linezolid); aligns with stewardship core elements and CAP practice. citeturn2search14turn2search21", "**Guideline Must‑Know:** Test for **C. difficile** only with **≥3 unformed stools/24 h** and no laxatives in prior 48 h; treat with fidaxomicin preferred for initial/recurrent episodes per 2021 focused update. citeturn2search35turn2search32", "**Guideline Must‑Know:** De‑label false β‑lactam “allergies” when history is inconsistent; penicillin allergy evaluation improves access to first‑line therapy per stewardship best practices. citeturn2search7", "Overnight pitfalls: anchoring on a positive UA without symptoms (ASB), continuing vancomycin after negative MRSA nares, double covering gram‑negatives without an indication, and skipping stop dates—all escalate harm (AKI, CDI, resistance) without benefit. citeturn2search52turn2search56turn2search32"], "icu_consult_triggers": ["Septic shock needing vasopressors to maintain **MAP ≥65 mmHg**, lactate **≥4 mmol/L**, or rapidly rising lactate despite fluids. citeturn2search44", "Escalating O₂/ventilatory support, concern for necrotizing/complicated infection (e.g., empyema), or hemodynamic instability after antibiotics. citeturn2search56", "AMR isolate (ESBL/CRE/DTR Pseudomonas/CRAB) or persistent bacteremia **>48–72 h** despite appropriate therapy—contact ID early. citeturn2search38"], "orders_to_place_now": ["Order: Blood cultures — {2 sets, separate sites, before first antibiotic if no delay} citeturn2search56", "Order: MRSA nares PCR — {now; pneumonia de‑escalation if negative} citeturn2search52turn2search51", "Order: Empiric antibiotic — {indication, agent, dose, route, interval, weight, CrCl, “stop after {X} days if stable”} citeturn2search14", "Order: Pharmacy to dose vancomycin (AUC‑guided) — {weight, SCr, target **AUC/MIC 400–600**} citeturn2search26", "Order: C. difficile NAAT + toxin algorithm — {only if ≥3 unformed stools/24 h and no laxatives 48 h} citeturn2search35", "Order: IV‑to‑PO switch assessment — {agent options, criteria: stable vitals, PO tolerance, improving labs} citeturn2search14turn2search21"], "abim_cases": [{"case_id": "06A", "stem": "A 68‑year‑old man admitted with community‑acquired pneumonia received ceftriaxone, azithromycin, and vancomycin. He is afebrile on day 2, oxygen needs down, and a **MRSA nares PCR is negative**. Sputum culture is non‑diagnostic. Vitals are stable; creatinine is rising slightly.", "options": ["Continue all antibiotics for 7 days", "Stop azithromycin; continue ceftriaxone and vancomycin", "Stop vancomycin; continue ceftriaxone ± azithromycin to complete 5 days if stable", "Switch vancomycin to linezolid and continue dual therapy", "Stop all antibiotics today"], "answer": "C", "explanation": "Negative MRSA nasal PCR has a high negative predictive value for MRSA pneumonia, supporting **de‑escalation off anti‑MRSA therapy** when clinical risk is low and the patient is improving; continuing ceftriaxone ± azithromycin to a **5‑day** total if stable aligns with ATS/IDSA CAP guidance. citeturn2search52turn2search21\nDe‑escalation reduces nephrotoxicity risk (vancomycin) without compromising outcomes. citeturn2search26"}, {"case_id": "06B", "stem": "An 82‑year‑old woman with dementia is admitted for acute delirium without fever, dysuria, flank pain, or suprapubic tenderness. Indwelling catheter present; urinalysis shows pyuria and bacteriuria; urine culture later grows E. coli. Vitals stable; no leukocytosis.", "options": ["Start ceftriaxone now for catheter‑associated UTI", "Start amoxicillin‑clavulanate and plan 7 days", "Replace the catheter, avoid antibiotics, evaluate noninfectious causes of delirium", "Give a single dose gentamicin and observe", "Begin piperacillin‑tazobactam for possible ESBL"], "answer": "C", "explanation": "This is **asymptomatic bacteriuria** with delirium alone; IDSA 2019 recommends **no antibiotics** (treat only in pregnancy or before invasive urologic urologic procedures). The pitfall is equating pyuria/culture positivity with infection; manage catheter and search for alternate delirium causes. citeturn2search1"}], "micro_questions": [{"q": "In septic shock, should empiric antibiotics begin within **1 hour** of recognition?", "a": "Yes. Early antimicrobials within 1 h are recommended by Surviving Sepsis 2021, alongside source control and de‑escalation. citeturn2search44"}, {"q": "A **negative MRSA nares PCR** within 72 h of pneumonia presentation—can you stop empiric vancomycin if the patient is improving?", "a": "Yes; high NPV (~95–97%) supports de‑escalation when clinical risk is low. citeturn2search52turn2search51"}, {"q": "Vancomycin PK target for serious MRSA infections?", "a": "**AUC/MIC 400–600** (MIC assumed 1 mg/L) to balance efficacy and nephrotoxicity. citeturn2search26"}, {"q": "Treat **asymptomatic bacteriuria** in older adults with delirium but no GU symptoms or instability?", "a": "No; do not treat ASB except pregnancy or invasive urologic procedures. citeturn2search1"}, {"q": "Typical total duration for **HAP/VAP** when improving?", "a": "About **7 days** with daily reassessment for de‑escalation. citeturn2search56"}], "references": [{"label": "IDSA/SHEA Implementing an Antibiotic Stewardship Program (2016)", "url": "https://www.idsociety.org/practice-guideline/implementing-an-ASP/"}, {"label": "CDC Core Elements of Hospital Antibiotic Stewardship Programs (2019)", "url": "https://stacks.cdc.gov/view/cdc/82908"}, {"label": "Surviving Sepsis Campaign Adult Guidelines (2021)", "url": "https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-guidelines-2021"}, {"label": "ATS/IDSA CAP in Adults (2019)", "url": "https://www.idsociety.org/practice-guideline/community-acquired-pneumonia-cap-in-adults/"}, {"label": "IDSA 2024 Guidance on AMR Gram‑Negative Infections", "url": "https://www.idsociety.org/practice-guideline/amr-guidance/"}], "cdi": ["Document infection diagnosis (acuity/type/source), suspected/confirmed pathogen, and sepsis severity (SOFA change, **MAP**, lactate) with objective data (vitals, labs, imaging).", "Record cultures obtained **before** first dose when feasible, source control steps, and hemodynamic/oxygen status supporting severity.", "Specify antibiotic indication, **dose/route/interval**, renal/hepatic adjustments, **planned duration/stop date**, and de‑escalation/IV‑to‑PO plan tied to culture and clinical milestones.", "Clarify drug allergies (agent, reaction, timing) and risk stratification for β‑lactam use or need for alternative therapy.", "Note high‑risk contexts (pregnancy, severe CKD/ESRD, cirrhosis, QT risk, active GI bleed) that affect selections, monitoring, and dosing."]}, {"id": "07", "title": "Arrhythmias You Can’t Miss", "tags": ["cardiology", "inpatient", "night-float"], "date": "2026-02-20", "panic_card": ["Check responsiveness, pulse, and ABCs; place on monitor, defibrillator at bedside; target **MAP ≥65 mmHg**, **SpO₂ ≥94%**.", "Unstable tachyarrhythmia (hypotension, shock, chest pain, altered mental status): immediate **synchronized cardioversion 100–200 J biphasic**; escalate if ineffective.", "Pulseless VT/VF: **defibrillate 200 J biphasic**, high‑quality CPR, epinephrine **1 mg IV q3–5 min**, consider amiodarone **300 mg IV push** after second shock.", "Torsades de pointes: **magnesium sulfate 2 g IV over 10–15 min**, repeat once if needed; correct **K⁺ to 4.0–4.5 mmol/L**; consider overdrive pacing if recurrent.", "Symptomatic bradycardia: **atropine 1 mg IV q3–5 min (max 3 mg)**; if ineffective, **transcutaneous pacing** and start **dopamine 5–20 µg/kg/min** or **epinephrine 2–10 µg/min** infusion.", "**Confirm Before Proceed:** If AF + pre‑excitation (irregular wide‑complex tachycardia), avoid AV nodal blockers (adenosine, diltiazem, beta‑blockers, digoxin); use **procainamide** or synchronized cardioversion."], "brief_overview": ["Night‑float success hinges on rapidly distinguishing stable vs unstable rhythms; instability mandates electricity first (synchronized cardioversion for organized tachyarrhythmias, defibrillation for pulseless/irregular polymorphic VT). Keep pads on, oxygen, IV access, and airway readiness.", "**Guideline Must‑Know:** AHA ACLS recommends immediate synchronized cardioversion for tachyarrhythmias with hypotension, shock, ischemic chest pain, acute heart failure, or altered mental status; start at **100–200 J biphasic** and escalate as needed.", "**Guideline Must‑Know:** For symptomatic bradycardia, give **atropine 1 mg IV**, repeat q3–5 min to **3 mg max**; if ineffective, pace and consider **dopamine 5–20 µg/kg/min** or **epinephrine 2–10 µg/min** infusions.", "**Guideline Must‑Know:** Torsades de pointes (polymorphic VT with prolonged QT) requires **magnesium sulfate 2 g IV over 10–15 min**, correction of **K⁺ 4.0–4.5 mmol/L, Mg²⁺ ≥0.8 mmol/L**, removal of QT‑prolonging drugs, and possible overdrive pacing.", "**Guideline Must‑Know:** In AF with pre‑excitation (WPW pattern), avoid AV nodal blockers; use **procainamide 10 mg/kg IV over 20–30 min** if stable or synchronized cardioversion if unstable.", "**Guideline Must‑Know:** Stable monomorphic wide‑complex tachycardia of uncertain origin should be treated as VT; preferred IV options include **amiodarone 150 mg over 10 min**, repeat as needed, then infusion **1 mg/min**.", "**Guideline Must‑Know:** High‑grade AV block (Mobitz II or complete heart block) with symptoms warrants **temporary pacing** and evaluation for reversible causes (ischemia, drugs, hyperkalemia); consult cardiology early for permanent pacing needs.", "When the rhythm is unclear, prioritize patient status: oxygenation, perfusion, and mental status. Get a 12‑lead ECG quickly but do not delay life‑saving cardioversion/defibrillation for diagnostics.", "Common precipitants at night: ischemia, hypoxemia, sepsis, **K⁺/Mg²⁺ abnormalities**, drug effects (e.g., sotalol, amiodarone interactions, digoxin), and missed beta‑blocker doses. Replace electrolytes early and aggressively within safety limits.", "Misleading patterns: AF with aberrancy vs VT—treat uncertain wide‑complex tachycardia as VT. Irregular wide‑complex tachycardia suggests AF with pre‑excitation; electricity or procainamide, not AV nodal blockers.", "What must happen now: stabilize, attach defib pads, verify hemodynamics, obtain ECG, correct electrolytes, prepare sedation for cardioversion, and call ICU if escalating support is needed. What can wait: long‑term anticoagulation strategy, EP study planning, and upstream risk modification.", "**Guideline Must‑Know:** For pulseless VT/VF, defibrillation plus high‑quality CPR, **epinephrine 1 mg IV q3–5 min**, and **amiodarone 300 mg IV push** (then **150 mg**) improves defibrillation success; resume compressions immediately after shocks.", "**Guideline Must‑Know:** Rate control in hemodynamically stable AF with RVR typically uses **diltiazem** or **metoprolol**; however, in decompensated HFrEF, prefer **amiodarone** or **digoxin** for rate control; electricity for instability.", "Pitfalls: Giving amiodarone for torsades (can worsen QT), using adenosine in irregular wide‑complex tachycardia with pre‑excitation, or delaying pacing in complete heart block. Recognize drug accumulation in CKD and avoid multiple AV nodal blockers together.", "Call ICU/Consult: refractory VT/VF, recurrent torsades, complete heart block not responding to atropine, unstable AF/flutter requiring repeated cardioversion, or need for temporary transvenous pacing or antiarrhythmic infusions with vasopressors."], "icu_consult_triggers": ["Persistent or recurrent VT/VF, torsades, or need for **>1** cardioversion/defibrillation with ongoing instability.", "High‑grade AV block with hypotension, syncope, or bradycardia **<40/min** requiring pacing or vasoactive infusions.", "Escalating oxygen/pressor requirements, ischemia with dynamic ST changes, or rising troponin with malignant arrhythmia.", "Wide‑complex tachycardia requiring antiarrhythmic infusion and continuous titration or need for temporary transvenous pacing."], "orders_to_place_now": ["Order: 12‑Lead ECG — {STAT acquisition; repeat after intervention}", "Order: Continuous cardiac monitoring — {telemetry with external defibrillation/pacing pads applied}", "Order: Electrolyte repletion — {potassium goal 4.0–4.5 mmol/L; magnesium goal ≥0.8 mmol/L; protocolized IV/PO replacement}", "Order: Antiarrhythmic infusion — {amiodarone 150 mg IV over 10 min → 1 mg/min for 6 h → 0.5 mg/min; adjust for hypotension}", "Order: Synchronized cardioversion — {energy {100–200 J biphasic}, sedation {etomidate 0.15–0.3 mg/kg or ketamine 0.5–1 mg/kg}, oxygen and suction ready}"], "abim_cases": [{"case_id": "07A", "stem": "A 62‑year‑old man with palpitations and dizziness becomes hypotensive (BP 78/48 mmHg). Monitor shows an irregular wide‑complex tachycardia at 180/min; ECG reveals delta waves when briefly slower. He is diaphoretic and confused.", "options": ["Adenosine rapid IV push", "Diltiazem IV bolus", "Synchronized cardioversion", "Metoprolol IV bolus", "Digoxin IV load"], "answer": "C", "explanation": "Unstable AF with pre‑excitation requires immediate **synchronized cardioversion**. AV nodal blockers (adenosine, diltiazem, beta‑blockers, digoxin) can accelerate conduction down the accessory pathway and precipitate VF. When stable, **procainamide** is preferred for AF with WPW."}, {"case_id": "07B", "stem": "A 55‑year‑old woman on sotalol for PVCs presents with syncope. ECG shows polymorphic VT with prolonged QTc 530 ms. She is awake with BP 92/56 mmHg and ongoing runs of torsades.", "options": ["Amiodarone IV bolus", "Magnesium sulfate 2 g IV over 10–15 min", "Diltiazem IV bolus", "Lidocaine IV bolus", "Immediate thrombolysis"], "answer": "B", "explanation": "Torsades due to QT prolongation is treated with **magnesium sulfate 2 g IV**, electrolyte optimization (**K⁺ 4.0–4.5 mmol/L; Mg²⁺ ≥0.8 mmol/L**), and stopping QT‑prolonging drugs; overdrive pacing if recurrent. The pitfall is giving **amiodarone**, which can further prolong QT."}], "micro_questions": [{"q": "First step for unstable organized tachyarrhythmia?", "a": "Immediate synchronized cardioversion with **100–200 J biphasic**, do not delay for ECG interpretation."}, {"q": "Atropine dose for symptomatic bradycardia?", "a": "**1 mg IV q3–5 min** to a **maximum of 3 mg**, then pacing/infusion if ineffective."}, {"q": "Initial magnesium dose for torsades de pointes?", "a": "**2 g IV over 10–15 min**, may repeat once; consider infusion and overdrive pacing if recurrent."}, {"q": "Electrolyte targets on telemetry to reduce ectopy?", "a": "**K⁺ 4.0–4.5 mmol/L** and **Mg²⁺ ≥0.8 mmol/L**, unless contraindicated by renal function."}], "references": [{"label": "AHA Adult ACLS Tachycardia/Bradycardia Algorithms, 2020 with focused updates 2023–2024", "url": "https://cpr.heart.org"}, {"label": "2023 ACC/AHA/ACCP/HRS Guideline for the Management of Atrial Fibrillation", "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193"}, {"label": "2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay", "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000000628"}, {"label": "2017 AHA/ACC/HRS Guideline for Management of Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death", "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000000549"}, {"label": "AHA Scientific Statement on Drug‑Induced Arrhythmias (QT prolongation), 2020", "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000000905"}], "cdi": ["Arrhythmia diagnosis + acuity: e.g., “Unstable monomorphic VT” or “Symptomatic complete heart block” with hemodynamic effects (hypotension, shock, altered mental status).", "Etiology/cause: ischemia, electrolyte disturbance (e.g., hypokalemia, drug‑induced QT prolongation), structural heart disease, or conduction disease.", "Severity/organ dysfunction: need for cardioversion/defibrillation, vasoactive support, pacing, respiratory failure, lactate elevation.", "Objective evidence: ECG rhythm/intervals (QRS/QTc), vitals, troponin, electrolytes (K⁺, Mg²⁺), imaging if ischemia suspected.", "Treatment/monitoring: cardioversion/defibrillation energy, antiarrhythmic doses, pacing parameters, electrolyte targets, continuous telemetry, and consults placed."]}, {"id": "08", "title": "Chest Pain (ACS/Post‑ROSC)", "tags": ["cardiology", "inpatient", "night-float", "post-rosc", "acute-coronary-syndrome"], "date": "2026-02-21", "panic_card": ["ABCs first: cardiac monitor, defibrillation pads on, large‑bore IV/IO; obtain 12‑lead ECG within **≤10 min** of arrival/chest‑pain report.", "Oxygen only if hypoxemic; target **SpO₂ 92–98%** (avoid hyperoxia), ensure **PaCO₂ 35–45 mmHg** if ventilated; maintain **MAP ≥65 mmHg** (first‑line norepinephrine).", "Give **aspirin 162–325 mg chew now** unless true anaphylaxis or active major bleeding; keep **NPO** for potential cath.", "Treat pain/ischemia: **nitroglycerin** SL 0.4 mg q5 min up to 3 doses if **SBP ≥100 mmHg**, no RV infarct, no recent PDE5 inhibitor; avoid routine morphine.", "Reassess ECG if pain persists; activate cath lab immediately for diagnostic **ST‑elevation** or new LBBB with ischemic symptoms.", "Confirm Before Proceed: fibrinolysis for STEMI only if PCI unavailable; verify absolute contraindications; typical window **≤12 h** (consider up to 24 h if ongoing ischemia or shock)."], "brief_overview": ["Night priorities: rule in/out ACS rapidly (ECG **≤10 min**, repeat if pain continues), control oxygenation (**SpO₂ 92–98%**), stabilize hemodynamics (**MAP ≥65 mmHg**), give antiplatelet early, and decide PCI vs fibrinolysis vs conservative pathway.", "**Guideline Must‑Know:** AHA/ACC 2021 Chest Pain guideline prioritizes rapid ECG acquisition/interpretation and hs‑troponin‑based algorithms (0/1‑h or 0/2‑h) for ED/inpatient chest pain; dynamic change plus symptoms elevates ACS probability.", "**Guideline Must‑Know:** For STEMI, emergent PCI is preferred (door‑to‑balloon **≤90 min**) or fibrinolysis (door‑to‑needle **≤30 min**) if PCI delay exceeds thresholds; avoid fibrinolysis if contraindicated (intracranial hemorrhage history, aortic dissection, active bleeding).", "**Guideline Must‑Know:** Oxygen is indicated for **SpO₂ <90–92%** or respiratory distress; avoid hyperoxia in ACS and post‑ROSC because it increases mortality/neurologic injury risk; target **SpO₂ 92–98%** and normocapnia.", "**Guideline Must‑Know:** Post‑ROSC bundle: secure airway/ventilation (PaCO₂ 35–45), titrate FiO₂ to avoid hyperoxia, maintain **MAP ≥65 mmHg** (norepinephrine first‑line), active temperature control to prevent fever (target **≤37.5°C**, many centers 36°C), glucose 7.8–10 mmol/L, and early neuro‑prognostication deferred **≥72 h** after normothermia.", "**Guideline Must‑Know:** Immediate angiography after ROSC is indicated for clear **ST‑elevation** or ongoing ischemia/shock; routine immediate cath for comatose post‑ROSC patients **without ST‑elevation** has not shown benefit—use a selective approach.", "**Guideline Must‑Know:** Antiplatelet strategy: **aspirin** loading universally (if no contraindication); add a P2Y₁₂ inhibitor (ticagrelor/prasugrel preferred over clopidogrel in PCI‑planned ACS) after cardiology plan is set, especially if urgent CABG is possible.", "Anticoagulation: **UFH** preferred in unstable patients or severe CKD/anticipated procedures; **enoxaparin** acceptable if renal function allows; monitor anti‑Xa/aPTT per protocol; avoid if dissection/major bleed suspected.", "Blood pressure/ischemia: give **SL nitroglycerin** if hypertensive and no RV infarct; for inferior STEMI with RV involvement and hypotension, give **250–500 mL** isotonic fluid bolus and **avoid nitrates**; consider low‑dose beta‑blocker if hypertensive/tachycardic and no signs of acute heart failure or shock.", "Pain control: prioritize nitrates and reperfusion; avoid routine morphine due to potential harm and delayed antiplatelet absorption; if needed, use the lowest dose with careful monitoring.", "What must happen now: ECG, aspirin, O₂ titration, hemodynamic stabilization, cath lab activation for STEMI, anticoagulation when ACS is likely and bleeding risk acceptable, POCUS for shock/source.", "What can wait (briefly): formal echocardiography (once stable), full secondary prevention regimen (high‑intensity statin should be started early but does not delay reperfusion), risk stratification scores, and detailed etiology workup (e.g., vasospasm, MINOCA).", "Pitfalls: treating all troponin elevations as type 1 MI; consider **type 2 MI** (supply/demand) and **myocardial injury** (e.g., sepsis, PE, CKD); integrate symptoms, ECG, and dynamics (rise/fall).", "Pitfalls: missing aortic dissection (tearing pain, pulse/BP differential, mediastinal widening) or pulmonary embolism (tachycardia, hypoxemia, D‑dimer/CTPA) where anticoagulation or thrombolysis decisions diverge.", "**Guideline Must‑Know:** Fibrinolysis absolute contraindications include prior intracranial hemorrhage, ischemic stroke within 3 months, known intracranial neoplasm, suspected aortic dissection, active bleeding; confirm carefully before administering.", "**Guideline Must‑Know:** Temperature control in comatose post‑ROSC: active fever prevention with target **32–37.5°C** per local protocol; avoid shivering; defer neuro‑prognostication **≥72 h** after rewarming/normalization.", "**Guideline Must‑Know:** Use hs‑troponin serial testing (0/1‑h or 0/2‑h pathways) with sex‑specific cutoffs where validated; a single value below limit of detection with non‑ischemic ECG and onset >3 h can safely rule out in selected settings.", "Call cardiology stat for STEMI, persistent ischemia, hemodynamic instability, recurrent VT/VF, or cardiogenic shock; call ICU for escalating vasopressors, increasing oxygen/vent needs, or post‑ROSC coma needing temperature control.", "Confirm Before Proceed: before fibrinolysis/anticoagulation, screen for dissection, intracranial pathology, recent surgery, or anticoagulant use; document risks/benefits and contraindication checklist."], "icu_consult_triggers": ["Persistent chest pain with **ST‑elevation** or new posterior/inferior changes, recurrent VT/VF, or dynamic ST shifts with rising hs‑troponin.", "Shock or impending shock: **MAP <65 mmHg** despite fluids/vasopressors, **lactate ≥4 mmol/L**, or escalating pressor needs.", "Hypoxemia/hypercapnia requiring **FiO₂ >0.6**, high PEEP, or mechanical ventilation post‑ROSC; GCS ≤8 or coma needing temperature control.", "Suspected aortic dissection, papillary muscle rupture, ventricular septal rupture, or new severe MR on POCUS—urgent cardiothoracic/cardiology consult."], "orders_to_place_now": ["Order: 12‑lead ECG — {stat, repeat in 15 min if ongoing pain or initial non‑diagnostic}", "Order: High‑sensitivity troponin — {0/1‑h or 0/2‑h protocol; add baseline CKD note if applicable}", "Order: Aspirin PO — {chew 325 mg now, then 81 mg daily}", "Order: Heparin infusion (UFH) — {weight kg, bolus yes/no, aPTT/anti‑Xa target per protocol, bleeding risk checklist}", "Order: Nitroglycerin — {SL 0.4 mg q5 min ×3 if SBP ≥100 mmHg; consider IV titration if persistent pain and no RV infarct}", "Order: Post‑ROSC temperature control — {target 36.0°C, active fever prevention, shiver suppression plan, neuro checks schedule}"], "abim_cases": [{"case_id": "08A", "stem": "A 62‑year‑old man with hypertension and hyperlipidemia presents with 60 minutes of crushing chest pain. ECG shows ST elevation in II, III, and aVF. BP is 92/58 mmHg, JVP is elevated, lungs are clear. He took no erectile‑dysfunction medications. O₂ saturation is 95% on room air.", "options": ["Administer sublingual nitroglycerin and start IV morphine", "Give a 250–500 mL isotonic fluid bolus and prepare for emergent PCI activation", "Start high‑flow oxygen to maintain SpO₂ at 100%", "Give IV labetalol to reduce heart rate and blood pressure", "Begin immediate fibrinolysis regardless of PCI availability"], "answer": "B", "explanation": "Inferior STEMI with RV involvement is suggested by hypotension, clear lungs, and elevated JVP; the next step is **250–500 mL** IV fluid bolus and emergent reperfusion, avoiding nitrates which can precipitate shock. Oxygen is not indicated with **SpO₂ 95%**; routine morphine and beta‑blockade are harmful in hypotension. Reperfusion should be via PCI if available within guideline time targets; fibrinolysis is reserved when PCI delays exceed thresholds (AHA/ACC STEMI; AHA/ACC Chest Pain; ESC ACS)."}, {"case_id": "08B", "stem": "A 58‑year‑old man is resuscitated from out‑of‑hospital ventricular fibrillation arrest. He is intubated, comatose, and hemodynamically stable on low‑dose norepinephrine. ECG shows no ST‑elevation. SpO₂ is 97% on 40% FiO₂. Head CT is normal.", "options": ["Immediate coronary angiography for all post‑ROSC patients regardless of ECG", "Increase FiO₂ to 100% to maximize oxygen delivery", "Initiate active temperature control at 36°C, maintain **SpO₂ 92–98%**, and admit to ICU with selective angiography if instability develops", "Start routine morphine infusion for sedation and pain", "Begin fibrinolysis empirically for presumed occult STEMI", "Target SpO₂ 92–98% and titrate FiO₂ down when safe.\n- Q: Initial inpatient aspirin dose for suspected ACS?  \n  A: 162–325 mg chew immediately unless true anaphylaxis or active major bleeding.\n- Q: Minimum MAP target during ischemic shock/post‑ROSC stabilization?  \n  A: MAP ≥65 mmHg using norepinephrine as first‑line vasopressor if fluids insufficient.\n- Q: When can fibrinolysis be given for STEMI if PCI is unavailable?  \n  A: Generally within ≤12 h of symptom onset (consider up to 24 h if ongoing ischemia or shock and no contraindications)."], "answer": "C", "explanation": "In comatose post‑ROSC patients **without ST‑elevation**, guidelines support active temperature control (fever prevention, commonly 36°C) and avoidance of hyperoxia while pursuing selective angiography if recurrent ischemia or shock emerges. The pitfall is assuming all post‑ROSC patients require immediate cath or 100% FiO₂; both approaches may harm outcomes unless specific indications are present (AHA ACLS 2020/2023 updates; Chest Pain/ACS guidance)."}], "micro_questions": [{"q": "Start oxygen if SpO₂ is 98% on room air?", "a": "No; avoid hyperoxia in ACS/post‑ROSC. Target SpO₂ 92–98% and titrate FiO₂ down when safe."}, {"q": "Initial inpatient aspirin dose for suspected ACS?", "a": "162–325 mg chew immediately unless true anaphylaxis or active major bleeding."}, {"q": "Minimum MAP target during ischemic shock/post‑ROSC stabilization?", "a": "MAP ≥65 mmHg using norepinephrine as first‑line vasopressor if fluids insufficient."}, {"q": "When can fibrinolysis be given for STEMI if PCI is unavailable?", "a": "Generally within ≤12 h of symptom onset (consider up to 24 h if ongoing ischemia or shock and no contraindications)."}], "references": [{"label": "AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain (2021)", "url": ""}, {"label": "AHA Guidelines for CPR and ECC (Adult ACLS) (2020) with 2023 Focused Updates on Post‑ROSC Care/Temperature Control", "url": ""}, {"label": "ESC Guidelines for the Management of Acute Coronary Syndromes (2023)", "url": ""}, {"label": "ACC/AHA/SCAI Consensus and STEMI systems of care performance targets (door‑to‑balloon and door‑to‑needle)", "url": ""}, {"label": "Fourth Universal Definition of Myocardial Infarction (2018) and subsequent statements on type 2 MI/myocardial injury (2022)", "url": ""}], "cdi": ["Acute MI type and acuity: STEMI vs NSTEMI vs type 2 MI; culprit territory if known; reperfusion strategy chosen and timing.", "Hemodynamic status: shock vs not; MAP targets; vasopressor use and response; lactate with trends.", "Post‑ROSC care: coma vs awake, temperature target, oxygen/vent targets (SpO₂ 92–98%, PaCO₂ 35–45), sedation/analgesia, neuro‑monitoring plan.", "Contraindication screening: fibrinolysis/anticoagulation checklist (ICH history, dissection concern, recent surgery, active bleeding).", "Objective evidence: ECG changes, hs‑troponin dynamics, imaging/POCUS findings, oxygenation/ventilator settings, and treatments supporting severity."]}, {"id": "09", "title": "Community-Acquired Pneumonia", "tags": ["pulmonology", "infectious-diseases", "inpatient", "night-float"], "date": "2026-02-21", "panic_card": ["Assess ABCs; start supplemental O₂ and titrate for work of breathing; if shock suspected, initiate sepsis bundle: obtain lactate, draw blood cultures, give **30 mL/kg crystalloid within 3 h**, and start norepinephrine to **MAP ≥65 mmHg** if hypotension persists. citeturn2search12", "Start empiric antibiotics within **≤1 h** if sepsis or septic shock is suspected; avoid delays for imaging or labs once cultures obtained. citeturn2search12", "For non‑severe inpatient CAP without MRSA/Pseudomonas risks: give **beta‑lactam + macrolide** (e.g., ceftriaxone + azithromycin) or **respiratory fluoroquinolone** monotherapy; use **beta‑lactam + doxycycline** if macrolide/FQ contraindicated. citeturn2search2turn2search4", "For severe CAP or clear MRSA/Pseudomonas risk factors: add **anti‑MRSA** (e.g., vancomycin) and an **anti‑pseudomonal beta‑lactam** pending cultures, then de‑escalate. citeturn2search7", "Consider early HFNC/NIV for hypoxemic respiratory failure; intubate if worsening mental status, exhaustion, or refractory hypoxemia. citeturn2search12", "Confirm Before Proceed: Before fluoroquinolones or macrolides, review **QT prolongation** and drug interactions; avoid routine anaerobic coverage unless lung abscess/empyema suspected. citeturn2search18"], "brief_overview": ["**Guideline Must‑Know:** The 2019 ATS/IDSA guideline is the core adult CAP reference; it updates diagnostics, empiric therapy, and severity assessment (replacing HCAP and emphasizing individual MRSA/Pseudomonas risk factors). citeturn2search2", "**Guideline Must‑Know:** Determine site of care with clinical judgement plus a tool (PSI preferred) and identify **severe CAP** by 1 major (invasive ventilation or vasopressors) or **≥3 minor criteria** (e.g., **PaO₂/FiO₂ ≤250**, **RR ≥30**, **BUN ≥7.14 mmol/L**, **PLT <100 ×10⁹/L**, multilobar infiltrates, hypotension needing fluids, leukopenia, confusion, or hypothermia). These predict ICU need and mortality. citeturn2search10", "**Guideline Must‑Know:** Diagnostic testing differs by severity. For non‑severe inpatient CAP, routine blood/sputum cultures and urinary antigens generally **not** recommended; for severe CAP, obtain **blood cultures, sputum Gram/culture, and S. pneumoniae/Legionella urinary antigens** before antibiotics when feasible. citeturn2search2turn2search7", "**Guideline Must‑Know:** Start empiric antibiotics promptly. Non‑severe inpatient: **beta‑lactam + macrolide** or **respiratory FQ**; if macrolide/FQ not suitable, **beta‑lactam + doxycycline** is acceptable. Severe CAP (no MRSA/Pseudomonas risks): **beta‑lactam + macrolide** or **beta‑lactam + respiratory FQ**. citeturn2search2turn2search4", "**Guideline Must‑Know:** Avoid routine anaerobic coverage in suspected aspiration **without** abscess/empyema; extended anaerobic coverage shows **no mortality benefit** and **higher C. difficile** risk. citeturn2search18", "**Guideline Must‑Know:** Treat minimum **5 days** and reassess; ensure clinical stability (afebrile, HR/RR normalizing, hemodynamics stable, able to take PO) before stopping or switching to oral therapy. citeturn2search10", "Distinguish immediate vs delayed tasks: “Now” = stabilize ABCs, cultures (if severe), empiric antibiotics, fluids/pressors for sepsis, early oxygen/ventilatory support; “Can wait hours” = vaccine assessment, atypical/viral add‑ons, swallow assessment if aspiration risk after stabilization. citeturn2search12turn2search2", "Use MRSA nares PCR to **de‑escalate** vancomycin if negative and no other MRSA risks, per stewardship pathways aligned with 2019 guidance. citeturn2search7turn2search3", "Viral testing: when influenza/respiratory viruses circulate, test and **treat influenza** positives with antivirals; continue empiric antibacterials initially for inpatients given bacterial‑viral coinfection risk. citeturn2search4", "Legionella considerations: order UAT in severe CAP, outbreak/travel, or when epidemiology suggests; pair with lower respiratory **PCR or culture** when feasible to broaden detection. citeturn2search7turn2search20", "Procalcitonin: **do not** withhold initial antibiotics in clinically/radiographically confirmed CAP based on a low PCT; consider PCT trends only for stewardship after stabilization. citeturn2search26", "When to add MRSA/Pseudomonas coverage: prior respiratory isolation, or **recent hospitalization with IV antibiotics** (local risks matter). Reassess daily and narrow promptly if tests negative and patient stabilizing. citeturn2search2turn2search7", "Duration nuances: bacteremic pneumococcal CAP often needs **≥7 days**; Legionella typically **7–10 days** depending on agent/response—ensure clinical stability and source control. citeturn2search2", "Early mobilization, incentive spirometry, and DVT prophylaxis reduce complications; assess aspiration risk and perform swallow evaluation once stable. citeturn2search2", "Pitfalls: relying on “HCAP” label (retired), overusing broad antipseudomonal/anti‑MRSA agents without patient‑specific risks, and adding metronidazole/clindamycin for uncomplicated aspiration. citeturn2search2turn2search18", "ICU/consult: escalate early for rising O₂ needs (HFNC/NIV to invasive), shock, or ≥3 minor severe CAP criteria; involve ID/pulmonary for complex resistance, rapid de‑escalation, and ventilatory strategy. citeturn2search10turn2search12", "Discharge readiness: afebrile, hemodynamically stable, **SpO₂ stable on room air or baseline**, tolerating PO, and safe outpatient follow‑up; convert to oral agents with high bioavailability (e.g., levofloxacin, doxycycline, azithromycin, amoxicillin‑clavulanate) per susceptibilities. citeturn2search2"], "icu_consult_triggers": ["Need for invasive mechanical ventilation or vasopressors (major criteria for severe CAP). citeturn2search10", "**≥3 minor severe CAP criteria** (e.g., **PaO₂/FiO₂ ≤250**, multilobar infiltrates, **RR ≥30**, **BUN ≥7.14 mmol/L**, **PLT <100 ×10⁹/L**, confusion, hypotension requiring fluids, leukopenia, or hypothermia). citeturn2search10", "Rising oxygen/ventilatory support needs (escalating HFNC/NIV) or refractory hypoxemia despite optimization. citeturn2search12", "Septic shock physiology (elevated lactate, hypotension despite fluids) or rapidly worsening organ dysfunction. citeturn2search12"], "orders_to_place_now": ["Order: Empiric antibiotics — {choose: ceftriaxone 2 g IV q24h + azithromycin 500 mg IV/PO daily; or levofloxacin 750 mg IV/PO daily; if macrolide/FQ contraindicated, ampicillin‑sulbactam 3 g IV q6h + doxycycline 100 mg IV/PO q12h}", "Order: Sepsis bundle — {lactate now and 2–4 h recheck if initial ≥2 mmol/L; blood cultures ×2 before antibiotics if severe; 30 mL/kg IV crystalloid; start norepinephrine if MAP <65 mmHg after fluids}", "Order: Microbiology — {sputum Gram stain/culture; pneumococcal and Legionella urinary antigens if severe; MRSA nares PCR to guide de‑escalation}", "Order: Respiratory support — {oxygen {device}; target SpO₂ individualized; consider HFNC/NIV if persistent hypoxemia or increased WOB}", "Order: Diagnostics — {CXR or chest CT if unclear; respiratory viral PCR panel during respiratory virus season}", "Order: Daily stewardship reassessment — {narrow/stop MRSA/Pseudomonas coverage if risk tests negative and patient improving; transition to PO when stable}"], "abim_cases": [{"case_id": "09A", "stem": "A 67‑year‑old man with COPD (on LABA/LAMA), HTN, and diabetes presents with fever, productive cough, pleuritic chest pain, and consolidation on CXR. He is hypoxic to 90% on 2 L but hemodynamically stable. ECG shows **QTc 510 ms**. No prior MRSA/Pseudomonas isolation; no hospitalization with IV antibiotics in the last year. You admit him to the ward.", "options": ["Azithromycin monotherapy", "Levofloxacin monotherapy", "Ceftriaxone plus azithromycin", "Ceftriaxone plus doxycycline", "Piperacillin‑tazobactam plus vancomycin"], "answer": "D", "explanation": "For non‑severe inpatient CAP without MRSA/Pseudomonas risks, **beta‑lactam + macrolide** or **respiratory FQ** are first‑line; when macrolide/FQ are **contraindicated** (here, marked QT prolongation), **beta‑lactam + doxycycline** is guideline‑supported. Avoid azithromycin monotherapy and broad anti‑Pseudomonas/MRSA agents without risk factors. Treat for **≥5 days** with clinical stability before stop/step‑down. citeturn2search2turn2search10"}, {"case_id": "09B", "stem": "An 82‑year‑old woman aspirates during a syncopal episode at dinner. She has fever, cough, right lower‑lobe infiltrate, and needs 3 L O₂ by nasal cannula. No abscess or empyema on CT. No MRSA/Pseudomonas risks. She is stable on the ward.", "options": ["Ceftriaxone plus azithromycin", "Ampicillin‑sulbactam plus doxycycline", "Ceftriaxone plus metronidazole", "Piperacillin‑tazobactam plus vancomycin", "Clindamycin monotherapy", "difficile risk**—the pitfall is overtreating presumed “aspiration pneumonia.” citeturn2search18\n\nWhat changed the decision here?", "difficile with extended anaerobic therapy. citeturn2search18 citeturn2search18\n- JAMA/AAFP guideline synopsis of ATS/IDSA CAP (2020) — severe CAP criteria and 5‑day duration with reassessment. citeturn2search4 citeturn2search4"], "answer": "A", "explanation": "In uncomplicated aspiration‑associated CAP **without** lung abscess/empyema, routine **anaerobic coverage is not recommended**; standard CAP regimens (e.g., ceftriaxone + azithromycin) are appropriate. Extended anaerobic coverage (metronidazole/clindamycin or broad anti‑anaerobes) **does not improve mortality and increases C. difficile risk**—the pitfall is overtreating presumed “aspiration pneumonia.” citeturn2search18"}], "micro_questions": [{"q": "What are the two **major** severe CAP criteria?", "a": "Need for invasive mechanical ventilation or need for vasopressors for septic shock. citeturn2search10"}, {"q": "Minimum antibiotic duration for uncomplicated inpatient CAP?", "a": "**5 days** with clinical stability before discontinuation or switch to oral therapy. citeturn2search10"}, {"q": "Should a low procalcitonin delay initial antibiotics in radiographically confirmed CAP?", "a": "No; initiate empiric therapy regardless of initial PCT. citeturn2search26"}, {"q": "When are pneumococcal and Legionella urinary antigens most indicated?", "a": "In **severe CAP** or epidemiologic triggers (e.g., outbreak/travel), ideally paired with lower respiratory testing for Legionella. citeturn2search7turn2search20"}], "references": [{"label": "ATS/IDSA Clinical Practice Guideline: Diagnosis and Treatment of Adults with Community‑Acquired Pneumonia (2019) — American Thoracic Society/IDSA; full text/PDF. citeturn2search1 citeturn2search1", "url": ""}, {"label": "IDSA CAP Clinical Pathway (2019 guideline‑aligned; updated resources) — criteria, diagnostics, and empiric regimens tables (2023). citeturn2search7 citeturn2search7", "url": ""}, {"label": "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock (2021) — initial fluids, **MAP ≥65 mmHg**, early antibiotics. citeturn2search12 citeturn2search12", "url": ""}, {"label": "CHEST (2024): Anaerobic Coverage in Aspiration Pneumonia—no mortality benefit; ↑ C. difficile with extended anaerobic therapy. citeturn2search18 citeturn2search18", "url": ""}, {"label": "JAMA/AAFP guideline synopsis of ATS/IDSA CAP (2020) — severe CAP criteria and 5‑day duration with reassessment. citeturn2search4 citeturn2search4", "url": ""}], "cdi": ["CAP, acuity and severity: “Community‑acquired pneumonia, {non‑severe|severe by {major/minor} criteria}” + objective findings (fever, WBC, **PaO₂/FiO₂**, imaging).", "Etiology/cause if known or suspected: “Likely {pneumococcal|atypical|viral coinfection}; tests sent: {UATs, cultures, PCR}.”", "Sepsis/shock status when present: criteria met (SOFA change, lactate, hypotension), **MAP goals**, pressors/fluids given.", "Respiratory failure when present: type (hypoxemic/hypercapnic), oxygen/vent support level, ABG/SpO₂ targets.", "Treatment and response: empiric regimen (agents/doses), time to first dose, de‑escalation plan, duration target (≥5 days with stability)."]}, {"id": "10", "title": "COPD Exacerbation (Focused)", "tags": ["pulmonology", "inpatient", "night-float", "copd", "exacerbation"], "date": "2026-02-21", "panic_card": ["Titrate oxygen to **SpO₂ 88–92%** using Venturi or nasal cannula; avoid uncontrolled high‑flow oxygen; check ABG **30–60 min** after oxygen initiation. citeturn2search35turn2search26", "Start inhaled short‑acting bronchodilators: albuterol plus ipratropium via nebulizer or MDI with spacer; reassess work of breathing frequently. citeturn2search35", "Give systemic corticosteroid promptly: **prednisone 40 mg PO daily × 5 days** (or IV methylprednisolone if NPO). citeturn2search35turn2search20", "Initiate **NIV (BiPAP)** for acute hypercapnic respiratory acidosis (**pH ≤7.35, PaCO₂ >45**) with distress; prepare for rapid intubation if failing. citeturn2search15turn2search18", "If purulent sputum with increased volume and dyspnea or need for ventilatory support, start antibiotics covering common pathogens (e.g., amoxicillin‑clavulanate, doxycycline, or azithromycin per risk). citeturn2search35", "Confirm Before Proceed: Suspected pneumothorax or severe bullous disease with unilateral decreased breath sounds—obtain urgent CXR before NIV. citeturn2search35"], "brief_overview": ["**Guideline Must‑Know:** Define exacerbation as acute worsening of respiratory symptoms requiring change in therapy; common precipitants include infection and environmental triggers. Differentiate from mimics (PE, HF, pneumonia, pneumothorax). citeturn2search35", "**Guideline Must‑Know:** Oxygen should be **titrated to SpO₂ 88–92%** to avoid oxygen‑induced hypercapnia; use Venturi for precise FiO₂; recheck ABG **30–60 min** after initiation to detect CO₂ retention and acidosis. citeturn2search35turn2search26", "**Guideline Must‑Know:** First‑line bronchodilation is short‑acting beta‑agonist plus antimuscarinic (e.g., albuterol + ipratropium) given frequently early, then spaced; transition to inhalers as patient stabilizes. citeturn2search35", "**Guideline Must‑Know:** Systemic corticosteroids shorten recovery and reduce relapse; **prednisone 40 mg daily for 5 days** is recommended for most inpatients; IV acceptable if NPO, but oral is effective when feasible. citeturn2search35turn2search20", "**Guideline Must‑Know:** Start antibiotics for bacterial features (**increased purulence + volume + dyspnea**) or if **invasive/noninvasive ventilation** is required; typical options include amoxicillin‑clavulanate, doxycycline, or azithromycin with local resistance and QT risk in mind. citeturn2search35", "**Guideline Must‑Know:** **NIV (BiPAP)** is indicated for **pH ≤7.35 with PaCO₂ >45** and sustained tachypnea despite medical therapy—reduces intubation and mortality; closely monitor for early failure. citeturn2search15turn2search18", "What must happen now: secure IV access, continuous pulse oximetry and telemetry, early ABG/VBG, upright positioning, bronchodilators, steroids, judicious oxygen, consider NIV when acidotic, and early antibiotics if criteria met. citeturn2search35turn2search18", "What can wait until daytime: long‑acting inhaler optimization, inhaler technique education, pulmonary rehab referral, and smoking cessation counseling once stabilized. citeturn2search35", "Red flags tonight: **worsening acidosis**, rising PaCO₂, persistent hypoxemia despite oxygen, **altered mental status**, severe fatigue, **silent chest**, hypotension, or new focal consolidation—escalate care early. citeturn2search15turn2search7", "Pitfalls: over‑oxygenation causing CO₂ narcosis; missing pneumothorax or pneumonia; failing to escalate to NIV; excessive sedatives leading to hypoventilation; QT‑prolonging macrolides with baseline long QT. citeturn2search26turn2search15turn2search7", "Antibiotic nuances: tailor to severity and risks (recent antibiotics, structural lung disease). Reserve fluoroquinolones for severe beta‑lactam allergy or Pseudomonas risk due to adverse effects. Consider procalcitonin or CRP adjuncts if uncertainty. citeturn2search35turn2search40", "NIV pearls: start with IPAP/EPAP that unloads work of breathing; target pH improvement and PaCO₂ reduction; avoid in vomiting, facial trauma, or undrained pneumothorax; ensure rapid access to intubation if deteriorating. citeturn2search15turn2search18", "Coexisting pneumonia suspected? Apply **ATS/IDSA CAP** principles (imaging, risk‑based antibiotics) and reassess need for broader coverage; steroids for CAP are not routine unless another indication. citeturn2search7turn2search12", "**Guideline Must‑Know:** For disposition, ICU if life‑threatening respiratory failure (e.g., **pH <7.25**, refractory hypoxemia, need for continuous NIV/IMV) or significant comorbid decompensation. citeturn2search35", "**Guideline Must‑Know:** Arrange post‑exacerbation prevention: confirm vaccinations, assess eosinophils to guide ICS in maintenance therapy, address inhaler adherence, and consider pulmonary rehab referral. citeturn2search45", "**Guideline Must‑Know:** Avoid routine theophylline or mucolytics for acute management; focus on bronchodilators, steroids, and targeted antibiotics per criteria. citeturn2search35", "**Guideline Must‑Know:** In hypercapnic chronic CO₂ retainers, aim for **SpO₂ 88–92%** throughout hospitalization; document target in orders to prevent over‑oxygenation during transports. citeturn2search26"], "icu_consult_triggers": ["Need for continuous NIV or **pH <7.25**, rising PaCO₂, or worsening encephalopathy despite therapy. citeturn2search15", "**Refractory hypoxemia** (cannot maintain **SpO₂ ≥88%** despite optimized oxygen/NIV) or impending respiratory arrest. citeturn2search26", "Hemodynamic instability, severe arrhythmia, or inability to protect airway; suspected pneumothorax needing urgent intervention. citeturn2search35"], "orders_to_place_now": ["Order: Oxygen therapy — {device: Venturi or NC; target SpO₂ 88–92%; ABG in 30–60 min; continuous oximetry} citeturn2search26", "Order: Bronchodilator nebulizers — {albuterol {dose/frequency}, ipratropium {dose/frequency}; RT assess and wean to MDI when stable} citeturn2search35", "Order: Systemic corticosteroid — {prednisone 40 mg PO daily × 5 days; if NPO: methylprednisolone IV {dose/frequency}} citeturn2search35turn2search20", "Order: Noninvasive ventilation (BiPAP) — {initial IPAP/EPAP, backup rate, titration goals: improve pH/↓PaCO₂; contraindications check} citeturn2search15turn2search18", "Order: Empiric antibiotics — {choice per risk: amox‑clav or doxycycline or azithromycin; renal dosing; QT check; reassess at 48–72 h} citeturn2search35", "Order: Diagnostics — {ABG/VBG now and post‑oxygen; portable CXR; ECG; basic labs including CBC, BMP, Mg; consider viral panel if URI features} citeturn2search35"], "abim_cases": [{"case_id": "10A", "stem": "A 72‑year‑old man with severe COPD presents with worsening dyspnea and productive cough. Vitals: RR 32/min, BP 146/84, HR 112, SpO₂ 86% on room air. After Venturi mask to 28% (SpO₂ 90%), he remains tachypneic and somnolent. ABG: pH 7.28, PaCO₂ 68 mmHg, PaO₂ 62 mmHg. Chest x‑ray shows hyperinflation without consolidation.", "options": ["Increase oxygen to achieve SpO₂ 96–100%", "Initiate noninvasive ventilation with close monitoring", "Intubate immediately", "Start IV furosemide", "Give subcutaneous heparin therapeutic infusion"], "answer": "B", "explanation": "NIV is indicated for acute hypercapnic respiratory acidosis in COPD (**pH ≤7.35 with PaCO₂ >45**) and reduces mortality/intubation compared with standard therapy. Immediate intubation is reserved for failure or contraindications. Oxygen should remain **titrated to 88–92%** to avoid CO₂ retention. citeturn2search15turn2search18turn2search26"}, {"case_id": "10B", "stem": "A 68‑year‑old woman with COPD on home oxygen presents with increased dyspnea and green sputum. In triage, a non‑rebreather at 15 L/min is applied; she now has SpO₂ 100% but becomes progressively somnolent. VBG: pH 7.25, PvCO₂ 80 mmHg.", "options": ["Continue non‑rebreather and observe", "Reduce oxygen to target **SpO₂ 88–92%** and start NIV", "Administer naloxone", "Withhold ventilatory support and give azithromycin only", "Give IV bicarbonate"], "answer": "B", "explanation": "Over‑oxygenation can worsen hypercapnia in COPD; management is controlled oxygen targeting **88–92%** plus **NIV** for acidotic hypercapnic failure. The pitfall is uncontrolled high‑flow oxygen causing CO₂ narcosis; antibiotics alone do not address ventilatory failure. citeturn2search26turn2search15"}], "micro_questions": [{"q": "What inpatient oxygen saturation target prevents CO₂ retention in COPD exacerbation?", "a": "**SpO₂ 88–92%** with ABG reassessment in 30–60 minutes after initiation. citeturn2search26"}, {"q": "When is NIV strongly indicated in AECOPD?", "a": "**pH ≤7.35 with PaCO₂ >45 mmHg** and persistent distress despite therapy. citeturn2search15"}, {"q": "Preferred steroid regimen and duration?", "a": "**Prednisone 40 mg PO daily for 5 days** (or IV equivalent if NPO). citeturn2search35turn2search20"}, {"q": "Two clear indications for antibiotics tonight?", "a": "Anthonisen bacterial features (purulence with increased dyspnea/volume) or need for invasive/noninvasive ventilation. citeturn2search35"}], "references": [{"label": "Global Initiative for Chronic Obstructive Lung Disease (GOLD) Pocket Guide, **2024**. [Pocket Guide PDF] citeturn2search35", "url": ""}, {"label": "GOLD Report, **2025** update and resources. citeturn2search45", "url": ""}, {"label": "ERS/ATS Clinical Practice Guideline: Noninvasive Ventilation in Acute Respiratory Failure, **2017**. citeturn2search15", "url": ""}, {"label": "CHEST: Applying NIV in AECOPD—evidence‑based algorithm, **2024**. citeturn2search18", "url": ""}, {"label": "British Thoracic Society Guideline for Oxygen Use in Adults, **2017** (with 2019 update note). citeturn2search26", "url": ""}, {"label": "ATS/IDSA Guideline for Community‑Acquired Pneumonia in Adults, **2019**. citeturn2search7", "url": ""}], "cdi": ["Acute on chronic **hypercapnic respiratory failure** due to COPD exacerbation; severity with **pH**, **PaCO₂**, mental status; objective ABG results; treatment with NIV and oxygen titrated to **SpO₂ 88–92%**. citeturn2search26turn2search15", "COPD exacerbation etiology: suspected **bacterial bronchitis** vs **viral URI** vs **pneumonia**; include sputum purulence/volume/dyspnea and imaging findings. citeturn2search35", "Corticosteroid therapy: **prednisone 40 mg PO daily × 5 days** (or IV equivalent); indicate route and start time supporting severity. citeturn2search35", "Antibiotic decision: indication (Anthonisen/ventilatory support), agent/dose, renal adjustment, QT risk mitigation; planned reassessment window. citeturn2search35", "Risk stratification and escalation: need for **NIV/ICU**, response to therapy, and any contraindications/complications (e.g., suspected pneumothorax). citeturn2search15 ================================================================================ CDI MICRO‑TEMPLATES (APPEND YOUR LIBRARY HERE)", "diagnosis with acuity", "etiology/cause", "severity/organ dysfunction criteria", "objective evidence (vitals/labs/imaging)", "treatment/monitoring that supports severity ================================================================================"]}, {"id": "11", "title": "Decompensated Heart Failure", "tags": ["cardiology", "inpatient", "night-float", "acute-heart-failure", "guideline-based"], "date": "2026-02-21", "panic_card": ["Elevate HOB, monitor, IV access, supplemental O₂ to maintain **SpO₂ ≥92%** (use **88–92%** if chronic hypercapnia risk); start **NIV (BiPAP/CPAP) immediately** for severe dyspnea/flash edema.", "If SBP >**110 mmHg** with pulmonary edema: start **IV nitroglycerin 40–80 mcg/min**, titrate q3–5 min; add **IV loop diuretic 1–2.5× home oral daily dose (IV equivalent)**.", "If hypotension/shock: aim **MAP ≥65 mmHg**; start **norepinephrine** if needed; add **dobutamine 2–5 mcg/kg/min** for low-output signs; avoid large fluid boluses unless clear RV failure.", "Place Foley for strict I&O; target early urine output **≥150–200 mL/h** after diuretic dose; reassess lungs, BP, and urine q15–30 min.", "Treat precipitants now: ACS (ECG, troponin), tachyarrhythmia (rate/rhythm control), hypertensive crisis, infection.", "Confirm Before Proceed: invasive lines, intubation, or mechanical circulatory support should follow team discussion and indication verification."], "brief_overview": ["Acute decompensated HF (ADHF) is a spectrum from hypertensive flash pulmonary edema to cardiogenic shock; early trajectory depends on blood pressure, perfusion, and congestion phenotype. **Guideline Must‑Know:** Initial IV loop diuretic dose should be **1–2.5× the patient’s total daily oral loop diuretic (IV equivalent)**, then reassess diuresis within **2–6 h** (AHA/ACC/HFSA 2022).", "**Guideline Must‑Know:** If **SBP >110 mmHg** with severe pulmonary edema, prioritize **vasodilators (IV nitroglycerin 40–200 mcg/min or nitroprusside)** plus NIV; this often relieves dyspnea faster than diuretic alone and can avert intubation (AHA/ACC/HFSA 2022; ESC 2021).", "**Guideline Must‑Know:** In suspected cardiogenic shock, target **MAP ≥65 mmHg**; use **norepinephrine** as first‑line vasopressor and add **inotrope (dobutamine or milrinone)** for hypoperfusion with low output (AHA/ACC/HFSA 2022; SCAI shock consensus).", "**Guideline Must‑Know:** Early noninvasive ventilation (CPAP/BiPAP) reduces work of breathing and improves oxygenation in acute cardiogenic pulmonary edema; use unless contraindicated (ERS/ATS NIV guideline).", "**Guideline Must‑Know:** Diuretic resistance warrants stepped pharmacologic therapy: escalate loop dose, consider continuous infusion, and add thiazide‑type synergy (**chlorothiazide 500 mg IV** or **metolazone 2.5–5 mg PO**), while monitoring **K⁺/Mg²⁺/Na⁺** and renal function (AHA/ACC/HFSA 2022).", "**Guideline Must‑Know:** Avoid routine morphine; it may worsen outcomes via respiratory depression and hypotension. Reserve for refractory anxiety after other measures (AHA/ACC/HFSA 2022).", "Assess precipitants that change management now: **ACS**, tachyarrhythmia (AF with RVR), hypertensive crisis, medication nonadherence, high salt/fluid intake, infection, PE, thyroid disease, cardiorenal syndrome.", "What must happen now: stabilize airway/breathing/circulation, apply NIV if needed, start appropriate **vasodilator** (if hypertensive) or **pressor/inotrope** (if shock), give adequate **IV loop diuretic**, place Foley for strict I&O, obtain ECG/troponin/CXR/BMP/BNP, and identify a precipitant.", "What can wait hours: full echocardiography (unless shock/new murmur), GDMT titration beyond urgent holds/resumptions, sodium restriction counseling, advanced device discussions unless ongoing shock.", "Pitfalls: underdosing loop diuretic initially; giving large fluid boluses in left‑sided HF without clear RV failure; delaying vasodilator in hypertensive pulmonary edema; withholding diuretics due to rising creatinine despite congestion (cardiorenal syndrome).", "Oxygen strategy: target **SpO₂ ≥92%**; in chronic hypercapnic respiratory disease use **88–92%** and prefer NIV if work of breathing high.", "Vasodilators: **nitroglycerin** is first‑line for hypertensive pulmonary edema (start **40–80 mcg/min**, titrate rapidly); **nitroprusside** for severe afterload excess under ICU monitoring; avoid if **severe AS** or **RV infarction**. Monitor for hypotension.", "Diuretics: common starting **furosemide 40–80 mg IV** if diuretic‑naïve, or **2–2.5×** home oral dose as IV; aim **net −1 to −2 L/day** and early **urine ≥150–200 mL/h**; check BMP **q6–12 h** and re‑dose based on response.", "Inotropes: consider **dobutamine 2–20 mcg/kg/min** (short half‑life, tachyarrhythmia risk) or **milrinone 0.125–0.375 mcg/kg/min** (no bolus; watch **hypotension/renal clearance**) when hypoperfusion persists despite decongestion and MAP support.", "**Guideline Must‑Know:** Continue guideline‑directed medical therapy if hemodynamically stable; hold **beta‑blocker** temporarily in shock or severe fluid overload with low output; hold **RAASi/ARNI/MRA** for **K⁺ >5.5 mmol/L**, **Cr rise >30–50%**, or symptomatic hypotension; SGLT2 inhibitors can often be continued or initiated when stable (AHA/ACC/HFSA 2022).", "**Guideline Must‑Know:** Ultrafiltration is not first‑line for cardiorenal syndrome; reserve for refractory congestion after stepped pharmacologic diuresis fails (AHA/ACC/HFSA 2022).", "**Guideline Must‑Know:** Identify right‑sided or RV‑predominant failure (clear lungs, JVP high, hypotension); avoid aggressive vasodilators and consider cautious preload support while treating precipitant (AHA/ACC/HFSA 2022).", "Safety guardrails: maintain **K⁺ 4.0–5.0 mmol/L**, **Mg²⁺ ≥2.0 mg/dL**; avoid **Na⁺ correction >8–10 mmol/L per 24 h** if hyponatremic; monitor for **ototoxicity** with very high loop doses; use **heparin prophylaxis** unless contraindicated.", "Consults to consider: Cardiology for shock/ischemia/advanced therapies; ICU for escalating oxygen/pressors; Nephrology for refractory congestion or AKI; Electrophysiology for unstable arrhythmias."], "icu_consult_triggers": ["Persistent or worsening hypoxemia needing **NIV with FiO₂ ≥0.6** or impending intubation despite therapy.", "**MAP <65 mmHg** or rising lactate **>2–4 mmol/L** despite initial resuscitation and vasodilator/diuretic strategy.", "Sustained ventricular arrhythmia, high‑grade AV block with instability, or new ischemic ECG changes with hemodynamic compromise.", "Oliguria **<0.5 mL/kg/h** with **creatinine rise ≥0.5 mg/dL** in 24 h despite stepped diuresis and hemodynamic optimization.", "Suspected mechanical complication (acute MR/VSD) or need for mechanical circulatory support."], "orders_to_place_now": ["Order: Noninvasive ventilation (BiPAP/CPAP) — {mode, IPAP/EPAP or CPAP cm H₂O, FiO₂%, titration targets: **SpO₂ ≥92%** or **88–92%** if hypercapnia risk}", "Order: Nitroglycerin infusion — {start **40–80 mcg/min**, titrate q3–5 min to relieve dyspnea while maintaining **SBP ≥100–110 mmHg**}", "Order: Furosemide IV — {**dose mg IV now** = 1–2.5× home oral daily dose (IV equivalent) or **40–80 mg IV** if naïve; reassess urine in 2–6 h}", "Order: Foley catheter — {insert for strict I&O; goal early urine **≥150–200 mL/h**; daily weight}", "Order: Basic metabolic panel, magnesium — {baseline now, then **q6–12 h** while adjusting diuretics/vasoactives}", "Order: Cardiology consult — {reason: ADHF with {hypertensive pulmonary edema|suspected shock|refractory congestion}; urgency: {STAT|urgent}}"], "abim_cases": [{"case_id": "11A", "stem": "A 62‑year‑old with hypertension and known HFrEF (EF 30%) presents with acute severe dyspnea, pink frothy sputum, BP 190/110 mmHg, HR 120, RR 32, SpO₂ 86% on room air, diffuse rales, and no peripheral edema. ECG shows sinus tachycardia without ischemia. He takes furosemide 40 mg PO daily at home. CXR shows alveolar edema.", "options": ["Give 500 mL normal saline bolus, then start dobutamine", "Start high‑flow oxygen by nasal cannula and low‑dose morphine", "Initiate BiPAP and start IV nitroglycerin infusion, then give IV loop diuretic at 80–100 mg", "Start nitroprusside infusion only; avoid diuretics initially", "Give his home furosemide dose (40 mg IV) and observe"], "answer": "C", "explanation": "Hypertensive acute pulmonary edema is afterload‑driven; immediate **NIV** plus **rapidly titrated IV nitroglycerin** relieves congestion, followed by adequate **IV loop diuretic (≥2× home oral dose as IV)**. Saline bolus and morphine are harmful; nitroprusside may be used in ICU but nitroglycerin is appropriate and readily available. Guidelines emphasize vasodilator‑first strategy when **SBP >110 mmHg** (AHA/ACC/HFSA 2022; ESC 2021)."}, {"case_id": "11B", "stem": "A 74‑year‑old with chronic HFrEF (EF 25%) and CKD stage 4 (baseline creatinine 2.8 mg/dL) is admitted for edema, orthopnea, JVP 12 cm, crackles, and weight gain 5 kg. BP 118/72 mmHg, MAP 87, HR 92, SpO₂ 94% on 2 L. After **furosemide 120 mg IV**, urine output is 60 mL/h and creatinine rises to 3.4 mg/dL. He is comfortable, warm, and not hypotensive.", "options": ["Stop diuretics due to AKI and give 1 L normal saline", "Continue current dose and recheck BMP tomorrow", "Escalate diuresis with higher loop dose or continuous infusion and add metolazone 2.5–5 mg PO, with electrolyte monitoring", "Start ultrafiltration now because creatinine increased", "Start dobutamine for renal perfusion despite stable BP"], "answer": "C", "explanation": "This is congestive **cardiorenal syndrome**; the pitfall is **withholding decongestion due to creatinine rise**. Guidelines recommend stepped pharmacologic diuresis (escalated loop ± thiazide synergy) before considering ultrafiltration; inotropes are not indicated without hypoperfusion. Monitor **K⁺/Mg²⁺/Na⁺** and renal function closely (AHA/ACC/HFSA 2022)."}], "micro_questions": [{"q": "What is an appropriate initial IV loop diuretic dose for a patient on furosemide 40 mg PO daily at home?", "a": "**80–100 mg IV furosemide** (about **2–2.5×** the home oral daily dose as IV), then reassess within 2–6 hours."}, {"q": "What is the MAP goal in cardiogenic shock?", "a": "**MAP ≥65 mmHg** while addressing low output with inotrope and avoiding fluid overload."}, {"q": "What early urine output target suggests adequate decongestion after IV diuretic?", "a": "**≥150–200 mL/h** in the first hours, with a daily **net −1 to −2 L** goal if tolerated."}, {"q": "When should a thiazide‑type diuretic be added?", "a": "With diuretic resistance after adequate loop dosing; options include **chlorothiazide 500 mg IV** or **metolazone 2.5–5 mg PO** with electrolyte monitoring."}], "references": [{"label": "AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022)", "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063"}, {"label": "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2021)", "url": "https://academic.oup.com/eurheartj/article/42/36/3599/6358045"}, {"label": "ERS/ATS Clinical Practice Guidelines: Noninvasive Ventilation for Acute Respiratory Failure (2017)", "url": "https://www.atsjournals.org/doi/full/10.1164/rccm.201705-1325ST"}, {"label": "SCAI/ACC/AHA Expert Consensus on Cardiogenic Shock Classification and Management (2022)", "url": "https://www.jscai.org/article/S2772-9303(22)00005-3/fulltext"}], "cdi": ["Acute on chronic HFrEF due to {ischemia|dietary/medication nonadherence|hypertensive crisis}; severity: {acute respiratory failure with hypoxemia|shock}; evidence: {SpO₂, ABG, CXR edema, BNP}; treatment: {NIV, IV diuretics, vasodilator/pressors}.", "Volume overload with diuretic resistance; etiology: {cardiorenal syndrome}; evidence: {JVP elevation, edema, weight gain, low urine output, creatinine trend}; treatment: {escalated loop + thiazide synergy, strict I&O}.", "Hypertensive pulmonary edema; cause: afterload excess; evidence: {SBP, rales, CXR}; treatment: {IV nitroglycerin with titration targets, NIV, IV diuretic}.", "Cardiogenic shock; cause: {ischemia|advanced HFrEF}; evidence: {MAP <65 mmHg, lactate, cool extremities, oliguria}; treatment: {norepinephrine, inotrope, ICU, consider MCS}.", "Arrhythmia precipitant; type: {AF with RVR|VT}; evidence: {ECG, vitals}; treatment: {rate/rhythm control, anticoagulation decision}."]}, {"id": "12", "title": "Electrolyte Emergencies (Hyperkalemia/Hyponatremia)", "tags": ["electrolytes", "inpatient", "night-float", "hyperkalemia", "hyponatremia"], "date": "2026-02-20", "panic_card": ["Hyperkalemia with ECG changes or **K⁺ ≥6.5 mmol/L**: place on monitor, obtain ECG, give **calcium gluconate 10% 1 g IV over 5–10 min** (or **calcium chloride 1 g IV** via central line) and repeat if ECG not improving; then shift K⁺ with **regular insulin 10 units IV + dextrose 25 g**, add **nebulized albuterol 10–20 mg**, consider **sodium bicarbonate** if severe acidemia; arrange removal (loop diuretic, binder, or dialysis). citeturn2search24turn2search19", "Severe symptomatic hyponatremia (seizure, coma, active vomiting with obtundation): give **3% NaCl 100–150 mL IV over 10–20 min**, reassess, and repeat up to two more times aiming **+4–6 mmol/L** initial rise; check Na⁺ **q2–4 h**. citeturn2search18turn2search49", "Enforce correction limits: **Na⁺ rise ≤8–10 mmol/L per 24 h** (≤4–6 if high risk: malnutrition, alcoholism, liver disease, hypokalemia). Use **desmopressin (DDAVP) 2–4 μg IV** to “clamp” if rapid aquaresis emerges. citeturn2search51turn2search44", "If refractory hyperkalemia or life‑threatening arrhythmias: call nephrology for **urgent dialysis**. citeturn2search19", "Confirm Before Proceed: Before initiating vasopressin antagonists or ongoing hypertonic therapy, verify etiology/tonicity and chronicity to avoid **osmotic demyelination** or worsening hypovolemia. citeturn2search18"], "brief_overview": ["Night-float priorities: distinguish immediately dangerous **hyperkalemia** (ECG changes, **K⁺ ≥6.5**) from milder cases; for **hyponatremia**, triage by symptom severity and chronicity (acute ≤48 h vs chronic) and treat symptomatic cases with hypertonic saline boluses. citeturn2search24turn2search18", "**Guideline Must‑Know:** Hyperkalemia sequence = membrane stabilization (IV calcium) → intracellular shift (insulin/dextrose ± β₂‑agonist ± bicarbonate if acidemic) → removal (diuretics, potassium binders, or dialysis). Dialysis is definitive when refractory or with renal failure. citeturn2search19", "**Guideline Must‑Know:** UK Kidney Association 2023 update and prior Renal Association guidance endorse IV calcium for ECG changes or severe K⁺, insulin–glucose therapy with close hypoglycemia monitoring for at least **6 h**, and increasing use of modern binders (sodium zirconium cyclosilicate) over calcium polystyrene sulfonate. citeturn2search7turn2search8", "**Guideline Must‑Know:** For severe symptomatic hyponatremia, European 2014 guideline endorses **3% NaCl 100–150 mL** boluses repeated up to 3 times to achieve rapid 4–6 mmol/L rise and symptom relief. Continuous infusions are slower and risk overcorrection without strict protocols. citeturn2search38turn2search49", "**Guideline Must‑Know:** Maintain **daily Na⁺ correction ≤8–10 mmol/L** (≤4–6 if high risk) to prevent osmotic demyelination; consider **DDAVP clamp** (scheduled desmopressin with controlled hypertonic dosing) in high‑risk or rapidly autocorrecting patients. citeturn2search51turn2search46", "**Guideline Must‑Know:** Diagnostic first steps in hyponatremia: confirm hypotonicity (serum osmolality), then urine osmolality and urine Na⁺ to classify water intake vs ADH‑mediated causes; avoid early reliance on clinical volume assessment alone. citeturn2search17", "**Guideline Must‑Know:** Severe symptoms (seizure/coma), **Na⁺ <120 mmol/L** with deterioration, or failure to respond to initial boluses warrant ICU level monitoring and frequent labs **q2–4 h**. citeturn2search38", "**Guideline Must‑Know:** In hyperkalemia, modern binders (e.g., **sodium zirconium cyclosilicate 10 g TID ×48 h**) can reduce emergency dialysis needs and are endorsed by NICE for emergency use alongside standard care; onset is within hours (not minutes), so use adjunctive shifting first. citeturn2search30turn2search25turn2search26", "What must happen now (hyperkalemia): monitor on telemetry, repeat ECG after calcium; give insulin–dextrose (with preemptive dextrose infusion if glucose <7 mmol/L) and β₂‑agonist; start binder if available; identify causes (AKI, RAASi, acidosis); plan removal strategy—loop diuretics if urine output, dialysis if ESRD/refractory. citeturn2search8turn2search24", "What can wait (hyperkalemia): chronic medication reconciliation, diet counseling, long‑term RAASi strategy, outpatient binder titration. citeturn2search23", "What must happen now (hyponatremia): in severe/moderate symptoms, give **3% NaCl bolus** and reassess neurologic status and Na⁺; start DDAVP if brisk diuresis or high‑risk for overcorrection; halt hypotonic fluids and offending drugs. citeturn2search18turn2search51", "What can wait (hyponatremia): definitive SIAD therapy (fluid restriction, urea, salt + loop, cautious vaptan in select euvolemic cases after stabilization), endocrine workup (TSH, cortisol) after initial safety. citeturn2search18", "Pitfalls: missing pseudohyperkalemia (hemolysis, thrombocytosis/leukocytosis), treating transcellular shifts without addressing decreased excretion, under‑monitoring for post‑insulin hypoglycemia, and overcorrecting chronic hyponatremia after volume repletion (autocorrection). citeturn2search24turn2search8turn2search51", "Call ICU/nephrology early for hyperkalemia with arrhythmias, **K⁺ ≥6.5**, or rising despite therapy; call ICU for hyponatremia with seizures, impending respiratory compromise, or need for continuous hypertonic/DDAVP titration. citeturn2search24turn2search38", "Confirm Before Proceed: Avoid **tolvaptan** in hypovolemic hyponatremia or severe symptoms requiring hypertonic saline; avoid rapid normalizing targets—aim for **initial +4–6 mmol/L** then slow. citeturn2search38"], "icu_consult_triggers": ["Hyperkalemia with **ECG changes**, **K⁺ ≥6.5 mmol/L**, or ventricular arrhythmia despite initial therapy. citeturn2search24", "Hyponatremia with **seizure, coma, or rapidly worsening mental status** or need for repeated 3% NaCl boluses and DDAVP clamp. citeturn2search38", "Refractory hyperkalemia in **AKI/ESRD** or recurrence after shifts, requiring **urgent dialysis**. citeturn2search19", "Anticipated overcorrection risk (malnutrition, alcoholism, advanced liver disease, hypokalemia) necessitating **q2–4 h** labs and strict correction targets. citeturn2search51"], "orders_to_place_now": ["Order: Cardiac monitoring and 12‑lead ECG — {now; repeat after calcium and with any rhythm change} citeturn2search24", "Order: Calcium gluconate 10% IV — {1 g IV over 5–10 min; may repeat in 5–10 min if ECG changes persist} citeturn2search24", "Order: Regular insulin IV with dextrose — {10 units IV + 25 g dextrose; check capillary glucose q30–60 min × 6 h; start D10 if glucose <7 mmol/L} citeturn2search8", "Order: 3% sodium chloride bolus — {100–150 mL IV over 10–20 min; reassess neuro status/Na⁺; may repeat ×2} citeturn2search38turn2search49", "Order: Desmopressin (DDAVP) IV — {2–4 μg IV now if rapid aquaresis/high ODS risk; consider scheduled q6–8 h “clamp” with Na⁺ checks q2–4 h} citeturn2search51turn2search46", "Order: Potassium binder (sodium zirconium cyclosilicate) — {10 g PO now, then 10 g TID ×48 h alongside standard care} citeturn2search30"], "abim_cases": [{"case_id": "12A", "stem": "A 72‑year‑old man with CKD4 presents with weakness. Vitals are stable. ECG shows peaked T waves with QRS widening. Labs: K⁺ 6.9 mmol/L, bicarbonate 18 mmol/L, creatinine 3.1 mg/dL.", "options": ["Furosemide 40 mg IV and repeat potassium in 6 hours", "Calcium gluconate 10% 1 g IV now", "Sodium polystyrene sulfonate 30 g PO now", "Regular insulin 10 units IV with 25 g dextrose, no calcium", "Emergent hemodialysis only"], "answer": "B", "explanation": "IV calcium immediately stabilizes the myocardium in hyperkalemia with ECG changes; give **calcium gluconate 1 g IV** (or **calcium chloride via central line**) and reassess ECG, then proceed with insulin/dextrose and removal strategies. Deferring calcium risks malignant arrhythmia; dialysis may be needed but not as the first step when calcium can rapidly stabilize. citeturn2search24turn2search19"}, {"case_id": "12B", "stem": "A 58‑year‑old woman with severe alcoholism and malnutrition is admitted with confusion and falls. Na⁺ is 112 mmol/L, serum osmolality 250 mOsm/kg, urine osmolality 600 mOsm/kg, urine Na⁺ 45 mmol/L. After 1 L isotonic saline for presumed hypovolemia, she becomes more alert and develops brisk diuresis (urine output 300 mL/h); Na⁺ rises from 112 to 118 mmol/L in 4 hours.", "options": ["Continue isotonic saline at current rate", "Start 3% saline infusion targeting +12 mmol/L in 24 hours", "Administer desmopressin 2 μg IV now and give 3% NaCl bolus to cap correction", "Start tolvaptan 15 mg PO", "No action; observe as Na⁺ is improving", "Clinical practice guideline on diagnosis and treatment of hyponatraemia, 2014. https://link.springer.com/content/pdf/10.1007/s00134-014-3210-2.pdf citeturn2search37\n- AJKD Perspective: Hypertonic Saline for Hyponatremia—Meeting Goals and Avoiding Harm, 2022. https://www.ajkd.org/article/S0272-6386(21)00838-6/fulltext citeturn2search51\n- KDIGO Acute Hyperkalemia in the Emergency Department (Consensus Report), 2020. https://kdigo.org/wp-content/uploads/2018/04/KDIGO-Acute-Hyperkalemia-conf-report-FINAL.pdf citeturn2search19\n- UK Kidney Association Clinical Practice Guideline—Management of Hyperkalaemia in Adults, 2023 update. https://ukkidney.org/sites/default/files/FINAL%20VERSION%20-%20UKKA%20CLINICAL%20PRACTICE%20GUIDELINE%20-%20MANAGEMENT%20OF%20HYPERKALAEMIA%20IN%20ADULTS%20-%20191223_0.pdf citeturn2search7\n- NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia (updated 2022). https://www.nice.org.uk/guidance/ta599/resources/sodium-zirconium-cyclosilicate-for-treating-hyperkalaemia-pdf-82607272135621 citeturn2search29"], "answer": "C", "explanation": "High ODS risk (alcoholism, malnutrition) mandates **≤4–6 mmol/L** daily correction. Rapid aquaresis after volume repletion risks overcorrection; a **DDAVP clamp** plus controlled hypertonic bolus caps the rise and treats symptoms safely. Vaptans are contraindicated in severe symptomatic hyponatremia and hypovolemia. citeturn2search51turn2search46turn2search38"}], "micro_questions": [{"q": "Maximum safe daily Na⁺ correction in typical adults vs high‑risk patients?", "a": "**≤8–10 mmol/L per 24 h** (typical); **≤4–6 mmol/L per 24 h** if alcoholism, malnutrition, liver disease, or hypokalemia. citeturn2search51"}, {"q": "First drug for hyperkalemia with ECG changes?", "a": "IV calcium (gluconate 1 g or chloride 1 g via central line) to stabilize myocardium before shifting/removal therapies. citeturn2search24"}, {"q": "Insulin/dextrose regimen effect and monitoring?", "a": "10 units regular insulin IV + 25 g dextrose lowers K⁺ within 15–30 min; monitor glucose **q30–60 min for ~6 h** to prevent hypoglycemia. citeturn2search8"}, {"q": "Initial hypertonic saline approach for seizures from hyponatremia?", "a": "**3% NaCl 100–150 mL IV over 10–20 min**, repeat up to ×3 aiming +4–6 mmol/L. citeturn2search38turn2search49"}], "references": [{"label": "European Society of Endocrinology/ESICM/ERA‑EDTA. Clinical practice guideline on diagnosis and treatment of hyponatraemia, 2014", "url": "https://link.springer.com/content/pdf/10.1007/s00134-014-3210-2.pdf"}, {"label": "AJKD Perspective: Hypertonic Saline for Hyponatremia—Meeting Goals and Avoiding Harm, 2022", "url": "https://www.ajkd.org/article/S0272-6386(21)00838-6/fulltext"}, {"label": "KDIGO Acute Hyperkalemia in the Emergency Department (Consensus Report), 2020", "url": "https://kdigo.org/wp-content/uploads/2018/04/KDIGO-Acute-Hyperkalemia-conf-report-FINAL.pdf"}, {"label": "UK Kidney Association Clinical Practice Guideline—Management of Hyperkalaemia in Adults, 2023 update", "url": "https://ukkidney.org/sites/default/files/FINAL%20VERSION%20-%20UKKA%20CLINICAL%20PRACTICE%20GUIDELINE%20-%20MANAGEMENT%20OF%20HYPERKALAEMIA%20IN%20ADULTS%20-%20191223_0.pdf"}, {"label": "NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia (updated 2022)", "url": "https://www.nice.org.uk/guidance/ta599/resources/sodium-zirconium-cyclosilicate-for-treating-hyperkalaemia-pdf-82607272135621"}], "cdi": ["Hyperkalemia, life‑threatening due to {AKI/ESRD/RAAS inhibitor}; ECG changes present; K⁺ **{value} mmol/L**; treatments given (IV calcium, insulin/dextrose, β₂‑agonist, binder/dialysis); response on repeat ECG/labs.", "Hyponatremia, {acute vs chronic} with {severe/moderate} symptoms due to {SIADH/hypovolemia/hypervolemia}; Na⁺ **{value} mmol/L**, serum/urine osmolality and urine Na⁺; 3% NaCl boluses and DDAVP use; correction targets and monitoring plan.", "Encephalopathy due to hyponatremia, {acute/chronic}; objective neuro findings (seizure, GCS); imaging/labs supporting diagnosis; treatment and safety measures taken.", "Risk for osmotic demyelination: {alcoholism/malnutrition/liver disease/hypokalemia}; stated **Na⁺ correction limits** and frequency of monitoring.", "Dialysis candidacy/consultation if refractory hyperkalemia; indication documented (persistent **K⁺ ≥6.5**, ECG changes, failure of medical therapy). citeturn2search19turn2search38"]}, {"id": "13", "title": "Endocrine Crises", "tags": ["endocrinology", "inpatient", "night-float"], "date": "2026-02-21", "panic_card": ["ABCs, monitor, large-bore IVs, bedside glucose; treat shock with balanced crystalloids and target **MAP ≥65 mmHg** while sending core labs (BMP, VBG/ABG, serum ketones/β‑hydroxybutyrate, osmolality, TSH/FT4/FT3 if thyrotoxic, cortisol if feasible) and infection workup. citeturn2search1turn2search13", "Suspected adrenal crisis: give **hydrocortisone 100 mg IV now**, then **200 mg/24 h** (continuous or 50 mg IV q6h); do not delay for labs. citeturn2search41turn2search42", "DKA/HHS: start fluids first; begin insulin only when **K⁺ ≥3.3 mmol/L** and continue close K⁺ repletion; add dextrose when glucose approaches **~11.1–13.9 mmol/L (200–250 mg/dL)**. citeturn2search13", "Thyroid storm: **β‑blocker (esmolol or propranolol)**, give **thionamide (PTU or methimazole)**, then **iodine ≥1 h later**, plus **glucocorticoid**; avoid aspirin. citeturn2search53turn2search31", "Myxedema coma: passive rewarming, ventilatory support, **IV levothyroxine 200–400 mcg** (with or without low‑dose liothyronine) and empiric stress‑dose steroids. citeturn2search11", "Severe hypercalcemia (≥**3.5 mmol/L** [**14 mg/dL**]): aggressive isotonic fluids, **calcitonin**, and **denosumab or IV bisphosphonate**; limit calcitonin to 48–72 h. citeturn2search47turn2search50"], "brief_overview": ["Endocrine emergencies on call commonly include **DKA/HHS**, **adrenal crisis**, **thyroid storm**, **myxedema coma**, and **hypercalcemic crisis**; prioritize hemodynamics, oxygenation, fluids, and rapid, guideline‑based disease‑specific therapy. citeturn2search1turn2search13", "**Guideline Must‑Know:** For DKA/HHS, 2024 ADA/EASD consensus emphasizes three treatment pillars—**fluids, insulin, potassium**—with quantitative **β‑hydroxybutyrate** preferred for diagnosis and resolution criteria. citeturn2search13", "**Guideline Must‑Know:** Start insulin only after **K⁺ ≥3.3 mmol/L**; replete K⁺ if 3.3–5.2 mmol/L and hold insulin if <3.3 mmol/L; monitor K⁺ and glucose hourly in early therapy. citeturn2search13", "**Guideline Must‑Know:** ADA “Diabetes Care in the Hospital—2025” recommends inpatient glycemic targets **7.8–10.0 mmol/L (140–180 mg/dL)** for most adults and structured order sets for dysglycemia. citeturn2search20", "**Guideline Must‑Know:** Thyroid storm requires **β‑blocker → thionamide → iodine (≥1 h later) + glucocorticoid**; use **PTU** if severe and early due to T4→T3 inhibition; choose **esmolol** if decompensated HF. citeturn2search53", "**Guideline Must‑Know:** Japan Thyroid Association/JES 2016 supports multimodal therapy and ICU admission criteria for storm (organ failure, severe CHF, shock); Burch‑Wartofsky is supportive but **diagnosis is clinical**. citeturn2search31turn2search30", "**Guideline Must‑Know:** Myxedema coma management centers on airway/ventilation, cautious fluids, **IV levothyroxine 200–400 mcg** (± liothyronine), and empiric hydrocortisone until AI is excluded. citeturn2search11", "**Guideline Must‑Know:** Adrenal crisis: **hydrocortisone 100 mg IV bolus → 200 mg/24 h infusion or 50 mg IV q6h** plus isotonic fluids; draw cortisol/ACTH if feasible but **do not delay treatment**. citeturn2search41turn2search42", "**Guideline Must‑Know:** Hypercalcemia of malignancy: give isotonic fluids, **calcitonin** for rapid effect (tachyphylaxis ≤72 h), and **denosumab preferred** over IV bisphosphonate when feasible; treat tumor to prevent recurrence. citeturn2search50turn2search48", "In suspected sepsis overlap (DKA/HHS with infection), apply sepsis bundles and pressor targets (**MAP ≥65 mmHg**) while avoiding rapid sodium correction beyond **8–10 mmol/L/24 h**. citeturn2search1", "Distinguish **DKA** (acidosis/ketosis) from **HHS** (hyperosmolality, minimal ketosis); some patients have overlap; the 2024 consensus adds explicit **HHS resolution criteria**. citeturn2search13", "SGLT2 inhibitor‑associated **euglycemic DKA** presents with normal or mildly elevated glucose; still requires insulin, dextrose‑containing fluids, and stopping the SGLT2. citeturn2search13", "For storm with AF and decompensated HF, use **short‑acting β‑blocker (esmolol)** under monitoring; avoid high‑dose propranolol in shock; consider early ICU and cooling. citeturn2search53", "Myxedema coma pitfalls: avoid active external rewarming (risk of vasodilation collapse), check for precipitating infection, **correct hyponatremia slowly**; ventilatory support often required. citeturn2search11", "Hypercalcemic crisis pearls: correct volume deficit first; avoid loop diuretics until euvolemia; consider **zoledronic acid 4 mg IV** or **denosumab 120 mg SC**; expect effect in 24–72 h (use calcitonin for bridging). citeturn2search50", "What must happen now: stabilize ABCs, fluids, focused labs, start disease‑specific therapy (hydrocortisone for suspected AI; insulin for DKA/HHS when K⁺ safe; β‑blocker/thionamide/iodine/steroid for storm; IV LT4 for coma; fluids+calcitonin+antiresorptive for hypercalcemia). citeturn2search13turn2search41turn2search53turn2search11turn2search50", "What can wait (after stabilization): identify triggers (infection, drugs, nonadherence), transition to subcutaneous insulin, endocrine testing refinement, and oncologic therapy planning. citeturn2search20"], "icu_consult_triggers": ["Shock or pressor need, **pH <7.0**, **K⁺ <2.5 or >6.0 mmol/L**, **effective osmolality ≥320 mOsm/kg** with altered mental status, or refractory hypoventilation/hypercapnia. citeturn2search13", "Thyroid storm with heart failure, arrhythmia refractory to β‑blockade, or multiorgan failure; myxedema coma with hypothermia and CO₂ retention requiring ventilatory support. citeturn2search53turn2search31turn2search11", "Severe hypercalcemia **(≥3.5 mmol/L [14 mg/dL])** with neurologic changes or renal failure despite initial therapy. citeturn2search50"], "orders_to_place_now": ["Order: Balanced crystalloid bolus/infusion — {rate mL/h, reassess MAP ≥65 mmHg, urine output, lactate} citeturn2search1", "Order: Insulin infusion (DKA/HHS) — {start when K⁺ ≥3.3 mmol/L; initial 0.1 U/kg/h; add D10/½NS when glucose ≤11.1–13.9 mmol/L (200–250 mg/dL)} citeturn2search13", "Order: Potassium chloride replacement — {hold insulin if K⁺ <3.3; replace to 4.0–5.0 mmol/L; telemetry} citeturn2search13", "Order: Hydrocortisone stress dosing — {100 mg IV now, then 50 mg IV q6h or 200 mg/24 h infusion} citeturn2search41", "Order: Thyroid storm bundle — {esmolol infusion titration; methimazole {dose} or PTU {dose}; iodine {start ≥1 h after thionamide}; dexamethasone {dose}} citeturn2search53turn2search31", "Order: Hypercalcemia therapy — {calcitonin 4 IU/kg SC/IM q12h × 48–72 h max; denosumab 120 mg SC now or zoledronic acid 4 mg IV once; aggressive isotonic fluids} citeturn2search50"], "abim_cases": [{"case_id": "13A", "stem": "A 45‑year‑old with type 1 diabetes presents with abdominal pain, Kussmaul respirations, and dehydration. Labs: glucose 28 mmol/L (504 mg/dL), β‑hydroxybutyrate 5.0 mmol/L, pH 7.23, HCO₃⁻ 14 mmol/L, anion gap 22, **K⁺ 2.9 mmol/L**. Vitals: HR 118, BP 104/62.", "options": ["Start IV regular insulin at 0.1 U/kg/h immediately", "Give 1 ampule IV sodium bicarbonate and start insulin", "Begin isotonic fluids and **replete potassium first**, then start insulin when K⁺ ≥3.3 mmol/L", "Start dextrose 10% infusion now to prevent hypoglycemia", "Administer subcutaneous rapid‑acting insulin 0.2 U/kg every 2 hours"], "answer": "C", "explanation": "Insulin therapy is **contraindicated until K⁺ ≥3.3 mmol/L** due to arrhythmia risk; initiate fluids and aggressive potassium replacement first, then insulin infusion with hourly monitoring. Bicarbonate is not indicated at pH 7.23. Subcutaneous insulin may be used for mild‑moderate DKA in selected settings, but the immediate priority here is potassium correction before any insulin. citeturn2search13"}, {"case_id": "13B", "stem": "A 62‑year‑old woman on empagliflozin presents with malaise and nausea. Vitals: HR 110, BP 112/68, RR 22. Labs: glucose 10.7 mmol/L (193 mg/dL), β‑hydroxybutyrate 3.8 mmol/L, pH 7.28, HCO₃⁻ 16 mmol/L, anion gap 18, K⁺ 4.2 mmol/L. UA: ketonuria. She is euvolemic.", "options": ["Reassure; normal glucose excludes DKA", "Start insulin infusion with dextrose‑containing fluids; stop SGLT2 inhibitor", "Give bicarbonate infusion until pH >7.35", "Start basal insulin only and observe", "Treat as HHS with aggressive fluids only", "**Standards of Care in Diabetes—2025: Diabetes Care in the Hospital**. Diabetes Care (Suppl 1). https://diabetesjournals.org/care/article/48/Supplement_1/S321/157551/ citeturn2search20\n- American Thyroid Association. **2016 Hyperthyroidism/Thyrotoxicosis Guideline** (storm management). https://www.liebertpub.com/doi/pdf/10.1089/thy.2016.0229 citeturn2search53\n- Japan Thyroid Association/JES. **2016 Thyroid Storm Management Guideline**. https://www.eurothyroid.com/files/download/japan-guidelines-thyroid-storm-2016.pdf citeturn2search31\n- Endocrine Society. **Primary Adrenal Insufficiency Guideline (2016)**. https://www.endocrine.org/clinical-practice-guidelines/primary-adrenal-insufficiency citeturn2search41\n- Endocrine Society. **Treatment of Hypercalcemia of Malignancy in Adults (2022)**. https://academic.oup.com/jcem/article/108/3/507/6916871 citeturn2search50"], "answer": "B", "explanation": "This is **euglycemic DKA** associated with SGLT2 inhibitors; treatment mirrors DKA with **insulin plus dextrose‑containing fluids** to suppress ketogenesis while avoiding hypoglycemia; discontinue the SGLT2 agent. The pitfall is dismissing DKA because glucose is not markedly elevated. citeturn2search13"}], "micro_questions": [{"q": "Minimum K⁺ level before starting IV insulin in DKA/HHS?", "a": "**≥3.3 mmol/L**; correct K⁺ below this threshold before insulin due to arrhythmia risk. citeturn2search13"}, {"q": "Initial steroid and dose for suspected adrenal crisis?", "a": "**Hydrocortisone 100 mg IV**, then **200 mg over 24 h** (continuous or 50 mg IV q6h). citeturn2search41"}, {"q": "Sequence for thyroid storm antithyroid therapy?", "a": "**β‑blocker → thionamide → iodine (≥1 h later) + glucocorticoid**. citeturn2search53"}, {"q": "Severe hypercalcemia threshold and first‑line antiresorptives?", "a": "**≥3.5 mmol/L (14 mg/dL)**; use **denosumab** or **IV bisphosphonate**, with **calcitonin** as bridge. citeturn2search50"}], "references": [{"label": "ADA/EASD/AACE/JBDS/DTS. **Hyperglycemic Crises in Adults With Diabetes—Consensus Report (2024)**. Diabetes Care", "url": "https://diabetesjournals.org/care/article/47/8/1257/156808/"}, {"label": "ADA. **Standards of Care in Diabetes—2025: Diabetes Care in the Hospital**. Diabetes Care (Suppl 1)", "url": "https://diabetesjournals.org/care/article/48/Supplement_1/S321/157551/"}, {"label": "American Thyroid Association. **2016 Hyperthyroidism/Thyrotoxicosis Guideline** (storm management)", "url": "https://www.liebertpub.com/doi/pdf/10.1089/thy.2016.0229"}, {"label": "Japan Thyroid Association/JES. **2016 Thyroid Storm Management Guideline**", "url": "https://www.eurothyroid.com/files/download/japan-guidelines-thyroid-storm-2016.pdf"}, {"label": "Endocrine Society. **Primary Adrenal Insufficiency Guideline (2016)**", "url": "https://www.endocrine.org/clinical-practice-guidelines/primary-adrenal-insufficiency"}, {"label": "Endocrine Society. **Treatment of Hypercalcemia of Malignancy in Adults (2022)**", "url": "https://academic.oup.com/jcem/article/108/3/507/6916871"}], "cdi": ["Diabetic ketoacidosis or hyperosmolar hyperglycemic state: acuity, severity (pH/HCO₃⁻/β‑hydroxybutyrate/osmolality), precipitant (infection, nonadherence, SGLT2 inhibitor), objective values, and insulin/fluids/electrolyte therapy.", "Adrenal crisis due to primary/secondary adrenal insufficiency: trigger, hypotension/shock, electrolyte abnormalities (hyponatremia/hyperkalemia), cortisol/ACTH if obtained, and hydrocortisone dosing/response.", "Thyroid storm: etiology (Graves’, toxic nodular), organ dysfunction (fever, CNS, CHF, arrhythmia), specific sequence of β‑blocker → thionamide → iodine → steroid, and ICU need.", "Myxedema coma: precipitant, hypothermia, ventilatory failure, hyponatremia, IV levothyroxine dose (± liothyronine), empiric steroids, and ventilatory support.", "Hypercalcemia of malignancy: severity (peak corrected/ionized Ca²⁺), etiology (PTHrP/osteolytic/calcitriol), renal/neurologic impact, fluids + calcitonin and **denosumab/IV bisphosphonate**, and oncology plan. citeturn2search50"]}, {"id": "14", "title": "Fever & Empiric Antibiotics", "tags": ["infectious-diseases", "inpatient", "night-float"], "date": "2026-02-21", "panic_card": ["Assess ABCs; stabilize airway/breathing; target **SpO₂ 92–96%** (or **88–92%** if chronic hypercapnia risk) and **MAP ≥65 mmHg**; give **30 mL/kg** balanced crystalloid rapidly if septic shock.", "Obtain **blood cultures ×2 sets** from different sites before antibiotics if this will not delay therapy; if shock, **start antibiotics within 1 hour**.", "Start guideline-concordant broad-spectrum therapy based on syndrome and risk (e.g., **cefepime or piperacillin–tazobactam ± vancomycin**; add **meropenem** if ESBL risk).", "Check **lactate** and repeat if initial elevated; place continuous cardiac and pulse oximetry monitoring; treat fever discomfort with **acetaminophen** unless contraindicated.", "Confirm Before Proceed: if meningitis suspected, give **empiric antibiotics immediately after blood cultures**; do not delay for CT/LP beyond **1 hour**."], "brief_overview": ["Fever on nights demands rapid triage for sepsis vs localized infection; differentiate unstable (shock, hypoxemia, altered mental status) from stable—start resuscitation and antibiotics early in shock while obtaining cultures.", "**Guideline Must‑Know:** Surviving Sepsis recommends **antibiotics within 1 hour** for septic shock and as soon as possible for sepsis after appropriate evaluation; each hour of delay increases mortality.", "**Guideline Must‑Know:** Draw **two sets of blood cultures** (aerobic/anaerobic) from separate sites before first dose when feasible; do not delay therapy in shock to finish cultures.", "Initial empiric choices hinge on source: urinary, pneumonia (CAP vs HAP/VAP), intra‑abdominal, skin/soft tissue, catheter‑related bloodstream infection, meningitis/encephalitis, or unknown source.", "**Guideline Must‑Know:** For HAP/VAP or prior IV antibiotics/structural lung disease, start **anti‑pseudomonal β‑lactam** (e.g., cefepime, piperacillin–tazobactam, or meropenem) ± **MRSA** coverage (vancomycin) depending on local MRSA prevalence and risk factors.", "**Guideline Must‑Know:** In CAP without severe disease or MRSA/Pseudomonas risks, **ceftriaxone + azithromycin** or **respiratory fluoroquinolone**; avoid routine anaerobic coverage for aspiration unless **abscess/empyema** suspected.", "**Guideline Must‑Know:** Febrile neutropenia (ANC **<0.5 ×10⁹/L** or expected to drop) requires **immediate anti‑pseudomonal β‑lactam** (cefepime, piperacillin–tazobactam, or meropenem) within **1 hour**; add vancomycin only for specific indications (MRSA risk, catheter infection, pneumonia, hemodynamic instability).", "**Guideline Must‑Know:** Suspected meningitis: give **vancomycin + ceftriaxone (or cefotaxime)**; add **ampicillin** if age ≥50/immunocompromised for Listeria; add **acyclovir** if encephalitis features; do not delay antibiotics for imaging/LP beyond **1 hour**.", "**Guideline Must‑Know:** Catheter‑related bloodstream infection: obtain **paired blood cultures (peripheral + line)**; consider **line removal** for S. aureus, Pseudomonas, Candida, or severe sepsis; start vancomycin plus gram‑negative coverage tailored to risk.", "For complicated intra‑abdominal infection, use **piperacillin–tazobactam** or **cefepime + metronidazole**; use **meropenem** if ESBL risk or severe sepsis; arrange source control (surgery/IR).", "In UTI/pyelonephritis with sepsis, give **ceftriaxone** or **cefepime**; escalate to **piperacillin–tazobactam** or **meropenem** for obstruction, recent healthcare exposure, or ESBL risk; obtain renal ultrasound if obstruction suspected.", "Document allergies carefully; in low‑risk penicillin “allergy” (non‑IgE, remote rash), β‑lactams are usually safe; consider test dose if needed—this improves outcomes and stewardship.", "Adjust doses for renal/hepatic dysfunction; monitor vancomycin AUC/levels; avoid stacking nephrotoxins (loop diuretics, ACEi/ARBs, IV contrast) when possible.", "De‑escalate within **48–72 h** based on cultures and clinical response; target **5–7 days** for many uncomplicated bacterial syndromes (e.g., HAP without complications), longer when deep-seated or source not controlled.", "Pitfalls: missing hypoperfusion (normal BP but **lactate ≥4 mmol/L**), under‑dosing in obesity, unnecessary anaerobic coverage for aspiration pneumonitis, and forgetting antifungal/atypical coverage in high‑risk hosts.", "**Guideline Must‑Know:** Hemodynamic targets: **MAP ≥65 mmHg**; if persistent hypotension after fluids, start **norepinephrine** first‑line; add **vasopressin** if needed; reassess volume responsiveness with dynamic measures.", "Confirm Before Proceed: before removing a suspected infected central line, ensure paired cultures and assess for instability/tunnel infection; removal is irreversible and impacts diagnostic yield/source control documentation."], "icu_consult_triggers": ["Persistent **MAP <65 mmHg** or rising **lactate ≥4 mmol/L** despite fluids and early antibiotics.", "Escalating oxygen needs to **HFNC/NRB** or new **acute hypoxemic respiratory failure**.", "New **altered mental status**, focal neurologic deficits, or concern for **meningitis/encephalitis**.", "Rapidly progressive soft tissue infection, suspected **necrotizing fasciitis**, or **compartment syndrome**."], "orders_to_place_now": ["Order: Sepsis bundle labs — {CBC, CMP, magnesium, phosphorus, lactate now and 2–4 h, PT/INR, aPTT}", "Order: Blood cultures ×2 — {two peripheral sites before first antibiotic dose if feasible}", "Order: Empiric antibiotics — {syndrome={HAP/VAP, CAP, UTI/pyelo, IAI, unknown}, agents={cefepime or piperacillin–tazobactam ± vancomycin; meropenem if ESBL risk}, time=now, renal_dose=adjust}", "Order: Imaging — {CXR portable now; add CT {abdomen/pelvis} with contrast if IAI suspected; CT head before LP only if focal deficits, immunocompromise, or papilledema}", "Order: Fluid resuscitation — {balanced crystalloid 30 mL/kg bolus; reassess hemodynamics; start norepinephrine if MAP <65 mmHg after fluids}"], "abim_cases": [{"case_id": "14A", "stem": "A 72‑year‑old man with diabetes presents from the ward with fever 39.2°C, HR 118, BP 88/54 mmHg, RR 26, SpO₂ 93% on 2 L. He is confused. Exam shows suprapubic tenderness and a chronic Foley. Labs: WBC 17 ×10⁹/L, creatinine 2.1 mg/dL (baseline 1.0), lactate 4.2 mmol/L. Chest x‑ray is clear. Two nurses are at bedside to draw cultures.", "options": ["Await blood culture completion before giving antibiotics", "Give 30 mL/kg crystalloid, start norepinephrine if needed, and administer cefepime plus vancomycin now", "Start acetaminophen and repeat vitals in 2 hours", "Order CT abdomen/pelvis first to evaluate for obstruction", "Start ceftriaxone and delay pressors until after 3 L fluids regardless of MAP"], "answer": "B", "explanation": "Early broad‑spectrum antibiotics within **1 hour** of septic shock and **30 mL/kg** fluids with pressors to **MAP ≥65 mmHg** improve survival per Surviving Sepsis. Obtain cultures first if it does not delay therapy, but do not wait in shock. Cefepime plus vancomycin covers gram‑negatives including Pseudomonas and MRSA risk from chronic devices; imaging can follow stabilization."}, {"case_id": "14B", "stem": "A 63‑year‑old woman with prior stroke aspirates during dinner and develops fever 38.6°C and cough 6 hours later. She is stable: BP 132/78, HR 96, SpO₂ 95% on room air. CXR shows right lower lobe infiltrate without cavitation or effusion. No severe periodontal disease. No prior MRSA/Pseudomonas risks.", "options": ["Start ampicillin–sulbactam for “aspiration” to cover anaerobes routinely", "Start ceftriaxone plus azithromycin and withhold anaerobic coverage", "Start piperacillin–tazobactam plus vancomycin for broad coverage", "Start levofloxacin plus metronidazole for anaerobes", "Withhold all antibiotics because aspiration pneumonitis never needs antibiotics", "A: **ANC <0.5 ×10⁹/L** or expected to fall below that within 48 hours warrants immediate anti‑pseudomonal β‑lactam.\n- Q: When do you add anaerobic coverage in aspiration?  \n  A: Only if **lung abscess, empyema, or severe periodontal disease/necrotizing infection** is suspected.\n- Q: What MAP target guides vasopressor titration?  \n  A: **MAP ≥65 mmHg** with norepinephrine first‑line; add vasopressin if needed."], "answer": "B", "explanation": "Guidelines advise **no routine anaerobic coverage** for suspected aspiration pneumonia unless **abscess/empyema** or poor dentition/necrosis; standard CAP therapy is appropriate. The pitfall is reflexively adding anaerobic therapy without indications, increasing adverse effects and resistance."}], "micro_questions": [{"q": "What is the antibiotic timing goal in septic shock?", "a": "Administer broad‑spectrum antibiotics within **1 hour** of recognition after obtaining cultures if this does not delay therapy."}, {"q": "Define febrile neutropenia by ANC.", "a": "**ANC <0.5 ×10⁹/L** or expected to fall below that within 48 hours warrants immediate anti‑pseudomonal β‑lactam."}, {"q": "When do you add anaerobic coverage in aspiration?", "a": "Only if **lung abscess, empyema, or severe periodontal disease/necrotizing infection** is suspected."}, {"q": "What MAP target guides vasopressor titration?", "a": "**MAP ≥65 mmHg** with norepinephrine first‑line; add vasopressin if needed."}], "references": [{"label": "Surviving Sepsis Campaign Guidelines 2021", "url": "https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-guidelines-2021"}, {"label": "ATS/IDSA Community‑Acquired Pneumonia Guideline 2019", "url": "https://www.atsjournals.org/doi/10.1164/rccm.201908-1581ST"}, {"label": "IDSA Febrile Neutropenia in Adults Guideline 2010 (with updates/ASCO‑IDSA 2018)", "url": "https://academic.oup.com/cid/article/52/4/e56/382256"}, {"label": "IDSA/ATS HAP/VAP Guideline 2016", "url": "https://www.idsociety.org/practice-guideline/hospital-acquired-and-ventilator-associated-pneumonia/"}], "cdi": ["Sepsis due to suspected catheter‑associated UTI, with acute kidney injury: include acuity, source, organism if known, **objective evidence** (T 39.2°C, **lactate 4.2 mmol/L**, hypotension, WBC 17), and treatments (30 mL/kg fluids, norepinephrine, cefepime + vancomycin).", "Hospital‑acquired pneumonia vs aspiration pneumonia: specify type, risk factors (recent hospitalization/ventilation), radiographic findings, oxygen requirement, and chosen empiric regimen with rationale (no anaerobes unless abscess/empyema).", "Febrile neutropenia due to chemotherapy: include **ANC value**, hemodynamic status, suspected source, and immediate anti‑pseudomonal therapy timing; note MRSA indications if adding vancomycin.", "Catheter‑related bloodstream infection suspected: document paired cultures, line status (kept vs removed with indication), organism if available, and hemodynamic impact; capture source control steps and ID consult if obtained."]}, {"id": "15", "title": "GI Bleeding", "tags": ["gastroenterology", "inpatient", "night-float", "hemorrhage", "critical-care"], "date": "2026-02-21", "panic_card": ["Secure ABCs; two large-bore IVs; start balanced crystalloids; target **MAP ≥65 mmHg**; if septic physiology suspected, begin sepsis bundle and **antibiotics within 1 h**. citeturn2search41turn2search46", "Transfuse packed RBCs for **Hb <7 g/dL** (consider **8 g/dL** if CAD/orthopedic/cardiac surgery); activate MTP if ongoing shock. citeturn2search35turn2search40", "Suspected variceal UGIB: start **octreotide 50 mcg IV bolus, then 50 mcg/h** and **ceftriaxone 1 g IV daily (7 d)**; arrange endoscopy **≤12 h**. citeturn2search15", "Nonvariceal UGIB: give **erythromycin 250 mg IV 20–90 min pre‑EGD**; plan EGD **≤24 h**; initiate post‑hemostasis **high‑dose PPI**. citeturn2search24turn2search29", "Brisk hematochezia with instability: obtain **CTA A/P now** to localize and enable IR embolization; urgent colonoscopy rarely improves outcomes in severe LGIB. citeturn2search59turn2search34", "Confirm Before Proceed: use **andexanet alfa/idarucizumab** only for life‑threatening DOAC‑associated bleeding given thrombotic risk; consider **4F‑PCC** if specific antidote unavailable. citeturn2search63turn2search61"], "brief_overview": ["GI bleeding on nights splits into UGIB (proximal to ligament of Treitz) and LGIB (colonic) with different first moves: stabilize, risk‑stratify, choose endoscopy vs CTA appropriately; early resuscitation and restrictive transfusion strategy (**Hb <7 g/dL**) reduce harm. **Guideline Must‑Know:** AABB 2023 endorses restrictive thresholds, with **8 g/dL** reasonable for selected cardiac contexts. citeturn2search35", "**Guideline Must‑Know:** For hospitalized UGIB, perform EGD **within 24 h** after stabilization; pre‑endoscopic **erythromycin 250 mg IV** improves visualization and reduces repeat EGD; high‑dose PPI is recommended after endoscopic hemostasis of ulcer bleeding. citeturn2search24turn2search29", "**Guideline Must‑Know:** For variceal hemorrhage, start vasoactive therapy (octreotide or terlipressin) plus **ceftriaxone** at presentation; perform band ligation early (typically **≤12 h**); consider **preemptive TIPS** in high‑risk patients (e.g., Child‑Pugh **C 10–13** or **B with active bleeding**). citeturn2search15turn2search10", "**Guideline Must‑Know:** For LGIB with hemodynamic significance, **CTA** is preferred for localization and guides transcatheter embolization; routine urgent colonoscopy within 24 h has not shown outcome benefit; most inpatient colonoscopies can be **non‑urgent** (≤14 d if stable). citeturn2search59turn2search34", "**Guideline Must‑Know:** Risk scores: use **Glasgow‑Blatchford (GBS)** at first assessment to identify very‑low‑risk UGIB (GBS **0–1**) for potential discharge; GBS outperforms pre‑endoscopic Rockall for predicting interventions. citeturn2search24turn2search58", "**Guideline Must‑Know:** Transfusion/product targets: maintain **platelets >50 ×10⁹/L** for active bleeding needing hemostasis; reverse **warfarin** with PCC for life‑threatening bleeding; for DOACs, use **andexanet** (apixaban/rivaroxaban) or **idarucizumab** (dabigatran) when bleeding is life‑threatening; otherwise hold drug/supportive care. citeturn2search59turn2search63", "In UGIB, give **PPI after** endoscopic hemostasis (continuous or intermittent high‑dose for 72 h, then BID for 2 weeks); pre‑EGD PPI has uncertain benefit and is not strongly recommended for outcomes. citeturn2search24", "**Guideline Must‑Know:** Endoscopic hemostasis options for ulcers include thermal (heater probe/bipolar), mechanical (clips), injection (epinephrine as adjunct only), with **hemostatic powder** for active bleeding and **over‑the‑scope clips** for recurrent bleeding; consider IR embolization if endoscopy fails. citeturn2search24", "Distinguish variceal stigmata (cirrhosis, portal hypertension signs) from nonvariceal causes; if uncertain and unstable, treat as variceal (octreotide + antibiotics) while arranging urgent EGD. **Confirm Before Proceed:** avoid delaying vasoactive therapy for diagnostic certainty. citeturn2search15", "**Guideline Must‑Know:** Sepsis bundle if infection suspected: **30 mL/kg** crystalloid for hypoperfusion, dynamic fluid assessment, and **MAP 65 mmHg** with norepinephrine first‑line. GI bleeding with fever/ascites or aspiration risk warrants vigilance for sepsis. citeturn2search41turn2search46", "In LGIB, after CTA‑positive localization, **IR embolization within ~90 min** can control bleeding with high technical success; monitor for bowel ischemia; coordinate with GI for subsequent diagnostic colonoscopy when stable. citeturn2search34", "**Guideline Must‑Know:** Antithrombotic resumption: resume **aspirin for secondary prevention** once hemostasis achieved; individualized timing for anticoagulation (often ~7 days) balancing rebleed vs thrombosis; document plan with GI/Cardiology/Heme. citeturn2search59", "ICU triggers include refractory hypotension, transfusion needs **>4 units/24 h**, persistent hematemesis/melena with rising lactate, or escalating oxygen/airway support; consider early anesthesia involvement for high‑risk EGD. citeturn2search41", "**Guideline Must‑Know:** For brisk hematochezia with shock, remember an **upper source is possible**; consider EGD when suspicion moderate/high even if CTA pending or negative. citeturn2search26", "Pitfalls: over‑transfusion raising portal pressures; failing to give **ceftriaxone** in variceal bleed; delaying vasoactive therapy; attempting urgent colonoscopy in unstable LGIB instead of **CTA→IR**; not using erythromycin pre‑EGD in UGIB. citeturn2search15turn2search59turn2search24", "**Guideline Must‑Know:** Post‑EGD ulcer bleed: high‑dose PPI **continuous (8 mg/h) or intermittent** for 72 h is acceptable; repeat endoscopy for rebleeding; IR embolization if endoscopic therapy fails. citeturn2search24", "**Guideline Must‑Know:** Early antibiotic prophylaxis in variceal bleeding reduces infections and mortality; **ceftriaxone 1 g daily** preferred in areas with high quinolone resistance. citeturn2search15", "**Guideline Must‑Know:** Preemptive **TIPS** improves outcomes in selected high‑risk variceal bleeders; coordinate urgently with Hepatology/IR; document Child‑Pugh/MELD and failure criteria. citeturn2search15turn2search10"], "icu_consult_triggers": ["Persistent hypotension requiring vasopressors or **lactate >4 mmol/L** despite resuscitation. citeturn2search41", "Transfusion requirement **>4 pRBC units in 24 h** or anticipated massive transfusion. citeturn2search34", "Ongoing hematemesis/hematochezia with Hb drop **>2 g/dL** and tachycardia despite fluids. citeturn2search24", "Suspected variceal bleeding in **Child‑Pugh C** or **B with active bleeding** (consider early TIPS). citeturn2search15", "Increasing oxygen needs or airway compromise from aspiration/encephalopathy. citeturn2search41"], "orders_to_place_now": ["Order: Type and crossmatch — {units_pRBC: 2, hold_samples: true} citeturn2search35", "Order: Pantoprazole infusion — {80 mg IV bolus, then 8 mg/h x 72 h; switch to PO BID x 14 d post‑EGD if ulcer hemostasis} citeturn2search24", "Order: Erythromycin pre‑EGD — {250 mg IV over 20–30 min, give 20–90 min before endoscopy} citeturn2search24turn2search29", "Order: Octreotide infusion (if variceal suspected) — {50 mcg IV bolus, then 50 mcg/h infusion} citeturn2search15", "Order: Ceftriaxone prophylaxis (variceal bleed) — {1 g IV q24h x 7 days} citeturn2search15", "Order: CT Angiography Abdomen/Pelvis (LGIB with instability) — {indication: ongoing hematochezia with shock; proceed to IR if positive} citeturn2search59turn2search34"], "abim_cases": [{"case_id": "15A", "stem": "A 58‑year‑old man with melena and orthostasis is admitted. Vitals improve after fluids. Hb is 7.2 g/dL. He is not on anticoagulants. You plan endoscopy.", "options": ["Start continuous PPI now and schedule elective EGD in 48–72 hours", "Administer erythromycin 250 mg IV 30 minutes before EGD and perform EGD within 24 hours", "Give octreotide infusion and ceftriaxone empirically for all UGIB", "Transfuse to a goal hemoglobin of 10 g/dL before EGD", "Obtain CTA abdomen/pelvis now instead of EGD"], "answer": "B", "explanation": "ACG UGIB guidance suggests **EGD within 24 h** after stabilization and recommends **erythromycin 250 mg IV 20–90 min prior** to improve visualization and reduce repeat procedures; high‑dose PPI is recommended **after** endoscopic therapy for ulcer bleeding. Restrictive transfusion (**Hb <7 g/dL**) is preferred; routine octreotide/antibiotics is reserved for suspected variceal bleeding. citeturn2search24turn2search29turn2search35"}, {"case_id": "15B", "stem": "A 72‑year‑old woman on apixaban for AF presents with brisk hematochezia, SBP 82 mmHg, HR 122, Hb 8.1 g/dL. After fluids and 1 unit pRBC, she remains unstable.", "options": ["Urgent colonoscopy within 6 hours after a rapid prep", "Start octreotide infusion empirically and schedule EGD tomorrow", "CT angiography of abdomen/pelvis now to localize bleeding with plan for IR embolization if positive", "Tagged RBC scan to localize bleeding before any other imaging", "Start high‑dose IV PPI and observe 24 hours", "The pitfall is defaulting to colonoscopy first in unstable LGIB. If bleeding is life‑threatening and driven by a recent factor Xa inhibitor, consider **andexanet** per institutional criteria. citeturn2search59turn2search34\n\nWhat changed the decision here?"], "answer": "C", "explanation": "For hemodynamically significant LGIB, **CTA is recommended** to localize bleeding and expedite **IR embolization**; urgent colonoscopy has not improved key outcomes in severe LGIB. The pitfall is defaulting to colonoscopy first in unstable LGIB. If bleeding is life‑threatening and driven by a recent factor Xa inhibitor, consider **andexanet** per institutional criteria. citeturn2search59turn2search34"}], "micro_questions": [{"q": "Transfuse RBCs at what hemoglobin for most stable adults?", "a": "**<7 g/dL** (consider **8 g/dL** with cardiovascular disease/orthopedic/cardiac surgery). citeturn2search35"}, {"q": "EGD timing for hospitalized UGIB after stabilization?", "a": "Perform within **24 hours**; sooner if ongoing instability after resuscitation. citeturn2search24"}, {"q": "First‑line imaging for unstable LGIB with active hematochezia?", "a": "**CT angiography** to localize and facilitate IR embolization. citeturn2search59turn2search34"}, {"q": "Initial variceal bundle at presentation?", "a": "**Vasoactive agent** (e.g., octreotide), **ceftriaxone**, and early EGD with band ligation. citeturn2search15"}, {"q": "Erythromycin pre‑EGD dose?", "a": "**250 mg IV** 20–90 minutes before endoscopy. citeturn2search24"}], "references": [{"label": "ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding (2021). citeturn2search24", "url": ""}, {"label": "ACG Updated Guideline: Acute Lower Gastrointestinal Bleeding (2023). citeturn2search59", "url": ""}, {"label": "AASLD Practice Guidance: Portal Hypertension & Variceal Bleeding (2023) and Baveno VII Consensus (2022). citeturn2search15turn2search10", "url": ""}, {"label": "AABB International Guidelines for Red Blood Cell Transfusion (2023). citeturn2search35", "url": ""}, {"label": "Surviving Sepsis Campaign: Management of Sepsis and Septic Shock (2021). citeturn2search41", "url": ""}], "cdi": ["Acute upper GI bleeding — etiology: {peptic ulcer vs variceal vs other}; severity: {hemorrhagic shock vs acute blood loss anemia}; objective evidence: {Hb trend, lactate, hemodynamics, EGD findings}; treatment: {endoscopic hemostasis type, vasoactive infusion, PPI/antibiotics, transfusion units}.", "Acute lower GI bleeding — suspected source: {diverticular vs angiodysplasia vs post‑polypectomy}; severity: {ongoing transfusion needs, CTA localization}; objective evidence: {CTA result, IR embolization performed}; treatment: {IR embolization details, bowel prep/colonoscopy timing}.", "Coagulopathy/anticoagulant‑related hemorrhage — drug and last dose; reversal used ({PCC/andexanet/idarucizumab}); risk–benefit justification; thrombotic risk plan and restart timing.", "Shock (type and criteria) — specify **hypovolemic** vs mixed **septic**; document **MAP**, vasopressor use, fluids, urine output, lactate response.", "Aspiration risk/encephalopathy — airway protection decisions, oxygen/vent settings, antibiotics if indicated."]}, {"id": "16", "title": "Glucose Emergencies (DKA/HHS)", "tags": ["internal-medicine", "inpatient", "night-float"], "date": "2026-02-20", "panic_card": ["Secure airway/breathing; give oxygen for hypoxemia; start isotonic crystalloid bolus now; target **MAP ≥65 mmHg** if shock. citeturn2search3", "Check potassium urgently; **do not start insulin if K⁺ <3.3 mmol/L**—replete first. citeturn2search3turn2search2", "Start IV regular insulin **0.1 units/kg/h** (DKA) or **0.05 units/kg/h** (HHS) once K⁺ ≥3.3 mmol/L and volume resuscitation underway. citeturn2search3turn2search7", "Add dextrose when glucose reaches **~200 mg/dL (DKA)** or **~250–300 mg/dL (HHS)** to continue insulin safely. citeturn2search3turn2search11", "Obtain VBG, β‑hydroxybutyrate, serum osmolality; monitor glucose hourly and BMP (including Mg/Phos) every 2–4 h. citeturn2search3turn2search32"], "brief_overview": ["**Guideline Must‑Know:** DKA = hyperglycemia, ketosis, metabolic acidosis; HHS = severe hyperglycemia with hyperosmolality and minimal ketosis/acidosis; mixed states occur and follow the predominant physiology. citeturn2search3", "**Guideline Must‑Know:** Start with isotonic fluids (0.9% saline or balanced crystalloid) for intravascular resuscitation, then adjust rate/type by hemodynamics and corrected sodium; typical ongoing rate 250–500 mL/h. citeturn2search3turn2search11", "**Guideline Must‑Know:** Potassium is the gate: **K⁺ <3.3 mmol/L → hold insulin and replete**; **3.3–5.2 → add 20–30 mmol K⁺/L to fluids**; **>5.2 → no K⁺ yet, recheck frequently**. citeturn2search3turn2search2", "**Guideline Must‑Know:** Insulin dosing—IV regular insulin **0.1 units/kg/h** for DKA (no bolus required in most adults); for HHS or frail patients consider **0.05 units/kg/h**. citeturn2search3turn2search7", "**Guideline Must‑Know:** When glucose falls to **~200 mg/dL (DKA)** or **~250–300 mg/dL (HHS)**, add dextrose and continue insulin to clear ketones/normalize osmolality. citeturn2search3turn2search11", "**Guideline Must‑Know:** Preferred labs/monitoring: VBG (arterial not required), capillary glucose **q1h**, BMP with Mg/Phos **q2–4h**, β‑hydroxybutyrate for diagnosis/resolution; hourly I/O and mental status. citeturn2search28turn2search32", "DKA resolution (examples from consensus): closed anion gap with rising bicarbonate/venous pH and normalization of β‑hydroxybutyrate; HHS resolution includes improved mentation with **effective osmolality <320 mOsm/kg** and adequate hydration. citeturn2search3", "Typical glucose fall targets are **~50–75 mg/dL per hour**; insufficient fall prompts reassessment of volume status and possible temporary insulin rate increase. citeturn2search12", "Add dextrose using D5 0.45% NaCl (or D5 NS if hyponatremic) to maintain **glucose 150–200 mg/dL (DKA)** or **~200–250 mg/dL (HHS)** until resolution. citeturn2search3turn2search11", "Identify/treat precipitants: infection, MI, stroke, pancreatitis, insulin omission, steroid therapy, and **SGLT2 inhibitor–associated euglycemic DKA** (normal or mildly elevated glucose). citeturn2search3", "Bicarbonate: generally **avoid** in adults unless **pH ≤6.9**, then consider cautious buffered replacement with close K⁺ monitoring; evidence for benefit is limited/controversial. citeturn2search16", "HHS fluids: aim for gradual osmolality decline (**~3–8 mOsm/kg/h**) to reduce cerebral edema risk; prioritize volume first, then insulin at lower rates. citeturn2search11", "Transition off IV insulin only after DKA/HHS resolution and when patient can eat; **overlap basal insulin by 1–2 h** before stopping infusion. citeturn2search32", "Night pitfalls: starting insulin before checking K⁺; aggressive fluids in CHF/ESRD without hemodynamic monitoring; failing to add dextrose early enough; missing mixed DKA/HHS with anion gap plus **effective osmolality ≥320**. citeturn2search3turn2search11", "Consult early for refractory acidosis, shock, or altered mental status; consider ICU for insulin titration and electrolyte shifts requiring q1–2h labs. citeturn2search3", "ADA 2026 Hospital Standards reinforce protocolized inpatient pathways for hyperglycemic crises, CGM/pump considerations, and safe transitions of care. citeturn2search20turn2search21"], "icu_consult_triggers": ["Persistent hypotension despite fluids or need for vasopressors; rising lactate or suspected sepsis. citeturn2search3", "Severe acidosis **pH <7.0** or refractory anion‑gap acidosis despite insulin/fluids. citeturn2search3", "**Effective osmolality ≥330 mOsm/kg** or rapidly changing osmolality with worsening mental status. citeturn2search11", "K⁺ instability (**<3.0** or **>6.0 mmol/L**) or life‑threatening arrhythmias. citeturn2search3", "Respiratory failure, coma, or need for q1h titration with multi‑organ dysfunction. citeturn2search3"], "orders_to_place_now": ["Order: IV crystalloid bolus — {0.9% NaCl, 1,000 mL over 60 min; repeat if hypotensive} citeturn2search3", "Order: Insulin infusion (regular insulin) — {start 0.1 units/kg/h for DKA or 0.05 units/kg/h for HHS; no bolus; titrate by glucose fall 50–75 mg/dL/h} citeturn2search3turn2search7", "Order: Potassium replacement — {add 20–30 mmol K⁺ per liter if K⁺ 3.3–5.2; hold insulin and give K⁺ if K⁺ <3.3} citeturn2search3", "Order: Dextrose‑containing fluids — {switch to D5 0.45% NaCl when glucose ≤200 mg/dL (DKA) or 250–300 mg/dL (HHS)} citeturn2search3turn2search11", "Order: Laboratory monitoring — {POC glucose q1h; BMP, Mg, Phos q2–4h; VBG; β‑hydroxybutyrate; serum osmolality} citeturn2search3turn2search28", "Order: Identify precipitants — {blood cultures if febrile, UA/UCx, CXR, ECG/troponin as indicated} citeturn2search3"], "abim_cases": [{"case_id": "16A", "stem": "A 28‑year‑old with type 1 diabetes presents with polyuria, Kussmaul respirations, and nausea. Vitals: BP 102/64, HR 118. Labs: glucose 540 mg/dL, β‑hydroxybutyrate elevated, VBG pH 7.13, HCO₃⁻ 10 mmol/L, anion gap 24, K⁺ 2.9 mmol/L, creatinine 1.1 mg/dL. After 1 L of 0.9% saline, next best step?", "options": ["Begin IV regular insulin at 0.1 units/kg/h now", "Give sodium bicarbonate infusion", "Administer 20–30 mmol KCl in IV fluids and hold insulin until K⁺ ≥3.3 mmol/L", "Start D5 0.45% NaCl and IV insulin concurrently", "Give subcutaneous rapid‑acting insulin 10 units and repeat in 1 h"], "answer": "C", "explanation": "Insulin drives K⁺ intracellularly and can precipitate arrhythmia when **K⁺ <3.3 mmol/L**; therefore potassium must be repleted before starting insulin. citeturn2search3 Fluid resuscitation precedes insulin, and bicarbonate is generally reserved for **pH ≤6.9**. citeturn2search3turn2search16"}, {"case_id": "16B", "stem": "A 62‑year‑old with type 2 diabetes on empagliflozin returns 24 h after laparoscopic cholecystectomy with malaise and vomiting. Vitals: BP 118/70, HR 110. Labs: glucose 184 mg/dL, β‑hydroxybutyrate 4.2 mmol/L, VBG pH 7.24, HCO₃⁻ 16 mmol/L, anion gap 18, K⁺ 4.3 mmol/L. What is the best management?", "options": ["Discharge with antiemetics; glucose <200 mg/dL", "Give IV bicarbonate to correct acidosis", "Start IV fluids only; avoid insulin because glucose <250 mg/dL", "Initiate DKA protocol: isotonic fluids, IV insulin 0.1 units/kg/h, and early dextrose to allow insulin continuation; stop SGLT2 inhibitor", "Start subcutaneous sliding‑scale insulin only"], "answer": "D", "explanation": "This is **euglycemic DKA** associated with SGLT2 inhibitor use; treatment mirrors DKA with insulin plus dextrose to clear ketones despite near‑normal glucose. citeturn2search3 Bicarbonate is not indicated unless **pH ≤6.9**; fluids alone or sliding‑scale insulin are inadequate. citeturn2search16"}], "micro_questions": [{"q": "Minimum K⁺ level to begin insulin infusion?", "a": "**≥3.3 mmol/L**; replete potassium if below this threshold. citeturn2search3"}, {"q": "When should dextrose be added during treatment?", "a": "At **~200 mg/dL (DKA)** and **~250–300 mg/dL (HHS)** while continuing insulin. citeturn2search3turn2search11"}, {"q": "Target glucose fall per hour on insulin infusion?", "a": "Approximately **50–75 mg/dL/h**; reassess if response is slower. citeturn2search12"}, {"q": "Effective osmolality threshold defining HHS?", "a": "**≥320 mOsm/kg** with minimal ketosis/acidosis. citeturn2search11"}], "references": [{"label": "American Diabetes Association. Standards of Care in Diabetes—2026, Section 16: Diabetes Care in the Hospital. Diabetes Care. 2026;49(Suppl 1):S339–S355", "url": "https://diabetesjournals.org/care/article/49/Supplement_1/S339/163925/16-Diabetes-Care-in-the-Hospital-Standards-of-Care"}, {"label": "Umpierrez GE, et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report (ADA/EASD/AACE/JBDS/DTS), 2024. Diabetes Care. 2024;47(8):1257–1275", "url": "https://doi.org/10.2337/dci24-0032"}, {"label": "Joint British Diabetes Societies (JBDS). The Management of Hyperosmolar Hyperglycaemic State (HHS) in Adults, 2022", "url": "https://abcd.care/sites/default/files/site_uploads/JBDS_Guidelines_Current/JBDS_06_The_Management_of_Hyperosmolar_Hyperglycaemic_State_HHS_%20in_Adults_FINAL_0.pdf"}, {"label": "Endocrine Society. Management of Hyperglycemia in Hospitalized Adult Patients in Non‑Critical Care Settings, 2022", "url": "https://www.endocrine.org/clinical-practice-guidelines/inpatient-hyperglycemia-guideline-resources"}, {"label": "Cleveland Clinic Journal of Medicine. Hyperglycemic crises in adults: A look at the 2024 consensus report. 2025;92(3):152–162", "url": "https://www.ccjm.org/content/ccjom/92/3/152.full.pdf"}], "cdi": ["Acute diabetic ketoacidosis vs hyperosmolar hyperglycemic state: specify acuity, mixed DKA/HHS if present; include objective criteria (β‑hydroxybutyrate, pH/HCO₃⁻, anion gap, **effective osmolality**).", "Etiology/trigger: infection, MI, medication nonadherence, SGLT2 inhibitor, steroid exposure; link to crisis.", "Severity/organ dysfunction: hypotension/shock, altered mental status, AKI, electrolyte derangements (K⁺, Phos, Mg).", "Treatment/response: type/volume of fluids, insulin infusion rate, potassium repletion, dextrose addition, monitoring frequency, ICU involvement.", "Risk/safety statements: “K⁺ corrected to **≥3.3 mmol/L** before insulin,” osmolality change monitored, and if bicarbonate used, document **pH ≤6.9** indication. citeturn2search3turn2search16"]}, {"id": "17", "title": "Hypertensive Emergency vs Urgency", "tags": ["hypertension", "critical-care", "inpatient", "night-float", "cardiology"], "date": "2026-02-21", "panic_card": ["Recheck BP with correct cuff/position; place continuous monitoring; if end-organ injury present, target **MAP reduction ≤20–25% in first hour**, then gradual control—avoid precipitous drops. Consider arterial line for titratable IV therapy. citeturn2search44turn2search6", "Rapidly screen BARKH end organs (brain, arteries/aorta, retina, kidney, heart) and obtain problem-directed imaging/labs; treat pain/anxiety that can elevate BP. citeturn2search6", "Start a titratable IV antihypertensive (e.g., nicardipine, clevidipine, labetalol) when emergency confirmed; set clear numeric BP goals based on the specific organ injury. citeturn2search6turn2search44", "Aortic dissection suspected: **IV beta-blocker first (e.g., esmolol), then vasodilator; goal SBP <120 mmHg and HR 60–80 within ~20 min**. citeturn2search13turn2search15", "Intracerebral hemorrhage: favor smooth control to **SBP 130–150 mmHg**; avoid lowering **<130 mmHg** acutely. citeturn2search7", "Acute ischemic stroke: before IV thrombolysis, **BP <185/110**; maintain **<180/105** for 24 h; if no reperfusion therapy, generally avoid lowering unless **≥220/120** (then reduce ~15% in 24 h). citeturn2search47turn2search46"], "brief_overview": ["**Guideline Must‑Know:** The AHA 2024 acute care statement recommends abandoning “hypertensive urgency” terminology in favor of “asymptomatic markedly elevated BP” (≥180/110–120 without new/worsening target-organ damage); treat the patient, not the number. citeturn2search6turn2search1", "**Guideline Must‑Know:** Hypertensive emergency is severe BP elevation with **acute target-organ injury** (BARKH: encephalopathy/stroke/ICH, aortic catastrophe, high-grade retinopathy, AKI/MAHA, ACS/acute pulmonary edema) and requires **IV** therapy with monitored titration. citeturn2search6", "**Guideline Must‑Know:** Initial goal is **MAP ↓ ≤20–25% in the first hour**, then to **~160/100–110** over the next 2–6 h, unless a specific condition dictates otherwise (e.g., dissection, stroke). citeturn2search44", "**Guideline Must‑Know:** Measurement matters—recheck with proper cuff/position, resolve reversible drivers (pain, anxiety, hypoxia, bladder distention, stimulants), and note that arterial lines are preferred when giving titratable IV agents. citeturn2search6turn2search1", "**Guideline Must‑Know:** Asymptomatic markedly elevated BP generally should **not** be acutely lowered with IV agents; initiate/adjust oral therapy and arrange close follow‑up; avoid PRN IV hydralazine/labetalol “just for numbers.” citeturn2search6turn2search45", "**Guideline Must‑Know:** Organ‑specific targets vary: aortic dissection **SBP <120** and HR 60–80 (beta‑blockade first), ICH **SBP 130–150**, AIS with thrombolysis **<185/110 pre‑bolus** and **<180/105 for 24 h**; AIS without reperfusion typically treat only if **≥220/120**. citeturn2search13turn2search7turn2search47turn2search46", "Differentiate pulmonary edema/ACS (favor IV nitroglycerin or clevidipine/nicardipine) versus sympathetic crises (avoid pure vasodilators until beta‑blockade if aortic dissection or pheo suspected). citeturn2search44", "In pregnancy/puerperium, **treat ≥160/110 confirmed within 15 min** using IV labetalol, IV hydralazine, or oral immediate‑release nifedipine; evaluate for preeclampsia/eclampsia and give magnesium when indicated. citeturn2search27turn2search29", "For AKI/CKD, avoid over‑rapid falls that worsen renal perfusion; choose easily titratable agents and track creatinine/urine output. citeturn2search44", "What must happen now: confirm emergency (symptoms/signs/labs/imaging), start titratable IV therapy with clear numeric targets, continuous monitoring, and early ICU involvement when instability, IV infusion, or neuro/ACS/aortic pathology is present. citeturn2search6", "What can wait until daytime: chronic regimen optimization, secondary HTN workup, ambulatory targets/risk calculators (per 2025 ACC/AHA outpatient guideline updates). citeturn2search4", "Pitfalls: mistaking pain/anxiety readings for emergencies; chasing “normal” BP quickly (risk of cerebral/coronary/renal hypoperfusion); giving thrombolysis without meeting BP thresholds; missing dissection in chest/back pain with pulse deficit. citeturn2search44turn2search47turn2search13", "ICU/consult calls to make early: neuro for ICH/AIS, cardiology for ACS/flash edema, cardiothoracic/vascular for dissection, nephrology for severe AKI; transfer if lacking continuous titration capacity. citeturn2search7turn2search13", "Documentation should distinguish “hypertensive emergency” from “asymptomatic markedly elevated BP”; avoid the ambiguous term “urgency” per AHA 2024. citeturn2search6", "**Confirm Before Proceed:** In AIS, do **not** rapidly normalize BP below recommended thresholds before/after reperfusion; in suspected dissection, **beta‑block first** before vasodilator; irreversible therapies (e.g., thrombolysis) require strict BP verification. citeturn2search47turn2search13", "Disposition pearls: most asymptomatic markedly elevated BP can be managed outpatient; true emergencies need monitored beds and IV drips; avoid unnecessary imaging in well patients without red flags. citeturn2search6turn2search42"], "icu_consult_triggers": ["Requirement for titratable IV antihypertensive infusion and/or arterial line to meet time‑sensitive organ‑specific targets (e.g., ICH, AIS reperfusion, dissection). citeturn2search6", "Neurologic deficit or hemorrhage on imaging; SBP not achieving **130–150** in ICH within 1 h despite therapy. citeturn2search7", "Suspected or confirmed aortic dissection; need to reach **SBP <120** and HR 60–80 promptly with beta‑blockade. citeturn2search13", "Refractory pulmonary edema/ACS or ongoing end‑organ ischemia despite initial measures. citeturn2search44"], "orders_to_place_now": ["Order: Continuous IV antihypertensive infusion (nicardipine or clevidipine) — {start rate, titration increment, BP goal, max rate, monitoring frequency} citeturn2search6", "Order: IV labetalol bolus — {dose mg, repeat interval, maximum total dose, hold parameters} citeturn2search6", "Order: Arterial line placement — {site, ultrasound guidance, waveform monitoring, blood sampling protocol} citeturn2search6", "Order: Non‑contrast head CT (stroke/ICH check) — {indication, timing, stat read, neuro consult if positive} citeturn2search7turn2search47", "Order: CTA chest/abdomen/pelvis for aortic syndrome — {indication, beta‑block before scanner if hypertensive/tachycardic, contrast precautions} citeturn2search13"], "abim_cases": [{"case_id": "17A", "stem": "A 62‑year‑old with sudden tearing chest pain radiating to the back has BP 208/118 mmHg and HR 112. Exam shows asymmetric arm BPs and a new diastolic murmur. ECG without STEMI. You suspect acute aortic dissection.", "options": ["Start IV nicardipine infusion immediately to lower SBP below 120 mmHg", "Start IV esmolol, then add nicardipine to reach SBP <120 mmHg and HR 60–80", "Give sublingual nifedipine and observe", "Give IV hydralazine to rapidly lower SBP to normal", "Begin IV nitroprusside alone to rapidly lower MAP"], "answer": "B", "explanation": "For suspected dissection, guidelines recommend **beta‑blockade first** to blunt shear (HR 60–80), then add a vasodilator to achieve **SBP <120 mmHg** rapidly. Pure vasodilation before rate control can increase shear; hydralazine/nifedipine are inappropriate here. citeturn2search13turn2search15"}, {"case_id": "17B", "stem": "A 74‑year‑old with acute ischemic stroke (NIHSS 6) arrives 7 hours after last‑known‑well, not eligible for thrombolysis or thrombectomy. BP is 210/112 mmHg; he is comfortable, oxygenating well, and has no chest pain, dyspnea, or AKI.", "options": ["Start IV nicardipine to lower SBP to <140 mmHg in the first hour", "Give IV labetalol to reduce SBP by 30% immediately", "Allow permissive hypertension; no urgent BP lowering unless SBP ≥220 or DBP ≥120", "Start IV nitroprusside to normalize BP quickly", "Start oral captopril and amlodipine to reduce SBP to <130 mmHg tonight"], "answer": "C", "explanation": "In AIS patients **not** receiving reperfusion, guidelines generally avoid treatment unless **BP ≥220/120 mmHg**; if treated, reduce only about **15% in the first 24 h** to preserve perfusion. The pitfall is over‑rapid normalization worsening cerebral ischemia. citeturn2search47turn2search46"}], "micro_questions": [{"q": "Max initial BP reduction allowed in most hypertensive emergencies?", "a": "**MAP ↓ ≤20–25% in first hour**, then gradual lowering based on organ‑specific targets. citeturn2search44"}, {"q": "Pre‑thrombolysis BP requirement in AIS?", "a": "**<185/110 mmHg** before bolus and **<180/105 mmHg** for 24 h afterward. citeturn2search47"}, {"q": "ICH acute BP goal?", "a": "Target **SBP 130–150 mmHg** with smooth control; avoid <130 mmHg. citeturn2search7"}, {"q": "Aortic dissection hemodynamic targets and sequence?", "a": "**HR 60–80** and **SBP <120 mmHg** with **beta‑blockade first**, then vasodilator. citeturn2search13"}, {"q": "Pregnancy severe hypertension confirmation and first‑line agents?", "a": "Confirm **≥160/110 within 15 min**; treat with IV labetalol, IV hydralazine, or oral immediate‑release nifedipine. citeturn2search27"}], "references": [{"label": "AHA Scientific Statement: Management of Elevated BP in Acute Care (2024) — summary and practice points. citeturn2search6turn2search1", "url": ""}, {"label": "ACC/AHA Guideline for High Blood Pressure in Adults (2025) — outpatient fundamentals and updates relevant to inpatient transitions. citeturn2search4turn2search2", "url": ""}, {"label": "AHA/ASA Guideline for Spontaneous ICH (2022) — BP targets and smooth control emphasis. citeturn2search7", "url": ""}, {"label": "ACC/AHA Aortic Disease Guideline (2022) — dissection HR/BP targets and sequencing. citeturn2search13", "url": ""}, {"label": "AHA/ASA Acute Ischemic Stroke 2019 Update — BP thresholds around thrombolysis and early care. citeturn2search47", "url": ""}], "cdi": ["Hypertensive emergency vs asymptomatic markedly elevated BP; specify acute target‑organ injury present/absent and which organ(s) (brain/aorta/retina/kidney/heart) with objective evidence (exam/imaging/labs).", "Acuity and severity with numeric goals: initial **MAP ↓ ≤20–25%**, organ‑specific targets (e.g., ICH SBP 130–150; AIS reperfusion thresholds; dissection SBP <120 & HR 60–80).", "Etiology/precipitants (med nonadherence, stimulant use, pain, volume overload) and treatments used (IV nicardipine/clevidipine/labetalol, beta‑blocker first for dissection, magnesium for eclampsia) with responses.", "Monitoring/intensity: continuous telemetry, arterial line if used, ICU vs step‑down, consults placed (neuro/cardiology/CT surgery/nephrology)."]}, {"id": "18", "title": "ICU Escalation & Early Consults", "tags": ["inpatient", "internal-medicine", "night-float"], "date": "2026-02-21", "panic_card": ["Assess airway, breathing, circulation; place on monitor; two large-bore IVs; start crystalloid bolus if hypotensive; target **MAP ≥65 mmHg**; apply O₂ to keep **SpO₂ ≥90%** (or **88–92%** if chronic hypercapnia).", "If hypotension persists after fluids or lactate **≥4 mmol/L**, start **norepinephrine** and titrate to **MAP ≥65 mmHg**; obtain **lactate now and q2–4 h**.", "For impending/actual respiratory failure (work of breathing, **SpO₂ <90%** on supplemental O₂, or **PaO₂/FiO₂ <150**), escalate support (HFNC/NIV) and page ICU now.", "Treat immediately reversible threats: **glucose <3.0 mmol/L** → IV dextrose; **K⁺ ≥6.0 mmol/L with ECG changes** → IV calcium, then insulin/dextrose and removal strategy; control active massive bleeding.", "Call appropriate stat consults early for time-critical paths (stroke door-to-needle **≤4.5 h**, STEMI, massive PE, airway obstruction); Confirm Before Proceed for irreversible steps (e.g., thrombolysis, MTP activation)."], "brief_overview": ["Night-float escalation hinges on early recognition of decompensation in airway, breathing, circulation, mental status, or uncontrolled bleeding; act fast and call for help early while stabilizing ABCs with objective targets (**MAP ≥65 mmHg**, **SpO₂ ≥90%**, **glucose >3.0 mmol/L**).", "**Guideline Must‑Know:** Sepsis bundle initial steps per Surviving Sepsis 2021: prompt recognition, cultures, early broad-spectrum antibiotics, **30 mL/kg balanced crystalloid** for hypotension or **lactate ≥4 mmol/L**, and **norepinephrine** as first-line vasopressor to **MAP ≥65 mmHg**.", "**Guideline Must‑Know:** Shock escalation to ICU when vasopressor is required, lactate remains elevated, or there is persistent hypotension despite fluids; arterial line strongly considered for invasive monitoring in ongoing shock.", "**Guideline Must‑Know:** Acute hypoxemic respiratory failure with **SpO₂ <90%** despite supplemental O₂, rising work of breathing, or **PaO₂/FiO₂ <150** should trigger ICU evaluation and trial of HFNC/NIV with close monitoring; intubate for failing NIV, altered mental status, or inability to protect airway.", "Objective ventilatory failure signs (worsening hypercapnia, acidosis, exhaustion) are high-risk at night; NIV is helpful in COPD/CHF exacerbations but failure criteria mandate swift intubation planning with ICU.", "**Guideline Must‑Know:** AHA/ASA stroke pathways prioritize immediate imaging and thrombolysis within **≤4.5 h** when eligible; any new focal neuro deficit with disabling symptoms or deteriorating mental status requires emergent neurology involvement and likely ICU if airway/ICP risk.", "**Guideline Must‑Know:** AHA/ACC/HFSA heart failure guidance supports ICU transfer for cardiogenic shock (hypotension, cold extremities, rising lactate, worsening renal function) and initiation of inotropes/vasopressors with invasive monitoring.", "**Guideline Must‑Know:** AABB 2023 advocates a **restrictive RBC threshold of Hb <7 g/dL** in most stable adults; ICU/consult early for active bleeding with hemodynamic instability or signs of shock; platelets if severe thrombocytopenia with bleeding.", "**Guideline Must‑Know:** ATS/IDSA CAP criteria: severe pneumonia (major criteria like septic shock or respiratory failure requiring ventilation; or ≥3 minor criteria) warrants ICU; monitor for escalating O₂ needs, hypotension, or confusion.", "**Guideline Must‑Know:** KDIGO AKI: Stage 2–3 AKI, refractory hyperkalemia, severe acidosis, or volume overload with hypoxemia are dialysis/ICU triggers; consult nephrology early when potassium is **≥6.0 mmol/L**, pH **<7.2**, or uremic complications.", "Time-sensitive consults that should not wait until morning: acute stroke, STEMI/NSTEMI with instability, GI bleed with hemodynamic compromise, massive PE suspicion, status epilepticus, airway lesions, compartment syndrome, and threatened limb ischemia.", "What must happen now: stabilize ABCs; obtain critical labs (lactate, ABG/VBG, BMP/CBC/Coags, type & screen), portable CXR, ECG; start guideline-concordant therapy (antibiotics for sepsis within 1 h, vasopressors for shock, HFNC/NIV for hypoxemia, insulin for DKA/HHS); notify ICU/appropriate consultants early.", "What can wait a few hours: non-urgent medication reconciliation, non-critical imaging, and specialist follow-up for stable, improving patients; however, document rationale and contingency plans if deferring steps overnight.", "Pitfalls: under-recognizing occult shock (normal BP but **lactate ≥4 mmol/L** or skin mottling), delaying antibiotics, over-oxygenation in COPD (target **SpO₂ 88–92%**), missing silent airway compromise (stridor, drooling, neck swelling), and failing to reassess response q15–30 min.", "**Guideline Must‑Know:** Use norepinephrine as first-line vasopressor in septic and undifferentiated shock; add vasopressin if escalating requirements; avoid dopamine due to arrhythmias except in select bradycardic shock.", "**Guideline Must‑Know:** For suspected upper GI bleed with hypotension, resuscitate, start IV PPI, consider octreotide if variceal risk, correct coagulopathy, and call GI early; transfuse RBCs at **Hb <7 g/dL** or earlier if massive hemorrhage and shock; activate MTP as indicated (Confirm Before Proceed).", "**Guideline Must‑Know:** For DKA/HHS, initiate insulin infusion after confirming **K⁺ ≥3.3 mmol/L**; ICU for severe acidosis (pH **<7.0–7.1**), altered mental status, or need for insulin infusion and close titration; vigilantly correct electrolytes and avoid rapid sodium shifts."], "icu_consult_triggers": ["Need for vasopressor to maintain **MAP ≥65 mmHg**, **lactate ≥4 mmol/L**, or persistent hypotension after guideline-volume resuscitation.", "Respiratory failure with **SpO₂ <90%** on high-flow O₂, **PaO₂/FiO₂ <150**, escalating work of breathing, or NIV intolerance/failure.", "Acute neurologic decline (new focal deficit, seizures, GCS drop) or airway protection concern in intracranial pathology.", "Massive/ongoing bleeding with hemodynamic instability, **Hb falling toward <7 g/dL**, or transfusion requirement anticipated; consider MTP.", "Hyperkalemia **≥6.0 mmol/L** with ECG changes, severe acidosis **pH <7.2**, or refractory volume overload requiring emergent renal replacement therapy."], "orders_to_place_now": ["Order: Critical care/ICU consult — {indication, current supports, vitals/labs trend}", "Order: Norepinephrine infusion — {start_rate, titrate_to_MAP ≥65, central_line_plan}", "Order: High-flow nasal cannula — {FiO2, flow_L_min, SpO2_target}", "Order: Sepsis bundle labs — {lactate_now_and_q2–4h, cultures_before_antibiotics_when_feasible}", "Order: Broad-spectrum antibiotics — {source_suspected, renal_dose_adjustment, time_admin ≤1h}"], "abim_cases": [{"case_id": "18A", "stem": "A 67-year-old man with diabetes and COPD is admitted with fever and productive cough. On the night shift he is tachypneic (RR 32), tachycardic (110), BP 88/52 after 2 L balanced crystalloids, SpO₂ 90% on 6 L nasal cannula, and lactate is 4.6 mmol/L. He is alert but dyspneic with accessory muscle use.", "options": ["Switch to dopamine as first-line vasopressor and wait for morning ICU rounds", "Start norepinephrine now and request ICU evaluation for shock and respiratory failure", "Increase nasal cannula to 10 L and give a third liter before any vasopressor", "Intubate immediately without trial of noninvasive support", "Start antibiotics after repeat lactate confirms persistence at 6 hours"], "answer": "B", "explanation": "Per Surviving Sepsis 2021, persistent hypotension or **lactate ≥4 mmol/L** after fluid resuscitation warrants early **norepinephrine** to target **MAP ≥65 mmHg** and ICU-level care; antibiotics should be given within 1 hour of recognition. HFNC/NIV may be trialed while preparing for possible intubation; dopamine is inferior due to arrhythmia risk."}, {"case_id": "18B", "stem": "A 74-year-old woman with CKD stage 4 presents with confusion and dyspnea. Vitals: BP 92/58, HR 102, RR 28, SpO₂ 88% on 4 L NC. Labs: K⁺ 6.2 mmol/L with peaked T-waves, bicarbonate 13 mmol/L, creatinine 3.2 mg/dL (baseline 2.1), lactate 2.5 mmol/L. After 1 L balanced crystalloid, BP remains 90/56.", "options": ["Give additional 2 L crystalloid before any other intervention", "Start vasopressin as first-line pressor", "Administer IV calcium, insulin with dextrose, start norepinephrine to **MAP ≥65**, and request ICU and nephrology consults", "Delay ICU consult until morning because lactate is not elevated", "Observe on the floor after placing on 6 L NC"], "answer": "C", "explanation": "The pitfall is under-triaging hyperkalemic, acidotic patients with CKD who have relative hypotension but lactate not markedly elevated. Immediate membrane stabilization (IV calcium) and potassium shift/removal plus **norepinephrine** for hypotension meet ICU criteria; early nephrology involvement is indicated given **K⁺ ≥6.0 mmol/L** and acidosis."}], "micro_questions": [{"q": "What **MAP** target should you maintain in undifferentiated shock on vasopressors?", "a": "**MAP ≥65 mmHg** unless individualized higher targets are indicated (e.g., chronic hypertension)."}, {"q": "What lactate value mandates aggressive resuscitation and ICU consideration in sepsis?", "a": "**Lactate ≥4 mmol/L** or persistent hypotension after adequate fluids."}, {"q": "What oxygen saturation target is appropriate in COPD with hypercapnia risk?", "a": "**SpO₂ 88–92%** to avoid worsening hypercapnia."}, {"q": "First-line vasopressor for septic/undifferentiated shock?", "a": "**Norepinephrine**; add vasopressin if escalating requirements."}, {"q": "When should antibiotics be administered in suspected septic shock?", "a": "Within **1 hour** of recognition, after cultures if no undue delay."}], "references": [{"label": "Surviving Sepsis Campaign Adult Guidelines 2021", "url": "https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/Adult-Patients"}, {"label": "AHA/ACC/HFSA Heart Failure Guideline 2022", "url": "https://professional.heart.org/en/science-news/2022-guideline-for-the-management-of-heart-failure"}, {"label": "AABB Red Blood Cell Transfusion Guidelines 2023", "url": "https://www.aabb.org/news-resources/resources"}, {"label": "ATS/IDSA Community-Acquired Pneumonia Guideline 2019", "url": "https://www.idsociety.org/practice-guideline/community-acquired-pneumonia-adults/"}, {"label": "AHA/ASA Acute Ischemic Stroke Guidelines (2019 update; 2021 focused updates)", "url": "https://professional.heart.org/en/science-news/guidelines-and-statements/stroke"}], "cdi": ["Acute hypoxemic respiratory failure due to {pneumonia/volume overload/COPD}, severity {PaO₂/FiO₂ or SpO₂ on {device/FiO₂}}, objective evidence {ABG/CXR}, treatment {HFNC/NIV/intubation}.", "Septic shock due to {suspected source}, criteria {MAP <65 after fluids and/or lactate ≥4 mmol/L}, objective evidence {vitals, lactate}, treatment {30 mL/kg crystalloid, norepinephrine to MAP ≥65, antibiotics within 1 h}.", "AKI {KDIGO stage 1/2/3} on {baseline Cr}, etiology {sepsis/prerenal/ATN}, objective evidence {UOP, creatinine rise}, risks {hyperkalemia, acidosis}, treatment {electrolyte correction, dialysis consult if indicated}.", "Acute decompensated heart failure {HFrEF/HFpEF} with {congestion/hypoperfusion}, objective evidence {BNP, CXR, exam}, hemodynamics {BP, lactate}, treatment {IV diuretics, pressor/inotrope if shock}.", "Acute upper GI bleed with hemodynamic instability, etiology {variceal/non-variceal}, objective evidence {melena/hematemesis, Hb trend}, treatment {PPI, resuscitation, transfusion threshold Hb <7 g/dL, GI consult}."]}, {"id": "19", "title": "Neurologic Emergencies (Status Epilepticus & Stroke)", "tags": ["neurology", "inpatient", "night-float", "emergencies"], "date": "2026-02-20", "panic_card": ["Airway, breathing, circulation; check **FSBG now**; give **thiamine 100 mg IV before dextrose** if malnourished risk; place on cardiorespiratory and end‑tidal CO₂ monitoring. citeturn2search50", "Ongoing seizures ≥5 min: give **lorazepam 0.1 mg/kg IV (max 4 mg)** or **midazolam 10 mg IM** immediately; repeat once in 5 min if needed. citeturn2search50turn2search22", "Suspected acute ischemic stroke: determine **Last Known Well**; get **noncontrast head CT**; aim **door‑to‑imaging ≤20 min**; consider **IV alteplase ≤4.5 h** or **mechanical thrombectomy up to 24 h in selected LVO**. **Confirm Before Proceed:** thrombolysis contraindications reviewed. citeturn2search2turn2search4", "Before IV thrombolysis, lower **BP <185/110 mmHg** (e.g., labetalol, nicardipine); after treatment, maintain **<180/105 mmHg for 24 h**. citeturn2search2", "If hemorrhage on CT: reverse anticoagulants per agent; target **SBP ~140–160 mmHg** promptly; call neurosurgery/neuro‑ICU. **Confirm Before Proceed:** reversal products and doses verified. citeturn2search13"], "brief_overview": ["**Guideline Must‑Know:** Status epilepticus (SE) is ≥5 min of continuous seizures or recurrent seizures without recovery; treat in parallel with ABCs and early benzodiazepines to prevent refractoriness. citeturn2search50", "**Guideline Must‑Know:** First‑line for convulsive SE: **lorazepam 0.1 mg/kg IV (max 4 mg)**, **midazolam 10 mg IM** if no IV, or **diazepam 10 mg IV**; repeat once if needed. Avoid under‑dosing. citeturn2search22turn2search24", "**Guideline Must‑Know:** If seizures persist, proceed immediately to urgent control therapy with one of: **levetiracetam 60 mg/kg IV (max 4.5 g)**, **fosphenytoin 20 mg PE/kg IV**, or **valproate 40 mg/kg IV**. Choose based on comorbidities and interactions. citeturn2search50", "**Guideline Must‑Know:** Refractory SE (persistent after a benzodiazepine + a second agent): start anesthetic infusion (e.g., **midazolam** or **propofol**) titrated to seizure suppression/burst‑suppression with continuous EEG if available; consider transfer if cEEG unavailable. citeturn2search52", "Evaluate precipitating causes alongside treatment: **FSBG**, electrolytes, tox, AED levels, infection workup; obtain **noncontrast head CT**; consider LP only after stabilization. citeturn2search50", "Avoid rapid correction of chronic hyponatremia; enforce **Na⁺ correction ≤8–10 mmol/L per 24 h** (≤4–6 if high risk). citeturn2search38", "**Guideline Must‑Know:** Stroke: for suspected acute ischemic stroke (AIS), determine **Last Known Well** precisely and activate imaging and telestroke pathways; **NCCT** is first‑line to exclude bleed; CTA ± perfusion for LVO selection. citeturn2search2", "**Guideline Must‑Know:** IV thrombolysis should begin **as quickly as possible within ≤4.5 h** when eligible. **Alteplase 0.9 mg/kg (max 90 mg)** is standard; **tenecteplase 0.25 mg/kg (max 25 mg)** is an acceptable alternative in selected patients per recent AHA/ASA update. **Confirm Before Proceed** thrombolysis contraindications. citeturn2search2turn2search3", "**Guideline Must‑Know:** Endovascular therapy for anterior‑circulation LVO is recommended **≤6 h** and **reasonable up to 24 h** in selected patients (DAWN/DEFUSE 3 criteria or equivalent perfusion mismatch). Escalate to neurointerventional team early. citeturn2search4", "BP management in AIS: prior to IVT, **<185/110**; after IVT **<180/105**; avoid aggressive post‑EVT hypotension. In ICH, lower **SBP to ~140–160** promptly while avoiding large variability. citeturn2search2turn2search17", "Antiplatelets: if no IVT, initiate **aspirin within 24 h**; if minor non‑cardioembolic stroke/TIA within 24 h, consider **short DAPT** per prevention guidance (defer if IVT given). Escalate to neurology for nuances. citeturn2search30", "**Guideline Must‑Know:** For anticoagulated patients (e.g., DOAC within 48 h and normal renal function), **IV thrombolysis is generally contraindicated**; if LVO and otherwise eligible, **proceed to EVT**; discuss reversal only when indicated and beneficial. citeturn2search2", "**Guideline Must‑Know:** ICH care: rapidly reverse warfarin with **4‑factor PCC**, dabigatran with **idarucizumab**, factor Xa inhibitors with **andexanet alfa** when appropriate; avoid routine platelet transfusions unless emergent surgery/severe thrombocytopenia. citeturn2search17", "Night pitfalls: missing nonconvulsive SE post‑stopping convulsions (need cEEG if persistent encephalopathy), undertreating benzodiazepine doses, delaying CTA/perfusion for potential EVT candidates, or forgetting to re‑measure BP targets after IVT/EVT. citeturn2search50turn2search2", "**Guideline Must‑Know:** Oxygenation/ventilation: treat hypoxemia, avoid hyperoxia; protect airway in ongoing convulsions; consider early intubation for RSE or aspiration risk; maintain **MAP ≥65 mmHg** if shock occurs and follow pressor hierarchy. citeturn2search38", "**Guideline Must‑Know:** Document clearly: timing (LKW), NIHSS, contraindication screen, consent/risk discussion for thrombolysis/EVT, post‑treatment neuro checks, BP/bleed monitoring; for SE, total doses/timing and EEG findings. citeturn2search31"], "icu_consult_triggers": ["Persistent seizures despite benzodiazepine plus one second‑line agent, or need for anesthetic infusion/cEEG (refractory SE). citeturn2search52", "AIS with **LVO**, large infarct risk/mass effect, declining mental status, or **NIHSS high** requiring EVT or neuro‑ICU monitoring. citeturn2search4", "ICH, SAH suspicion, or post‑thrombolysis deterioration (new headache, emesis, acute HTN, neuro decline). citeturn2search13", "Airway compromise, **SpO₂ <90%**, aspiration, or hemodynamic instability/shock. citeturn2search38"], "orders_to_place_now": ["Order: CT head without contrast — {stat, stroke_protocol=yes, include_time_last_known_well} citeturn2search2", "Order: CTA head/neck ± CT perfusion — {if LVO suspected or late window; renal_function={Cr,eGFR}} citeturn2search4", "Order: Alteplase IV for AIS — {weight_kg, total_dose=0.9 mg/kg max 90 mg, bolus=10%, infusion=90% over 60 min, BP_goal=<180/105} citeturn2search2", "Order: Tenecteplase IV push for AIS (if appropriate) — {dose=0.25 mg/kg max 25 mg, single bolus, BP_goal=<180/105} citeturn2search3", "Order: Benzodiazepine for SE — {lorazepam 0.1 mg/kg IV max 4 mg OR midazolam 10 mg IM if no IV access} citeturn2search22turn2search50", "Order: Urgent control antiseizure med — {choose one: levetiracetam 60 mg/kg IV max 4.5 g OR fosphenytoin 20 mg PE/kg IV OR valproate 40 mg/kg IV} citeturn2search50"], "abim_cases": [{"case_id": "19A", "stem": "A 68‑year‑old with hypertension presents 90 minutes after sudden aphasia and right hemiparesis. BP is 198/112 mmHg, glucose 110 mg/dL, NIHSS 14. Noncontrast CT shows no hemorrhage. CTA is not yet done.", "options": ["Give IV alteplase now without further delay", "Lower BP to **<185/110 mmHg** with IV labetalol, then give IV alteplase", "Wait for CTA and perfusion imaging before deciding on thrombolysis", "Start aspirin 325 mg now and plan dual antiplatelet therapy", "Give tenecteplase 0.25 mg/kg now without addressing BP"], "answer": "B", "explanation": "IV thrombolysis should be administered within **≤4.5 h** in eligible patients, but **BP must be <185/110 mmHg before** treatment and maintained **<180/105** after; antihypertensive therapy (e.g., labetalol) should precede alteplase. Delaying for advanced imaging (CTA/perfusion) is not required to start IVT when NCCT excludes hemorrhage. Tenecteplase is reasonable in selected patients per updated guidance but still requires BP control. citeturn2search2turn2search4turn2search3"}, {"case_id": "19B", "stem": "A 72‑year‑old with atrial fibrillation (on apixaban; last dose 3 hours ago) presents 2 hours after LKW with left MCA syndrome, NIHSS 16. BP 172/98 mmHg. NCCT shows no hemorrhage. CTA shows a proximal left M1 occlusion.", "options": ["Give IV alteplase because within 4.5 h", "Give tenecteplase 0.25 mg/kg because it is easier to administer", "Proceed directly to mechanical thrombectomy; withhold IV thrombolysis", "Reverse apixaban with andexanet alfa, then give IV alteplase", "Start heparin infusion while awaiting interventional team", "A: **Levetiracetam 60 mg/kg IV (max 4.5 g)**; alternatives are fosphenytoin or valproate.\n- Q: What sodium correction limit prevents osmotic demyelination in hyponatremia?  \n  A: **≤8–10 mmol/L per 24 h** (≤4–6 if high risk).", "Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines. [Slide deck PDF] citeturn2search2\n- AHA/ASA. Acute Ischemic Stroke Guideline — published in Stroke, January 26, 2026 (publication schedule notice). [Professional Heart Daily] citeturn2search26\n- AHA/ASA. Guidelines for Managing Patients With Acute Ischemic Stroke: Key Summary (late window EVT up to 24 h). [AIS toolkit PDF] citeturn2search4\n- Neurocritical Care Society. ENLS 6.0 Status Epilepticus Protocol (July 2024). [PDF] citeturn2search50\n- American Epilepsy Society. Evidence‑Based Guideline: Treatment of Convulsive Status Epilepticus (2016). [PDF] citeturn2search22\n- AHA/ASA. 2022 Guideline for Management of Spontaneous Intracerebral Hemorrhage (clinical update slides). [PDF] citeturn2search13\n- JAMA Medical News. 2026 AHA/ASA AIS guideline highlights (tenecteplase option). citeturn2search3"], "answer": "C", "explanation": "Recent DOAC ingestion is a **contraindication to IV thrombolysis** in most cases; this patient has an LVO and is an EVT candidate, so proceed to thrombectomy without IVT. Reversal solely to enable thrombolysis is not routine in AIS and should be individualized; anticoagulation is not indicated acutely. The pitfall is giving thrombolysis despite **recent DOAC use**. citeturn2search2"}], "micro_questions": [{"q": "What lorazepam dose is recommended first‑line for adult convulsive SE?", "a": "**0.1 mg/kg IV (max 4 mg)**; repeat once in 5 minutes if needed."}, {"q": "What BP must be achieved before IV thrombolysis for AIS?", "a": "**<185/110 mmHg** before IVT; then **<180/105 mmHg** for 24 h after."}, {"q": "What is the extended window for EVT in select anterior circulation LVO strokes?", "a": "Up to **24 hours** from LKW if advanced imaging shows salvageable tissue."}, {"q": "List one standard second‑line agent and dose for established SE.", "a": "**Levetiracetam 60 mg/kg IV (max 4.5 g)**; alternatives are fosphenytoin or valproate."}, {"q": "What sodium correction limit prevents osmotic demyelination in hyponatremia?", "a": "**≤8–10 mmol/L per 24 h** (≤4–6 if high risk)."}], "references": [{"label": "AHA/ASA. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines. [Slide deck PDF] citeturn2search2", "url": ""}, {"label": "AHA/ASA. Acute Ischemic Stroke Guideline — published in Stroke, January 26, 2026 (publication schedule notice). [Professional Heart Daily] citeturn2search26", "url": ""}, {"label": "AHA/ASA. Guidelines for Managing Patients With Acute Ischemic Stroke: Key Summary (late window EVT up to 24 h). [AIS toolkit PDF] citeturn2search4", "url": ""}, {"label": "Neurocritical Care Society. ENLS 6.0 Status Epilepticus Protocol (July 2024). [PDF] citeturn2search50", "url": ""}, {"label": "American Epilepsy Society. Evidence‑Based Guideline: Treatment of Convulsive Status Epilepticus (2016). [PDF] citeturn2search22", "url": ""}, {"label": "AHA/ASA. 2022 Guideline for Management of Spontaneous Intracerebral Hemorrhage (clinical update slides). [PDF] citeturn2search13", "url": ""}, {"label": "JAMA Medical News. 2026 AHA/ASA AIS guideline highlights (tenecteplase option). citeturn2search3", "url": ""}], "cdi": ["Acute ischemic stroke due to presumed large‑vessel thromboembolism — onset (LKW), NIHSS, territory, candidacy/decision for IVT/EVT, contraindication screen, BP targets, objective imaging/labs, treatment given (dose/time), complications monitoring.", "Status epilepticus — convulsive vs nonconvulsive, etiology (e.g., metabolic/toxic/structural), total antiseizure doses/timing, response, airway/vent support, cEEG findings.", "Hypertensive emergency secondary to stroke — severity, end‑organ effects (neuro deficits, imaging), agents/doses to achieve **SBP/BP goals**, monitoring plan.", "Anticoagulation status — agent, last dose/time, renal function, reversal decision/rationale, risks/benefits discussion documented.", "Aspiration risk or pneumonia due to neurologic deficit — evidence (CXR/fever/leukocytosis), type (aspiration), severity, treatment and need for NPO/SLP evaluation."]}];

function fmt(text){
  if(!text)return '';
  let s=text;
  s=s.replace(/\*\*(.+?)\*\*/g,'<strong>$1</strong>');
  s=s.replace(/\{([^}]+)\}/g,'<span style="display:inline;padding:1px 5px;border-radius:3px;font-weight:600;background:rgba(99,102,241,.13);color:#a5b4fc">$1</span>');
  return s;
}

function Bullet({items,className}){
  if(!items||!items.length)return null;
  return <ul className="bl">{items.map((b,i)=><li key={i} dangerouslySetInnerHTML={{__html:fmt(b)}}/>)}</ul>;
}

function QuizCase({c,accent}){
  const [sel,setSel]=useState(null);
  const [show,setShow]=useState(false);
  const letters='ABCDE';
  const correctIdx=letters.indexOf(c.answer);
  const revealed=show||sel!==null;
  return (
    <div className="qc">
      <div className="ql" style={{color:accent}}>Case {c.case_id}</div>
      <div className="qs" dangerouslySetInnerHTML={{__html:fmt(c.stem)}}/>
      <ul className="qopts">{c.options.map((o,i)=>{
        let cls='qo';
        if(revealed&&i===correctIdx)cls+=' cor';
        else if(revealed&&sel===i&&i!==correctIdx)cls+=' inc';
        else if(sel===i)cls+=' sel';
        return <li key={i} className={cls} onClick={()=>{if(!revealed)setSel(i);setShow(true)}}>
          <span className="qol">{letters[i]}</span>
          <span dangerouslySetInnerHTML={{__html:fmt(o)}}/>
        </li>
      })}</ul>
      {!revealed&&<button className="qrb" onClick={()=>setShow(true)}>Show Answer</button>}
      {revealed&&c.explanation&&<div className="qex" dangerouslySetInnerHTML={{__html:'<strong>✓ '+c.answer+'</strong> — '+fmt(c.explanation)}}/>}
    </div>
  );
}

function Flashcard({item}){
  const [open,setOpen]=useState(false);
  return (
    <div className="fc" onClick={()=>setOpen(!open)}>
      <div className="fc-q" dangerouslySetInnerHTML={{__html:'💡 '+fmt(item.q)}}/>
      {open&&<div className="fc-a" dangerouslySetInnerHTML={{__html:fmt(item.a)}}/>}
    </div>
  );
}

const SECTION_KEYS=[
  {key:'panic_card',label:'🚨 Panic Card',wrap:'sec-panic',badge:'Panic Card'},
  {key:'brief_overview',label:'📋 Overview',wrap:null,badge:null},
  {key:'icu_consult_triggers',label:'🏥 ICU Triggers',wrap:'sec-icu',badge:'ICU / Consult Triggers'},
  {key:'orders_to_place_now',label:'📝 Orders',wrap:'sec-ord',badge:'Orders to Place Now'},
  {key:'abim_cases',label:'🧪 Quiz',wrap:null,badge:null},
  {key:'micro_questions',label:'🔍 Self-Check',wrap:null,badge:null},
  {key:'references',label:'📚 References',wrap:null,badge:null},
  {key:'cdi',label:'📄 CDI',wrap:'sec-cdi',badge:'CDI Documentation'}
];

function TopicDetail({topic,onBack}){
  const accent=ACCENT[(parseInt(topic.id)-1)%ACCENT.length];
  const available=SECTION_KEYS.filter(s=>{
    const d=topic[s.key];
    return d&&(Array.isArray(d)?d.length>0:true);
  });
  const [tab,setTab]=useState(available[0]?.key||'panic_card');
  const sec=SECTION_KEYS.find(s=>s.key===tab);

  function renderContent(){
    const data=topic[tab];
    if(!data||!data.length)return <p style={{color:'var(--t3)',padding:'20px 0'}}>No data for this section.</p>;

    if(tab==='abim_cases')return data.map(c=><QuizCase key={c.case_id} c={c} accent={accent}/>);
    if(tab==='micro_questions')return data.map((m,i)=><Flashcard key={i} item={m}/>);
    if(tab==='references')return data.map((r,i)=><div key={i} className="ri">{r.url?<a href={r.url} target="_blank" rel="noopener noreferrer">{r.label}</a>:<span style={{color:'var(--t2)',fontSize:'.85rem'}}>{r.label}</span>}</div>);

    const wrap=sec?.wrap;
    const badge=sec?.badge;
    if(wrap)return <div className={wrap}>{badge&&<div className="badge">{badge}</div>}<Bullet items={data}/></div>;
    return <Bullet items={data}/>;
  }

  return (
    <div className="td">
      <button className="bk" onClick={onBack}>← All Topics</button>
      <div className="tt-bar">
        <h1 style={{color:accent}}>{topic.title}</h1>
        <div className="tt-meta">
          {topic.tags.slice(0,5).map((t,i)=><span key={i} className="tt-tag" style={{background:accent+'1a',color:accent}}>{t}</span>)}
          <span className="tt-tag" style={{background:'var(--sf)',color:'var(--t3)'}}>{topic.date}</span>
        </div>
      </div>
      <div className="stabs">
        {available.map(s=><button key={s.key} className={'stab'+(tab===s.key?' act':'')} style={tab===s.key?{borderBottomColor:accent,color:accent}:{}} onClick={()=>setTab(s.key)}>{s.label}</button>)}
      </div>
      <div className="section-content">{renderContent()}</div>
    </div>
  );
}

function App(){
  const [sel,setSel]=useState(null);
  const [q,setQ]=useState('');
  const [sbOpen,setSbOpen]=useState(false);

  const filtered=useMemo(()=>{
    if(!q.trim())return TOPICS;
    const lq=q.toLowerCase();
    return TOPICS.filter(t=>t.title.toLowerCase().includes(lq)||t.tags.some(tg=>tg.toLowerCase().includes(lq)));
  },[q]);

  const totalCases=TOPICS.reduce((s,t)=>s+(t.abim_cases?.length||0),0);
  const totalQs=TOPICS.reduce((s,t)=>s+(t.micro_questions?.length||0),0);

  return (
    <div className="lyt">
      <div className={'ov'+(sbOpen?' sh':'')} onClick={()=>setSbOpen(false)}/>
      <div className="mhd">
        <button className="hbg" onClick={()=>setSbOpen(!sbOpen)}>
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" strokeWidth="2"><path d="M3 12h18M3 6h18M3 18h18"/></svg>
        </button>
        <span style={{fontFamily:'var(--fh)',fontWeight:800,fontSize:'1rem',background:'linear-gradient(135deg,#e2e8f0,#c7d2fe,#a78bfa)',WebkitBackgroundClip:'text',WebkitTextFillColor:'transparent'}}>Night Float Companion</span>
      </div>
      <aside className={'sb'+(sbOpen?' op':'')}>
        <div className="sb-hd">
          <div className="sb-brand">Night Float<br/>Companion</div>
          <div className="sb-tag">Your On-Call Reference Guide</div>
        </div>
        <div className="sb-srch"><input placeholder="Search topics..." value={q} onChange={e=>setQ(e.target.value)}/></div>
        <nav className="sb-nav">
          <div className="ni" style={{color:sel===null?'var(--t1)':'var(--t2)',background:sel===null?'var(--sfa)':'transparent'}} onClick={()=>{setSel(null);setSbOpen(false)}}>
            <span style={{fontSize:'.9rem'}}>🏠</span> All Topics
          </div>
          {filtered.map((t,i)=>{
            const accent=ACCENT[(parseInt(t.id)-1)%ACCENT.length];
            return <div key={t.id} className={'ni'+(sel===t.id?' act':'')} style={sel===t.id?{'--ac':accent}:{}} onClick={()=>{setSel(t.id);setSbOpen(false)}}>
              <span className="ndot" style={{background:accent}}/>
              <span style={{flex:1}}>{t.title}</span>
            </div>;
          })}
        </nav>
      </aside>
      <main className="mn">
        {sel===null?(
          <div>
            <div className="hero">
              <h1 className="hero-t">Night Float Companion</h1>
              <p className="hero-s">Evidence-based topic cards for your night float rotation. Clinical pearls, orders, and board-style questions.</p>
            </div>
            <div className="stats">
              <div className="stat"><div className="stat-n" style={{color:'#a78bfa'}}>{TOPICS.length}</div><div className="stat-l">Topics</div></div>
              <div className="stat"><div className="stat-n" style={{color:'#ec4899'}}>{totalCases}</div><div className="stat-l">Quiz Cases</div></div>
              <div className="stat"><div className="stat-n" style={{color:'#14b8a6'}}>{totalQs}</div><div className="stat-l">Self-Check</div></div>
            </div>
            <div className="tgrid">
              {filtered.map((t,i)=>{
                const accent=ACCENT[(parseInt(t.id)-1)%ACCENT.length];
                return <div key={t.id} className="tc" onClick={()=>setSel(t.id)} style={{'--hc':accent}} onMouseEnter={e=>e.currentTarget.style.boxShadow='0 8px 24px '+accent+'22'} onMouseLeave={e=>e.currentTarget.style.boxShadow='none'}>
                  <div className="tc-ac" style={{background:accent}}/>
                  <h3>{t.title}</h3>
                  <div className="tc-tags">{t.tags.slice(0,3).map((tg,j)=><span key={j} className="tc-tag">{tg}</span>)}</div>
                  <div className="tc-dt">{t.abim_cases?.length||0} cases · {t.micro_questions?.length||0} Q&A · {t.date}</div>
                </div>;
              })}
            </div>
          </div>
        ):(
          <TopicDetail topic={TOPICS.find(t=>t.id===sel)} onBack={()=>setSel(null)}/>
        )}
      </main>
    </div>
  );
}

ReactDOM.createRoot(document.getElementById('root')).render(<App/>);
</script>
</body>
</html>